Compounds and compositions for intracellular delivery of therapeutic agents - Patents.com
Novel lipid nanoparticle formulations address safety and specificity issues in delivering therapeutic agents by using specific lipid compositions, enhancing delivery efficacy and reducing immunogenicity.
Patent Information
- Application Number
- JP2022171116
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-03-22
- Filing Date
- 2022-10-26
- Publication Date
- 2024-12-09
- Estimated Expiration
- 2038-03-15
AI Technical Summary
Existing lipid-containing nanoparticle compositions for delivering biologically active substances like small molecule drugs, proteins, and nucleic acids face challenges in safety, efficacy, and specificity.
Development of novel compounds and compositions, including specific lipid nanoparticle formulations such as formulas (I) and (III), which incorporate cationic and/or ionic lipids, phospholipids, and PEG lipids, to enhance delivery efficiency and safety.
The novel compositions improve the safety and specificity of intracellular delivery of therapeutic agents, including mRNA, by reducing immunogenicity and enhancing target cell uptake.
Smart Images

Figure 0007596343000580 
Figure 0007596343000581 
Figure 0007596343000582
Abstract
Description
[Technical Field]
[0001] Related Applications This application claims priority to and the benefit of U.S. Provisional Patent Application Nos. 62 / 471,937, filed March 15, 2017; and 62 / 475,140, filed March 22, 2017, the entire contents of each of which are incorporated herein by reference.
[0002] Incorporation by reference of sequence listing This application is filed with an electronic Sequence Listing, which is provided as a file named "MRNA032001WOSequenceListing.txt" created on February 26, 2018, and is 715 bytes in size. The information in the electronic Sequence Listing is incorporated herein by reference in its entirety.
[0003] Disclosure Areas The present disclosure provides novel compounds, compositions comprising such compounds, and methods involving lipid nanoparticle compositions for delivering one or more therapeutic and / or prophylactic agents and / or producing polypeptides in mammalian cells or organs. In addition to the novel lipids, the lipid nanoparticle compositions of the present disclosure may contain, in specific proportions, one or more cationic and / or ionic amino lipids, phospholipids including polyunsaturated lipids, PEG lipids, structured lipids, and / or therapeutic and / or prophylactic agents. [Background technology]
[0004] Effective targeted delivery of biologically active substances, such as small molecule drugs, proteins, and nucleic acids, is an ongoing medical challenge. In particular, delivery of nucleic acids into cells is made difficult by the relative instability and poor cell permeability of such species. Thus, there is a need to develop methods and compositions to facilitate the delivery of therapeutic and / or prophylactic agents, such as nucleic acids, into cells.
[0005] Lipid-containing nanoparticle compositions, liposomes, and lipoplexes have proven effective as delivery vehicles for biologically active substances, such as small molecule drugs, proteins, and nucleic acids, into cells and / or intracellular compartments. Such compositions generally contain one or more "cationic" and / or amino (ionic) lipids, phospholipids including polyunsaturated lipids, structural lipids (e.g., sterols), and / or polyethylene glycol-containing lipids (PEG lipids). Cationic and / or ionic lipids include, for example, amine-containing lipids that can be easily protonated. Summary of the Invention [Problem to be solved by the invention]
[0006] Although a variety of such lipid-containing nanoparticle compositions have been demonstrated, improvements in safety, efficacy, and specificity remain lacking. [Means for solving the problem]
[0007] The present disclosure provides novel compounds and compositions and methods involving same. A first aspect of the present disclosure is a compound of formula (I): [ka] (In the formula: R1 is C 5~30 Alkyl, C 5~20 Alkenyl, -R * selected from the group consisting of -YR", -YR", and -R"M'R'; R2 and R3 are independently H, C 1~14 Alkyl, C 2~14 Alkenyl, -R * YR”, -YR”, and -R * OR”, or R2 and R3 together with the atoms to which they are attached form a heterocycle or a carbocycle; R4 is hydrogen, C 3~6 Carbocyclic ring, -(CH2) n Q, -(CH2)n CHQR, -(CH2) o C(R 10 )2(CH2) n~o Q, -CHQR, -CQ(R)2, and unsubstituted C 1~6 alkyl, where Q is a carbocycle, a heterocycle, -OR, -O(CH) n N(R)2, -C(O)OR, -OC(O)R, -CX3, -CX2H, -CXH2, -CN, -N(R)2, -C(O)N(R)2, -N(R)C(O)R , -N(R)S(O)2R, -N(R)C(O)N(R)2, -N(R)C(S)N(R)2, -N(R)R8, -N(R)S(O)2R8, -O(CH2) n OR, -N(R)C(=NR9)N(R)2, -N(R)C(=CHR9)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(OR)C (O)R, -N(OR)S(O)2R, -N(OR)C(O)OR, -N(OR)C(O)N(R)2, -N(OR)C(S)N(R)2, -N(OR)C(= -NR9)N(R), -N(OR)C(=CHR9)N(R), -C(=NR9)N(R), -C(=NR9)R, -C(O)N(R)OR, and -C(R)N(R)C(O)OR, wherein each o is independently selected from 1, 2, 3, and 4, and each n is independently selected from 1, 2, 3, 4, and 5; Each R5 is independently OH, C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; Each R6 is independently OH, C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; M and M′ are independently selected from —C(O)O—, —OC(O)—, —OC(O)—M″—C(O)O—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)—, —SS—, an aryl group, and a heteroaryl group; 1~13 Alkyl or C 2~13 is alkenyl; R7 is C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; R8, C 3~6 selected from the group consisting of carbocycles and heterocycles; R9 is H, CN, NO2, C 1~6 Alkyl, -OR, -S(O)2R, -S(O)2N(R)2, C 2~6 Alkenyl, C 3~6 selected from the group consisting of carbocycles and heterocycles; R 10 But H, OH, C 1~3 Alkyl, and C 2~3 alkenyl; Each R is independently C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; Each R' is independently C 1~18 Alkyl, C 2~18 Alkenyl, -R * YR”, -YR”, (CH2) q OR * and H; each q is independently selected from 1, 2, and 3; Each R" is independently C 3~15 Alkyl and C 3~15 alkenyl; Each R * But independently, C 1~12 Alkyl and C 2~12 alkenyl; Each Y is independently C 3~6 It is a carbocyclic ring; each X is independently selected from the group consisting of F, Cl, Br, and I; m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13 or an N-oxide thereof, or a salt or isomer thereof.
[0008] In another aspect, the present disclosure provides a compound of formula (III): [ka] (In the ceremony R1 is C 5~30 Alkyl, C 5~20 Alkenyl, -R * selected from the group consisting of -YR", -YR", and -R"M'R'; R2 and R3 are independently H, C 1~14 Alkyl, C 2~14 Alkenyl, -R * YR”, -YR”, and -R * OR”, or R2 and R3 together with the atoms to which they are attached form a heterocycle or a carbocycle; R4 is hydrogen, C 3~6 Carbocyclic ring, -(CH2) n Q, -(CH2) n CHQR, -(CH2) o C(R 10 )2(CH2) n~o Q, -CHQR, -CQ(R)2, and unsubstituted C 1~6 alkyl, where Q is a carbocycle, a heterocycle, -OR, -O(CH) n N(R)2, -C(O)OR, -OC(O)R, -CX3, -CX2H, -CXH2, -CN, -N(R)2, -C(O)N(R)2, -N(R)C(O) R, -N(R)S(O)2R, -N(R)C(O)N(R)2, -N(R)C(S)N(R)2, N(R)R8, -N(R)S(O)2R8, -O(CH2) n OR, -N(R)C(=NR9)N(R)2, -N(R)C(=CHR9)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(OR)C (O)R, -N(OR)S(O)2R, -N(OR)C(O)OR, -N(OR)C(O)N(R)2, -N(OR)C(S)N(R)2, -N(OR)C(= -NR9)N(R), -N(OR)C(=CHR9)N(R), -C(=NR9)N(R), -C(=NR9)R, -C(O)N(R)OR, and -C(R)N(R)C(O)OR, wherein each o is independently selected from 1, 2, 3, and 4, and each n is independently selected from 1, 2, 3, 4, and 5; R x But C 1~6 Alkyl, C 2~6 Alkenyl, -(CH2) r OH, and -(CH2) r NR2, where r is selected from 1, 2, 3, 4, 5, and 6; Each R5 is independently OH, C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; Each R6 is independently OH, C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; M and M′ are independently selected from —C(O)O—, —OC(O)—, —OC(O)—M″—C(O)O—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)—, —SS—, an aryl group, and a heteroaryl group; 1~13 Alkyl or C 2~13 is alkenyl; R7 is C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; R8, C 3~6 selected from the group consisting of carbocycles and heterocycles; R9 is H, CN, NO2, C 1~6 Alkyl, -OR, -S(O)2R, -S(O)2N(R)2, C 2~6 Alkenyl, C 3~6 selected from the group consisting of carbocycles and heterocycles; R 10 But H, OH, C 1~3 Alkyl, and C 2~3 alkenyl; Each R is independently C 1~3 Alkyl, C 2~3 Alkenyl, (CH2) q OR * and H; each q is independently selected from 1, 2, and 3; Each R' is independently C 1~18 Alkyl, C 2~18 Alkenyl, -R * selected from the group consisting of Y-R", -Y-R", and H; Each R" is independently C 3~15 Alkyl and C 3~15 alkenyl; Each R * But independently, C 1~12 Alkyl and C 2~12 alkenyl; Each Y is independently C 3~6 It is a carbocyclic ring; each X is independently selected from the group consisting of F, Cl, Br, and I; m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13 or an N-oxide thereof, or a salt or isomer thereof.
[0009] In certain embodiments, a subset of compounds of Formula (I) are those in which R4 is -(CH2) n Q, -(CH2) n When CHQR, -CHQR, or -CQ(R), compounds in which (i) when n is 1, 2, 3, 4, or 5, Q is not -N(R), or (ii) when n is 1 or 2, Q is not a 5-, 6-, or 7-membered heterocycloalkyl are included.
[0010] For example, if R4 is -(CH2) n Q, -(CH2) n CHQR, -(CH2) o C(R 10 )2(CH2) n~o When Q, -CHQR, or -CQ(R), (i) when n is 1, 2, 3, 4, or 5, Q is not -N(R), or (ii) when n is 1 or 2, Q is not a 5-, 6-, or 7-membered heterocycloalkyl.
[0011] In another embodiment, another subset of compounds of formula (I) is R1 is C 5~30 Alkyl, C 5~20 Alkenyl, -R * selected from the group consisting of -YR", -YR", and -R"M'R'; R2 and R3 are independently H, C 1~14 Alkyl, C 2~14 Alkenyl, -R * YR”, -YR”, and -R * OR”, or R2 and R3 together with the atoms to which they are attached form a heterocycle or a carbocycle; R4 is hydrogen, C 3~6 Carbocyclic ring, -(CH2) n Q, -(CH2) n CHQR, -(CH2) o C(R 10 )2(CH2) n~o Q, -CHQR, -CQ(R)2, and unsubstituted C 1~6 alkyl, wherein Q is selected from the group consisting of C 3~6 Carbocycles, N, O, and S, -OR, -O(CH2) n N(R)2, -C(O)OR, -OC(O)R, -CX3, -CX2H, -CXH2, -CN, -C(O)N(R)2, -N(R)C(O)R, -N(R)S(O)2 R, -N(R)C(O)N(R)2, -N(R)C(S)N(R)2, -CRN(R)2C(O)OR, -N(R)R8, -N(R)S(O)2R8, -O(CH2) n 5- to 14-membered heteroaryl having one or more heteroatoms selected from OR, -N(R)C(=NR9)N(R)2, -N(R)C(=CHR9)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(OR)C(O)R, -N(OR)S(O)2R, -N(OR)C(O)OR, -N(OR)C(O)N(R)2, -N(OR)C(S)N(R)2, -N(OR)C(=NR9)N(R)2, -N(OR)C(=CHR9)N(R)2, -C(=NR9)N(R)2, -C(=NR9)R, -C(O)N(R)OR, as well as oxo (=O), OH, amino, mono- or dialkylamino, and C 1~35- to 14-membered heterocycloalkyl having one or more heteroatoms selected from N, O, and S substituted with one or more substituents selected from alkyl, wherein each o is independently selected from 1, 2, 3, and 4, and each n is independently selected from 1, 2, 3, 4, and 5; Each R5 is independently OH, C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; Each R6 is independently OH, C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; M and M′ are independently selected from —C(O)O—, —OC(O)—, —OC(O)—M″—C(O)O—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)—, —SS—, an aryl group, and a heteroaryl group; 1~13 Alkyl or C 2~13 is alkenyl; R7 is C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; R8, C 3~6 selected from the group consisting of carbocycles and heterocycles; R9 is H, CN, NO2, C 1~6 Alkyl, -OR, -S(O)2R, -S(O)2N(R)2, C 2~6 Alkenyl, C 3~6 selected from the group consisting of carbocycles and heterocycles; R 10 But H, OH, C 1~3 Alkyl, and C 2~3 alkenyl; Each R is independently C 1~3 Alkyl, C 2~3 Alkenyl, (CH2) q OR * selected from the group consisting of Each R' is independently C 1~18 Alkyl, C2~18 Alkenyl, -R * selected from the group consisting of Y-R″, -Y-R″, and H; each q is independently selected from 1, 2, and 3; Each R" is independently C 3~15 Alkyl and C 3~15 alkenyl; Each R * But independently, C 1~12 Alkyl and C 2~12 alkenyl; Each Y is independently C 3~6 It is a carbocyclic ring; each X is independently selected from the group consisting of F, Cl, Br, and I; m includes compounds selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, or N-oxides thereof, or salts or isomers thereof.
[0012] In yet another embodiment, another subset of compounds of formula (I) is R1 is C 5~30 Alkyl, C 5~20 Alkenyl, -R * selected from the group consisting of -YR", -YR", and -R"M'R'; R2 and R3 are independently H, C 1~14 Alkyl, C 2~14 Alkenyl, -R * YR”, -YR”, and -R * OR”, or R2 and R3 together with the atoms to which they are attached form a heterocycle or a carbocycle; R4 is hydrogen, C 3~6 Carbocyclic ring, -(CH2) n Q, -(CH2) n CHQR, -(CH2) o C(R 10 )2(CH2) n~o Q, -CHQR, -CQ(R)2, and unsubstituted C 1~6 alkyl, wherein Q is selected from the group consisting of C 3~6 Carbocycles, N, O, and S, -OR, -O(CH2) nN(R)2, -C(O)OR, -OC(O)R, -CX3, -CX2H, -CXH2, -CN, -C(O)N(R)2, -N(R)C(O)R, -N(R)S(O)2 R, -N(R)C(O)N(R)2, -N(R)C(S)N(R)2, -CRN(R)2C(O)OR, -N(R)R8, -N(R)S(O)2R8, -O(CH2) n OR, -N(R)C(=NR9)N(R)2, -N(R)C(=CHR9)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(OR)C(O)R, -N(OR )S(O)2R, -N(OR)C(O)OR, -N(OR)C(O)N(R)2, -N(OR)C(S)N(R)2, -N(OR)C(=NR9)N(R)2, -N(OR)C(=C and (i) R is -(CH)N(R), -C(=NR)R, -C(O)N(R)OR, and -C(=NR)N(R), where each o is independently selected from 1, 2, 3, and 4, and each n is independently selected from 1, 2, 3, 4, and 5; Q is a 5- to 14-membered heterocycle, and (i) R is -(CH) n Q, where n is 1 or 2, or (ii) R4 is -(CH2) n CHQR, where n is 1, or (iii) when R4 is -CHQR and -CQ(R)2, Q is either a 5- to 14-membered heteroaryl or an 8- to 14-membered heterocycloalkyl; Each R5 is independently OH, C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; Each R6 is independently OH, C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; M and M′ are independently selected from —C(O)O—, —OC(O)—, —OC(O)—M″—C(O)O—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)—, —SS—, an aryl group, and a heteroaryl group;1~13 Alkyl or C 2~13 is alkenyl; R7 is C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; R8, C 3~6 selected from the group consisting of carbocycles and heterocycles; R9 is H, CN, NO2, C 1~6 Alkyl, -OR, -S(O)2R, -S(O)2N(R)2, C 2~6 Alkenyl, C 3~6 selected from the group consisting of carbocycles and heterocycles; R 10 But H, OH, C 1~3 Alkyl, and C 2~3 alkenyl; Each R is independently C 1~3 Alkyl, C 2~3 Alkenyl, (CH2) q OR * and H; each q is independently selected from 1, 2, and 3; Each R' is independently C 1~18 Alkyl, C 2~18 Alkenyl, -R * selected from the group consisting of Y-R", -Y-R", and H; Each R" is independently C 3~15 Alkyl and C 3~15 alkenyl; Each R * But independently, C 1~12 Alkyl and C 2~12 alkenyl; Each Y is independently C 3~6 It is a carbocyclic ring; each X is independently selected from the group consisting of F, Cl, Br, and I; m includes compounds selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, or N-oxides thereof, or salts or isomers thereof.
[0013] In yet another embodiment, another subset of compounds of formula (I) is R1 is C 5~30 Alkyl, C 5~20 Alkenyl, -R * selected from the group consisting of -YR", -YR", and -R"M'R'; R2 and R3 are independently H, C 1~14 Alkyl, C 2~14 Alkenyl, -R * YR”, -YR”, and -R * OR”, or R2 and R3 together with the atoms to which they are attached form a heterocycle or a carbocycle; R4 is hydrogen, C 3~6 Carbocyclic ring, -(CH2) n Q, -(CH2) n CHQR, -(CH2) o C(R 10 )2(CH2) n~o Q, -CHQR, -CQ(R)2, and unsubstituted C 1~6 alkyl, wherein Q is selected from the group consisting of C 3~6 Carbocycles, N, O, and S, -OR, -O(CH2) n N(R)2, -C(O)OR, -OC(O)R, -CX3, -CX2H, -CXH2, -CN, -C(O)N(R)2, -N(R)C(O)R, -N(R)S(O)2 R, -N(R)C(O)N(R)2, -N(R)C(S)N(R)2, -CRN(R)2C(O)OR, -N(R)R8, -N(R)S(O)2R8, -O(CH2) nOR, -N(R)C(=NR9)N(R)2, -N(R)C(=CHR9)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(OR)C(O)R , -N(OR)S(O)2R, -N(OR)C(O)OR, -N(OR)C(O)N(R)2, -N(OR)C(S)N(R)2, -N(OR)C(=NR9)N(R) 2, 5- to 14-membered heteroaryl having one or more heteroatoms selected from -N(OR)C(=CHR9)N(R)2, -C(=NR9)R, -C(O)N(R)OR, and -C(=NR9)N(R)2, wherein each o is independently selected from 1, 2, 3, and 4, and each n is independently selected from 1, 2, 3, 4, and 5; Each R5 is independently OH, C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; Each R6 is independently OH, C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; M and M′ are independently selected from —C(O)O—, —OC(O)—, —OC(O)—M″—C(O)O—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)—, —SS—, an aryl group, and a heteroaryl group; 1~13 Alkyl or C 2~13 is alkenyl; R7 is C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; R8, C 3~6 selected from the group consisting of carbocycles and heterocycles; R9 is H, CN, NO2, C 1~6 Alkyl, -OR, -S(O)2R, -S(O)2N(R)2, C 2~6 Alkenyl, C 3~6 selected from the group consisting of carbocycles and heterocycles; R 10 But H, OH, C 1~3 Alkyl, and C 2~3alkenyl, Each R is independently C 1~3 Alkyl, C 2~3 Alkenyl, (CH2) q OR * and H; each q is independently selected from 1, 2, and 3; Each R' is independently C 1~18 Alkyl, C 2~18 Alkenyl, -R * selected from the group consisting of Y-R", -Y-R", and H; Each R" is independently C 3~15 Alkyl and C 3~15 alkenyl; Each R * But independently, C 1~12 Alkyl and C 2~12 alkenyl; Each Y is independently C 3~6 It is a carbocyclic ring; each X is independently selected from the group consisting of F, Cl, Br, and I; m includes compounds selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, or N-oxides thereof, or salts or isomers thereof.
[0014] In yet another embodiment, another subset of compounds of formula (I) is R1 is C 5~30 Alkyl, C 5~20 Alkenyl, -R * selected from the group consisting of -YR", -YR", and -R"M'R'; R2 and R3 are independently H, C 1~14 Alkyl, C 2~14 Alkenyl, -R * YR”, -YR”, and -R * OR”, or R2 and R3 together with the atoms to which they are attached form a heterocycle or a carbocycle; R4 is hydrogen, C 3~6 Carbocyclic ring, -(CH2) n Q, -(CH2)n CHQR, -(CH2) o C(R 10 )2(CH2) n~o Q, -CHQR, -CQ(R)2, and unsubstituted C 1~6 alkyl, where Q is a carbocycle, —OR, —O(CH) n N(R)2, -C(O)OR, -OC(O)R, -CX3, -CX2H, -CXH2, -CN, -C(O)N(R)2, -N(R)C(O)R, -N (R)S(O)2R, -N(R)C(O)N(R)2, -N(R)C(S)N(R)2, N(R)R8, -N(R)S(O)2R8, -O(CH2) n OR, -N(R)C(=NR9)N(R)2, -N(R)C(=CHR9)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(OR)C (O)R, -N(OR)S(O)2R, -N(OR)C(O)OR, -N(OR)C(O)N(R)2, -N(OR)C(S)N(R)2, -N(OR)C(= -NR9)N(R), -N(OR)C(=CHR9)N(R), -C(=NR9)N(R), -C(=NR9)R, -C(O)N(R)OR, and -C(R)N(R)C(O)OR, wherein each o is independently selected from 1, 2, 3, and 4, and each n is independently selected from 1, 2, 3, 4, and 5; Each R5 is independently OH, C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; Each R6 is independently OH, C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; M and M′ are independently selected from —C(O)O—, —OC(O)—, —OC(O)—M″—C(O)O—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)—, —SS—, an aryl group, and a heteroaryl group; 1~13 Alkyl or C 2~13 is alkenyl; R7 is C1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; R8, C 3~6 selected from the group consisting of carbocycles and heterocycles; R9 is H, CN, NO2, C 1~6 Alkyl, -OR, -S(O)2R, -S(O)2N(R)2, C 2~6 Alkenyl, C 3~6 selected from the group consisting of carbocycles and heterocycles; R 10 But H, OH, C 1~3 Alkyl, and C 2~3 alkenyl; Each R is independently C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; Each R' is independently C 1~18 Alkyl, C 2~18 Alkenyl, -R * YR”, -YR”, (CH2) q OR * and H; each q is independently selected from 1, 2, and 3; Each R" is independently C 3~15 Alkyl and C 3~15 alkenyl; Each R * But independently, C 1~12 Alkyl and C 2~12 alkenyl; Each Y is independently C 3~6 It is a carbocyclic ring; each X is independently selected from the group consisting of F, Cl, Br, and I; m includes compounds selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, or N-oxides thereof, or salts or isomers thereof.
[0015] In yet another embodiment, another subset of compounds of formula (I) is R1 is C 5~30 Alkyl, C5~20 Alkenyl, -R * selected from the group consisting of -YR", -YR", and -R"M'R'; R2 and R3 are independently H, C 2~14 Alkyl, C 2~14 Alkenyl, -R * YR”, -YR”, and -R * OR”, or R2 and R3 together with the atoms to which they are attached form a heterocycle or a carbocycle; R4 is -(CH2) n Q or -(CH2) n CHQR, where Q is -N(R)2 and n is selected from 3, 4, and 5; Each R5 is independently C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; Each R6 is independently C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; M and M′ are independently selected from —C(O)O—, —OC(O)—, —OC(O)—M″—C(O)O—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)—, —SS—, an aryl group, and a heteroaryl group; 1~13 Alkyl or C 2~13 is alkenyl; R7 is C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; Each R is independently C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; Each R' is independently C 1~18 Alkyl, C 2~18 Alkenyl, -R * selected from the group consisting of Y-R", -Y-R", and H; Each R" is independently C 3~15 Alkyl and C3~15 alkenyl; Each R * But independently, C 1~12 Alkyl and C 1~12 alkenyl; Each Y is independently C 3~6 It is a carbocyclic ring; each X is independently selected from the group consisting of F, Cl, Br, and I; m includes compounds selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, or N-oxides thereof, or salts or isomers thereof.
[0016] In yet another embodiment, another subset of compounds of formula (I) is R1 is C 5~30 Alkyl, C 5~20 Alkenyl, -R * selected from the group consisting of -YR", -YR", and -R"M'R'; R2 and R3 are independently C 1~14 Alkyl, C 2~14 Alkenyl, -R * YR”, -YR”, and -R * OR”, or R2 and R3 together with the atoms to which they are attached form a heterocycle or a carbocycle; R4 is -(CH2) n Q, -(CH2) n -CHQR, -CHQR, and -CQ(R)2, where Q is -N(R)2 and n is selected from 1, 2, 3, 4, and 5; Each R5 is independently C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; Each R6 is independently C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; M and M′ are independently selected from —C(O)O—, —OC(O)—, —OC(O)—M″—C(O)O—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)—, —SS—, an aryl group, and a heteroaryl group; 1~13 Alkyl or C 2~13 is alkenyl; R7 is C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; Each R is independently C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; Each R' is independently C 1~18 Alkyl, C 2~18 Alkenyl, -R * selected from the group consisting of Y-R", -Y-R", and H; Each R" is independently C 3~15 Alkyl and C 3~15 alkenyl; Each R * But independently, C 1~12 Alkyl and C 1~12 alkenyl; Each Y is independently C 3~6 It is a carbocyclic ring; each X is independently selected from the group consisting of F, Cl, Br, and I; m includes compounds selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, or N-oxides thereof, or salts or isomers thereof.
[0017] In certain embodiments, a subset of compounds of formula (III) are those in which R4 is -(CH2) n Q, -(CH2) nWhen CHQR, -CHQR, or -CQ(R), compounds in which (i) when n is 1, 2, 3, 4, or 5, Q is not -N(R), or (ii) when n is 1 or 2, Q is not a 5-, 6-, or 7-membered heterocycloalkyl are included.
[0018] In another embodiment, a subset of compounds of formula (III) is R1 is C 5~30 Alkyl, C 5~20 Alkenyl, -R * selected from the group consisting of -YR", -YR", and -R"M'R'; R2 and R3 are independently H, C 1~14 Alkyl, C 2~14 Alkenyl, -R * YR”, -YR”, and -R * OR”, or R2 and R3 together with the atoms to which they are attached form a heterocycle or a carbocycle; R4 is hydrogen, C 3~6 Carbocyclic ring, -(CH2) n Q, -(CH2) n CHQR, -(CH2) o C(R 10 )2(CH2) n~o Q, -CHQR, -CQ(R)2, and unsubstituted C 1~6 alkyl, wherein Q is selected from the group consisting of C 3~6 Carbocyclic ring, 5-14 membered heteroaryl having one or more heteroatoms selected from N, O, and S, -OR, -O(CH2) n N(R)2, -C(O)OR, -OC(O)R, -CX3, -CX2H, -CXH2, -CN, -C(O)N(R)2, -N(R)C(O)R, -N(R)S(O)2 R, -N(R)C(O)N(R)2, -N(R)C(S)N(R)2, -CRN(R)2C(O)OR, -N(R)R8, -N(R)S(O)2R8, -O(CH2) nOR, -N(R)C(=NR9)N(R)2, -N(R)C(=CHR9)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(OR)C(O)R, -N(OR)S(O)2R, -N(OR)C(O)OR, -N(OR)C(O)N(R)2, -N(OR)C(S)N(R)2, -N(OR)C(=NR9)N(R)2, -N(OR)C(=CHR9)N(R)2, -C(=NR9)N(R)2, -C(=NR9)R, -C(O)N(R)OR, as well as oxo(=O), OH, amino, mono- or di-alkylamino, and C 1~3 5-14 membered heterocycloalkyl having one or more heteroatoms selected from N, O, and S substituted with one or more substituents selected from alkyl, wherein each o is independently selected from 1, 2, 3, and 4, and each n is independently selected from 1, 2, 3, 4, and 5; R x But C 1~6 Alkyl, C 2~6 Alkenyl, -(CH2) r OH, and -(CH2) r NR2, where r is selected from 1, 2, 3, 4, 5, and 6; Each R5 is independently OH, C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; Each R6 is independently OH, C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; M and M′ are independently selected from —C(O)O—, —OC(O)—, —OC(O)—M″—C(O)O—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)—, —SS—, an aryl group, and a heteroaryl group; 1~13 Alkyl or C 2~13 is alkenyl; R7 is C 1~3 Alkyl, C 2~3selected from the group consisting of alkenyl, and H; R8, C 3~6 selected from the group consisting of carbocycles and heterocycles; R9 is H, CN, NO2, C 1~6 Alkyl, -OR, -S(O)2R, -S(O)2N(R)2, C 2~6 Alkenyl, C 3~6 selected from the group consisting of carbocycles and heterocycles; R 10 But H, OH, C 1~3 Alkyl, and C 2~3 alkenyl; Each R is independently C 1~3 Alkyl, C 2~3 Alkenyl, (CH2) q OR * selected from the group consisting of Each R' is independently C 1~18 Alkyl, C 2~18 Alkenyl, -R * selected from the group consisting of Y-R″, -Y-R″, and H; each q is independently selected from 1, 2, and 3; Each R" is independently C 3~15 Alkyl and C 3~15 alkenyl; Each R * But independently, C 1~12 Alkyl and C 2~12 alkenyl; Each Y is independently C 3~6 It is a carbocyclic ring; each X is independently selected from the group consisting of F, Cl, Br, and I; m includes compounds selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, or N-oxides thereof, or salts or isomers thereof.
[0019] In yet another embodiment, another subset of compounds of formula (III) is R1 is C 5~30 Alkyl, C 5~20 Alkenyl, -R *selected from the group consisting of -YR", -YR", and -R"M'R'; R2 and R3 are independently H, C 1~14 Alkyl, C 2~14 Alkenyl, -R * YR”, -YR”, and -R * OR”, or R2 and R3 together with the atoms to which they are attached form a heterocycle or a carbocycle; R4 is hydrogen, C 3~6 Carbocyclic ring, -(CH2) n Q, -(CH2) n CHQR, -(CH2) o C(R 10 )2(CH2) n~o Q, -CHQR, -CQ(R)2, and unsubstituted C 1~6 alkyl, wherein Q is selected from the group consisting of C 3~6 Carbocycle, 5-14 membered heterocycle having one or more heteroatoms selected from N, O, and S, -OR, -O(CH2) n N(R)2, -C(O)OR, -OC(O)R, -CX3, -CX2H, -CXH2, -CN, -C(O)N(R)2, -N(R)C(O)R, -N(R)S(O)2 R, -N(R)C(O)N(R)2, -N(R)C(S)N(R)2, -CRN(R)2C(O)OR, -N(R)R8, -N(R)S(O)2R8, -O(CH2) n OR, -N(R)C(=NR9)N(R)2, -N(R)C(=CHR9)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(OR)C(O) R, -N(OR)S(O)2R, -N(OR)C(O)OR, -N(OR)C(O)N(R)2, -N(OR)C(S)N(R)2, -N(OR)C(=NR9)N (R)2, -N(OR)C(=CHR9)N(R)2, -C(=NR9)R, -C(O)N(R)OR, and -C(=NR9)N(R)2, where each o is independently selected from 1, 2, 3, and 4, and each n is independently selected from 1, 2, 3, 4, and 5; Q is a 5- to 14-membered heterocycle, and (i) R4 is -(CH2) n Q, where n is 1 or 2, or (ii) R4 is -(CH2) nor (iii) when R4 is -CHQR and -CQ(R)2, Q is either a 5- to 14-membered heteroaryl or an 8- to 14-membered heterocycloalkyl; R x But C 1~6 Alkyl, C 2~6 Alkenyl, -(CH2) r OH, and -(CH2) r NR2, where r is selected from 1, 2, 3, 4, 5, and 6; Each R5 is independently OH, C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; Each R6 is independently OH, C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; M and M′ are independently selected from —C(O)O—, —OC(O)—, —OC(O)—M″—C(O)O—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)—, —SS—, an aryl group, and a heteroaryl group; 1~13 Alkyl or C 2~13 is alkenyl; R7 is C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; R8, C 3~6 selected from the group consisting of carbocycles and heterocycles; R9 is H, CN, NO2, C 1~6 Alkyl, -OR, -S(O)2R, -S(O)2N(R)2, C 2~6 Alkenyl, C 3~6 selected from the group consisting of carbocycles and heterocycles; R 10 But H, OH, C 1~3 Alkyl, and C 2~3 alkenyl; Each R is independently C1~3 Alkyl, C 2~3 Alkenyl, (CH2) q OR * and H; each q is independently selected from 1, 2, and 3; Each R' is independently C 1~18 Alkyl, C 2~18 Alkenyl, -R * selected from the group consisting of Y-R", -Y-R", and H; Each R" is independently C 3~15 Alkyl and C 3~15 alkenyl; Each R * But independently, C 1~12 Alkyl and C 2~12 alkenyl; Each Y is independently C 3~6 It is a carbocyclic ring; each X is independently selected from the group consisting of F, Cl, Br, and I; m includes compounds selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, or N-oxides thereof, or salts or isomers thereof.
[0020] In yet another embodiment, another subset of compounds of formula (III) is R1 is C 5~30 Alkyl, C 5~20 Alkenyl, -R * selected from the group consisting of -YR", -YR", and -R"M'R'; R2 and R3 are independently H, C 1~14 Alkyl, C 2~14 Alkenyl, -R * YR”, -YR”, and -R * OR”, or R2 and R3 together with the atoms to which they are attached form a heterocycle or a carbocycle; R4 is hydrogen, C 3~6 Carbocyclic ring, -(CH2) n Q, -(CH2) n CHQR, -(CH2) o C(R10 )2(CH2) n~o Q, -CHQR, -CQ(R)2, and unsubstituted C 1~6 alkyl, wherein Q is selected from the group consisting of C 3~6 Carbocyclic ring, 5-14 membered heteroaryl having one or more heteroatoms selected from N, O, and S, -OR, -O(CH2) n N(R)2, -C(O)OR, -OC(O)R, -CX3, -CX2H, -CXH2, -CN, -C(O)N(R)2, -N(R)C(O)R, -N(R)S(O)2 R, -N(R)C(O)N(R)2, -N(R)C(S)N(R)2, -CRN(R)2C(O)OR, -N(R)R8, -N(R)S(O)2R8, -O(CH2) n OR, -N(R)C(=NR9)N(R)2, -N(R)C(=CHR9)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(OR)C(O) R, -N(OR)S(O)2R, -N(OR)C(O)OR, -N(OR)C(O)N(R)2, -N(OR)C(S)N(R)2, -N(OR)C(=NR9)N (R), -N(OR)C(=CHR)N(R), -C(=NR)R, -C(O)N(R)OR (wherein each o is independently selected from 1, 2, 3, and 4), and -C(=NR)N(R), where each o is independently selected from 1, 2, 3, and 4, and each n is independently selected from 1, 2, 3, 4, and 5; R x But C 1~6 Alkyl, C 2~6 Alkenyl, -(CH2) r OH, and -(CH2) r NR2, where r is selected from 1, 2, 3, 4, 5, and 6; Each R5 is independently OH, C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; Each R6 is independently OH, C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; M and M′ are independently selected from —C(O)O—, —OC(O)—, —OC(O)—M″—C(O)O—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)—, —SS—, an aryl group, and a heteroaryl group; 1~13 Alkyl or C 2~13 is alkenyl; R7 is C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; R8, C 3~6 selected from the group consisting of carbocycles and heterocycles; R9 is H, CN, NO2, C 1~6 Alkyl, -OR, -S(O)2R, -S(O)2N(R)2, C 2~6 Alkenyl, C 3~6 selected from the group consisting of carbocycles and heterocycles; R 10 But H, OH, C 1~3 Alkyl, and C 2~3 alkenyl; Each R is independently C 1~3 Alkyl, C 2~3 Alkenyl, (CH2) q OR * and H; each q is independently selected from 1, 2, and 3; Each R' is independently C 1~18 Alkyl, C 2~18 Alkenyl, -R * selected from the group consisting of Y-R", -Y-R", and H; Each R" is independently C 3~15 Alkyl and C 3~15 alkenyl; Each R * But independently, C 1~12 Alkyl and C 2~12 alkenyl; Each Y is independently C 3~6 It is a carbocyclic ring; each X is independently selected from the group consisting of F, Cl, Br, and I; m includes compounds selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, or N-oxides thereof, or salts or isomers thereof.
[0021] In yet another embodiment, another subset of compounds of formula (III) is R1 is C 5~30 Alkyl, C 5~20 Alkenyl, -R * selected from the group consisting of -YR", -YR", and -R"M'R'; R2 and R3 are independently H, C 1~14 Alkyl, C 2~14 Alkenyl, -R * YR”, -YR”, and -R * OR”, or R2 and R3 together with the atoms to which they are attached form a heterocycle or a carbocycle; R4 is hydrogen, C 3~6 Carbocyclic ring, -(CH2) n Q, -(CH2) n CHQR, -(CH2) o C(R 10 )2(CH2) n~o Q, -CHQR, -CQ(R)2, and unsubstituted C 1~6 alkyl, where Q is a carbocycle, —OR, —O(CH) n N(R)2, -C(O)OR, -OC(O)R, -CX3, -CX2H, -CXH2, -CN, -C(O)N(R)2, -N(R)C(O)R, -N (R)S(O)2R, -N(R)C(O)N(R)2, -N(R)C(S)N(R)2, N(R)R8, -N(R)S(O)2R8, -O(CH2) nOR, -N(R)C(=NR9)N(R)2, -N(R)C(=CHR9)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(OR)C (O)R, -N(OR)S(O)2R, -N(OR)C(O)OR, -N(OR)C(O)N(R)2, -N(OR)C(S)N(R)2, -N(OR)C(= -NR9)N(R), -N(OR)C(=CHR9)N(R), -C(=NR9)N(R), -C(=NR9)R, -C(O)N(R)OR, and -C(R)N(R)C(O)OR, wherein each o is independently selected from 1, 2, 3, and 4, and each n is independently selected from 1, 2, 3, 4, and 5; R x But C 1~6 Alkyl, C 2~6 Alkenyl, -(CH2) r OH, and -(CH2) r NR2, where r is selected from 1, 2, 3, 4, 5, and 6; Each R5 is independently OH, C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; Each R6 is independently OH, C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; M and M′ are independently selected from —C(O)O—, —OC(O)—, —OC(O)—M″—C(O)O—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)—, —SS—, an aryl group, and a heteroaryl group; 1~13 Alkyl or C 2~13 is alkenyl; R7 is C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; R8, C 3~6 selected from the group consisting of carbocycles and heterocycles; R9 is H, CN, NO2, C 1~6Alkyl, -OR, -S(O)2R, -S(O)2N(R)2, C 2~6 Alkenyl, C 3~6 selected from the group consisting of carbocycles and heterocycles; R 10 But H, OH, C 1~3 Alkyl, and C 2~3 alkenyl; Each R is independently C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; Each R' is independently C 1~18 Alkyl, C 2~18 Alkenyl, -R * YR”, -YR”, (CH2) q OR * and H; each q is independently selected from 1, 2, and 3; Each R" is independently C 3~15 Alkyl and C 3~15 alkenyl; Each R * But independently, C 1~12 Alkyl and C 2~12 alkenyl; Each Y is independently C 3~6 It is a carbocyclic ring; each X is independently selected from the group consisting of F, Cl, Br, and I; m includes compounds selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, or N-oxides thereof, or salts or isomers thereof.
[0022] In yet another embodiment, another subset of compounds of formula (III) is R1 is C 5~30 Alkyl, C 5~20 Alkenyl, -R * selected from the group consisting of -YR", -YR", and -R"M'R'; R2 and R3 are independently H, C 2~14 Alkyl, C 2~14 Alkenyl, -R *YR”, -YR”, and -R * OR”, or R2 and R3 together with the atoms to which they are attached form a heterocycle or a carbocycle; R4 is -(CH2) n Q or -(CH2) n CHQR, where Q is -N(R)2 and n is selected from 3, 4, and 5; R x But C 1~6 Alkyl, C 2~6 Alkenyl, -(CH2) r OH, and -(CH2) r NR2, where r is selected from 1, 2, 3, 4, 5, and 6; Each R5 is independently C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; Each R6 is independently C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; M and M′ are independently selected from —C(O)O—, —OC(O)—, —OC(O)—M″—C(O)O—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)—, —SS—, an aryl group, and a heteroaryl group; 1~13 Alkyl or C 2~13 is alkenyl; R7 is C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; Each R is independently C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; Each R' is independently C 1~18 Alkyl, C 2~18 Alkenyl, -R * selected from the group consisting of Y-R", -Y-R", and H; Each R" is independently C 3~15 Alkyl and C 3~15 alkenyl; Each R * But independently, C 1~12 Alkyl and C 1~12 alkenyl; Each Y is independently C 3~6 It is a carbocyclic ring; each X is independently selected from the group consisting of F, Cl, Br, and I; m includes compounds selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, or N-oxides thereof, or salts or isomers thereof.
[0023] In yet another embodiment, another subset of compounds of formula (III) is R1 is C 5~30 Alkyl, C 5~20 Alkenyl, -R * selected from the group consisting of -YR", -YR", and -R"M'R'; R2 and R3 are independently C 1~14 Alkyl, C 2~14 Alkenyl, -R * YR”, -YR”, and -R * OR”, or R2 and R3 together with the atoms to which they are attached form a heterocycle or a carbocycle; R4 is -(CH2) n Q, -(CH2) n -CHQR, -CHQR, and -CQ(R), where Q is -N(R) and n is selected from 1, 2, 3, 4, and 5; R x But C 1~6 Alkyl, C 2~6 Alkenyl, -(CH2) r OH, and -(CH2) r NR2, where r is selected from 1, 2, 3, 4, 5, and 6; Each R5 is independently C 1~3 Alkyl, C 2~3selected from the group consisting of alkenyl, and H; Each R6 is independently C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; M and M′ are independently selected from —C(O)O—, —OC(O)—, —OC(O)—M″—C(O)O—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)—, —SS—, an aryl group, and a heteroaryl group; 1~13 Alkyl or C 2~13 is alkenyl; R7 is C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; Each R is independently C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; Each R' is independently C 1~18 Alkyl, C 2~18 Alkenyl, -R * selected from the group consisting of Y-R", -Y-R", and H; Each R" is independently C 3~15 Alkyl and C 3~15 alkenyl; Each R * But independently, C 1~12 Alkyl and C 1~12 alkenyl; Each Y is independently C 3~6 It is a carbocyclic ring; each X is independently selected from the group consisting of F, Cl, Br, and I; m includes compounds selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, or N-oxides thereof, or salts or isomers thereof.
[0024] In certain embodiments, a subset of compounds of formula (I) is of formula (IA): [ka] wherein l is selected from 1, 2, 3, 4, and 5; m is selected from 5, 6, 7, 8, and 9; M is a bond or M'; and R is hydrogen, unsubstituted C 1~3 Alkyl, -(CH2) o C(R 10 )2(CH2) n~o Q, or -(CH2) n Q, where Q is OH, —NHC(S)N(R), —NHC(O)N(R), —N(R)C(O)R, —N(R)S(O)R, —N(R)R, —NHC(═NR)N(R), —NHC(═CHR)N(R), —OC(O)N(R), —N(R)C(O)OR, heteroaryl, or heterocycloalkyl; M and M′ are independently selected from —C(O)O—, —OC(O)—, —OC(O)—M″—C(O)O—, —C(O)N(R′)—, —P(O)(OR′)O—, —SS—, an aryl group, and a heteroaryl group; R and R are independently selected from H, C 1~14 Alkyl, and C 2~14 For example, m is 5, 7, or 9. For example, Q is OH, -NHC(S)N(R), or -NHC(O)N(R). For example, Q is -N(R)C(O)R, or -N(R)S(O)R.
[0025] In certain embodiments, a subset of compounds of formula (I) is of formula (IB): [ka] wherein all variables are as defined herein, or an N-oxide thereof, or a salt or isomer thereof. For example, m is selected from 5, 6, 7, 8, and 9; M and M′ are independently selected from —C(O)O—, —OC(O)—, —OC(O)—M″—C(O)O—, —C(O)N(R′)—, —P(O)(OR′)O—, —SS—, an aryl group, and a heteroaryl group; R2 and R3 are independently selected from H, C 1~14 Alkyl, and C 2~14 For example, m is 5, 7, or 9.
[0026] In certain embodiments, a subset of compounds of formula (I) is represented by formula (II): [ka] wherein l is selected from 1, 2, 3, 4, and 5; M is a bond or M'; and R is hydrogen, unsubstituted C 1~3 Alkyl, -(CH2) o C(R 10 )2(CH2) n~o Q, or -(CH2) n Q, where n is 2, 3, or 4, and Q is OH, —NHC(S)N(R), —NHC(O)N(R), —N(R)C(O)R, —N(R)S(O)R, —N(R)R, —NHC(═NR)N(R), —NHC(═CHR)N(R), —OC(O)N(R), —N(R)C(O)OR, heteroaryl, or heterocycloalkyl; M and M′ are independently selected from —C(O)O—, —OC(O)—, —OC(O)—M″—C(O)O—, —C(O)N(R′)—, —P(O)(OR′)O—, —SS—, an aryl group, and a heteroaryl group; R and R are independently selected from H, C 1~1 Alkyl, and C 2~14 alkenyl) or an N-oxide thereof, or a salt or isomer thereof.
[0027] In certain embodiments, a subset of compounds of formula (I) is represented by formula (IIa), (IIb), (IIc), or (IIe): [ka] or an N-oxide thereof, or a salt or isomer thereof, wherein R4 is as described herein.
[0028] In certain embodiments, a subset of compounds of formula (I) is represented by formula (IId): [ka] wherein n is 2, 3, or 4; and m, R', R", and R2-R6 are as described herein, or an N-oxide thereof, or a salt or isomer thereof. For example, each of R2 and R3 is independently selected from the group consisting of C 5~14 Alkyl and C 5~14 alkenyl.
[0029] In another embodiment, a subset of compounds of formula (I) has the formula (IIf): [ka] wherein n is 2, 3, or 4; m, M, M″, R′, R″, and R2-R6 are as described herein, or an N-oxide thereof, or a salt or isomer thereof. For example, each of R2 and R3 is C 5~14 Alkyl and C 5~14 alkenyl, wherein n is selected from 2, 3, and 4.
[0030] In another embodiment, a subset of compounds of formula (I) is represented by formula (IIg): [ka] wherein l, m, M, M1, R', R2 and R3 are as described herein, or an N-oxide thereof, or a salt or isomer thereof. For example, each of R2 and R3 is C 5~14 Alkyl and C 5~14 alkenyl, where l is selected from 1, 2, 3, 4, and 5, and m is selected from 5, 6, 7, 8, and 9. In another aspect, the disclosure features a nanoparticle composition that includes a lipid component that includes a compound described herein (e.g., a compound represented by Formula (I), (IA), (IB), (II), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), or (III)).
[0031] In another aspect, the present disclosure features a pharmaceutical composition comprising a nanoparticle composition according to the previous aspect and a pharmaceutically acceptable carrier. For example, the pharmaceutical composition may be refrigerated or frozen for storage and / or transportation (e.g., stored at a temperature of 4°C or less, such as about -150°C to about 0°C or about -80°C to about -20°C (e.g., about -5°C, -10°C, -15°C, -20°C, -25°C, -30°C, -40°C, -50°C, -60°C, -70°C, -80°C, -90°C, -130°C, or -150°C). For example, the pharmaceutical composition may be a solution refrigerated for storage and / or transportation, e.g., at about -20°C, -30°C, -40°C, -50°C, -60°C, -70°C, or -80°C.
[0032] In another aspect, the disclosure provides a method for delivering a therapeutic and / or prophylactic agent (e.g., mRNA) to a cell (e.g., a mammalian cell), the method comprising administering to a subject (e.g., a mammal, a human, etc.) a nanoparticle composition comprising (i) a lipid component comprising a phospholipid (e.g., a polyunsaturated lipid), a PEG-lipid, a structured lipid, and a compound of Formula (I), (IA), (IB), (II), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), or (III), and (ii) a therapeutic and / or prophylactic agent, wherein the administration comprises contacting the cell with the nanoparticle composition, whereby the therapeutic and / or prophylactic agent is delivered to the cell.
[0033] In another aspect, the disclosure provides a method for producing a polypeptide of interest in a cell (e.g., a mammalian cell), comprising contacting the cell with (i) a nanoparticle composition comprising a lipid component comprising a phospholipid (such as a polyunsaturated lipid), a PEG-lipid, a structured lipid, and a compound of Formula (I), (IA), (IB), (II), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), or (III), and (ii) an mRNA encoding the polypeptide of interest, whereby the mRNA can be translated within the cell to produce the polypeptide.
[0034] In another aspect, the present disclosure provides a method for treating a disease or disorder in a mammal (e.g., a human) in need thereof. The method comprises administering to the mammal a therapeutically effective amount of a nanoparticle composition comprising: (i) a lipid component comprising a phospholipid (e.g., a polyunsaturated lipid), a PEG-lipid, a structured lipid, and a compound of Formula (I), (IA), (IB), (II), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), or (III); and (ii) a therapeutic and / or prophylactic agent (e.g., mRNA). In some embodiments, the disease or disorder is characterized by dysfunctional or abnormal protein or polypeptide activity. For example, the disease or disorder is selected from the group consisting of rare diseases, infectious diseases, cancer and proliferative diseases, genetic diseases (e.g., cystic fibrosis), autoimmune diseases, diabetes, neurodegenerative diseases, cardiovascular and renal vascular diseases, and metabolic diseases.
[0035] In another aspect, the present disclosure provides nanoparticle compositions for use in treating a disease or disorder in a mammal (e.g., a human) in need thereof. The nanoparticle compositions comprise (i) a lipid component comprising a phospholipid (e.g., a polyunsaturated lipid), a PEG-lipid, a structured lipid, and a compound of Formula (I), (IA), (IB), (II), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), or (III); and (ii) a therapeutic and / or prophylactic agent (e.g., mRNA). In some embodiments, the disease or disorder is characterized by dysfunctional or abnormal protein or polypeptide activity. For example, the disease or disorder is selected from the group consisting of rare diseases, infectious diseases, cancer and proliferative diseases, genetic diseases (e.g., cystic fibrosis), autoimmune diseases, diabetes, neurodegenerative diseases, cardiovascular and renal vascular diseases, and metabolic diseases.
[0036] In another aspect, the present disclosure provides a nanoparticle composition for use in the manufacture of a medicament for treating a disease or disorder in a mammal (e.g., a human) in need thereof. The nanoparticle composition comprises (i) a lipid component comprising a phospholipid (e.g., a polyunsaturated lipid), a PEG-lipid, a structured lipid, and a compound of Formula (I), (IA), (IB), (II), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), or (III); and (ii) a therapeutic and / or prophylactic agent (e.g., mRNA). In some embodiments, the disease or disorder is characterized by dysfunctional or abnormal protein or polypeptide activity. For example, the disease or disorder is selected from the group consisting of rare diseases, infectious diseases, cancer and proliferative diseases, genetic diseases (e.g., cystic fibrosis), autoimmune diseases, diabetes, neurodegenerative diseases, cardiovascular and renal vascular diseases, and metabolic diseases.
[0037] In another aspect, the present disclosure provides use of a nanoparticle composition in the manufacture of a medicament for treating a disease or disorder in a mammal (e.g., a human) in need thereof. The nanoparticle composition comprises (i) a lipid component comprising a phospholipid (e.g., a polyunsaturated lipid), a PEG-lipid, a structured lipid, and a compound of Formula (I), (IA), (IB), (II), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), or (III); and (ii) a therapeutic and / or prophylactic agent (e.g., mRNA). In some embodiments, the disease or disorder is characterized by dysfunctional or abnormal protein or polypeptide activity. For example, the disease or disorder is selected from the group consisting of rare diseases, infectious diseases, cancer and proliferative diseases, genetic diseases (e.g., cystic fibrosis), autoimmune diseases, diabetes, neurodegenerative diseases, cardiovascular and renal vascular diseases, and metabolic diseases.
[0038] In another aspect, the disclosure provides a method for delivering (e.g., specifically delivering) a therapeutic and / or prophylactic agent to an organ (e.g., liver, spleen, lung, or femur) of a mammal, the method comprising administering to a subject (e.g., a mammal) a nanoparticle composition comprising (i) a lipid component comprising a phospholipid, a PEG-lipid, a structured lipid, and a compound of Formula (I), (IA), (IB), (II), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), or (III), and (ii) a therapeutic and / or prophylactic agent (e.g., mRNA), wherein the administration comprises contacting cells with the nanoparticle composition, whereby the therapeutic and / or prophylactic agent is delivered to the target organ (e.g., liver, spleen, lung, or femur).
[0039] In another aspect, the disclosure features a method for enhanced delivery of a therapeutic and / or prophylactic agent (e.g., mRNA) to a target tissue (e.g., liver, spleen, lung, or femur). The method includes administering to a subject (e.g., a mammal) a nanoparticle composition including: (i) a lipid component including a compound of Formula (I), (IA), (IB), (II), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), or (III), a phospholipid, a structured lipid, and a PEG-lipid; and (ii) a therapeutic and / or prophylactic agent, wherein the administration includes contacting the target tissue with the nanoparticle composition, whereby the therapeutic and / or prophylactic agent is delivered to the target tissue.
[0040] In yet another aspect, the disclosure features a method of reducing immunogenicity, comprising introducing into a cell a nanoparticle composition of the disclosure, wherein the nanoparticle composition reduces induction of a cellular immune response in the cell to the nanoparticle composition compared to induction of a cellular immune response in the cell induced by a control composition comprising a control lipid instead of a compound of Formula (I), (IA), (IB), (II), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), or (III). For example, the cellular immune response can be an innate immune response, an adaptive immune response, or both.
[0041] The present disclosure also includes methods of synthesizing compounds of Formula (I), (IA), (IB), (II), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), or (III), and methods of making nanoparticle compositions comprising a lipid component comprising a compound of Formula (I), (IA), (IB), (II), (II), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), or (III). [Brief explanation of the drawings]
[0042] [Figure 1] FIG. 1 shows the results of pre-treatment of non-human primates with methotrexate or dexamethasone prior to administration of a nanoparticle composition comprising MC3. [Figure 2] FIG. 1 shows hEPO mRNA expression measured after intravenous administration of various nanoparticle compositions at a dose of 0.01 mpk via a 60 minute infusion to naive cynomolgus monkeys. [Figure 3] 1 shows the results of hEPO expression measured after intravenous administration of various nanoparticle compositions containing compounds 26, 18, 25, and MC3 to rats at various doses, respectively. [Figure 4] 1 shows the results of hEPO expression measured after intravenous administration of various nanoparticle compositions containing compounds 26, 18, 25, and MC3 to rats at various doses, respectively. [Figure 5] 1 shows the results of hEPO expression measured after intravenous administration of various nanoparticle compositions containing compounds 26, 18, 25, and MC3 to rats at various doses, respectively. [Figure 6] 1 shows the results of hEPO expression measured after intravenous administration of various nanoparticle compositions containing compounds 26, 18, 25, and MC3 to rats at various doses, respectively. [Figure 7] FIG. 1 shows the area under the curve (AUC) for nanoparticle compositions comprising compounds 18, 25, and 26 and MC3 at various doses ranging from 0.005 mpk to 2 mpk. [Figure 8]Figure 1 shows the results of luciferase expression measured after intramuscular administration of various nanoparticle compositions containing MC3, compounds 168-170, and 173-175 to mice at 0.01 mpk at various time points: 3 hours (left panel), 6 hours (middle panel), and 24 hours (right panel). Numbers 1-7 in this figure correspond to MC3, compounds 168-170, and 173-175, respectively. [Figure 9] Figure 1 shows the results of hEPO expression measured after intramuscular administration of various nanoparticle compositions containing MC3, compounds 18, 25, 30, 108-112, 60, and 122 to mice at 0.01 mpk at various time points: 3 hours (left panel), 6 hours (middle panel), and 24 hours (right panel). Numbers 1-11 in this figure correspond to MC3, compounds 18, 25, 30, 108-112, 60, and 122, respectively. [Figure 10] Figure 1 shows the results of luciferase expression (total luminous flux) measured after intravenous administration of various nanoparticle compositions containing MC3 or various compounds disclosed herein, where numbers 1-12 correspond to compound 18, MC3, compounds 48-50, 54, 111, 60, 75, 68, 66, 128, 65, 130, 133-135, 147, 96, and 151, respectively. [Figure 11] Figure 1 shows the results of anti-HA (anti-hemagglutinin) antibody expression measured after intravenous administration of various nanoparticle compositions containing MC3 and compound 18 at a dose of 0.1 mpk (A) or 0.3 mpk (B) via a 60-minute infusion to naive cynomolgus monkeys. [Figure 12-1] A series of graphs summarizing luciferase expression levels in mice at (A) 3 hours, (B) 6 hours, and (C) 24 hours after intravenous administration of nanoparticle compositions containing compounds of the present disclosure. Total luminous flux values were obtained by body luminescence imaging (BLI). In the figures, numbers 1-14 refer to compositions containing compounds 160, 98, 161-165, 171, 172, 183-186, and MC3, respectively. [Figure 12-2]A series of graphs summarizing luciferase expression levels in mice at (A) 3 hours, (B) 6 hours, and (C) 24 hours after intravenous administration of nanoparticle compositions containing compounds of the present disclosure. Total luminous flux values were obtained by body luminescence imaging (BLI). In the figures, numbers 1-14 refer to compositions containing compounds 160, 98, 161-165, 171, 172, 183-186, and MC3, respectively. [Figure 13-1] A series of graphs summarizing luciferase expression levels in mice (A) 3 hours, (B) 6 hours, and (C) 24 hours after intravenous administration of nanoparticle compositions containing compounds of the present disclosure. Total luminous flux values were obtained by body luminescence imaging (BLI). PBS (phosphate-buffered saline) was used as a control. Results are presented on a logarithmic scale. In these figures, numbers 1-15 refer to compositions containing MC3, compounds 18, 111, 168-170, 174, 175, 178, 179, 181, 182, 218, 198, and PBS, respectively. [Figure 13-2] A series of graphs summarizing luciferase expression levels in mice (A) 3 hours, (B) 6 hours, and (C) 24 hours after intravenous administration of nanoparticle compositions containing compounds of the present disclosure. Total luminous flux values were obtained by body luminescence imaging (BLI). PBS (phosphate-buffered saline) was used as a control. Results are presented on a logarithmic scale. In these figures, numbers 1-15 refer to compositions containing MC3, compounds 18, 111, 168-170, 174, 175, 178, 179, 181, 182, 218, 198, and PBS, respectively. [Figure 14-1] A series of graphs summarizing ex vivo luciferase expression levels in (A) liver, (B) spleen, and (C) kidney of mice 6 hours after intravenous administration of nanoparticle compositions containing compounds of the present disclosure. Total flux values were obtained by body luminescence imaging (BLI). PBS (phosphate-buffered saline) was used as a control. In these figures, numbers 1-15 refer to compositions containing MC3, compounds 18, 111, 168-170, 174, 175, 178, 179, 181, 182, 218, 198, and PBS, respectively. [Figure 14-2]A series of graphs summarizing ex vivo luciferase expression levels in (A) liver, (B) spleen, and (C) kidney of mice 6 hours after intravenous administration of nanoparticle compositions containing compounds of the present disclosure. Total flux values were obtained by body luminescence imaging (BLI). PBS (phosphate-buffered saline) was used as a control. In these figures, numbers 1-15 refer to compositions containing MC3, compounds 18, 111, 168-170, 174, 175, 178, 179, 181, 182, 218, 198, and PBS, respectively. [Figure 15] A pair of graphs showing the frequency of activated B cells in the spleens of CD-1 mice administered a compound of the present disclosure compared to MC3 and compared to mice not receiving any treatment (naive test subjects). PBS was used as a control. A shows the percentage of CD19+ cells. B shows the percentage of CD19+CD69+CD86+ cells. Numbers 1-16 refer to compositions containing luciferase-expressing mRNA, including: 1: MC3; 2: Compound 18; 3: Compound 111; 4: Compound 168; 5: Compound 169; 6: Compound 170; 7: Compound 174; 8: Compound 175; 9: Compound 178; 10: Compound 179; 11: Compound 181; 12: Compound 182; 13: Compound 218; 14: Compound 198; 15: PBS; and 16: naive test subjects. [Figure 16] A pair of graphs showing the frequency of activated B cells in the spleens of CD-1 mice administered a compound of the present disclosure compared to MC3 and compared to mice not receiving any treatment (naive test subjects). PBS was used as a control. A shows the percentage of CD19+ cells. B shows the percentage of CD19+CD69+CD86+ cells. Numbers 1-14 refer to compositions containing mRNA expressing luciferase and the following: 1: Compound 147, 2: Compound 184, 3: Compound 232; 4: Compound 189; 5: Compound 200; 6: Compound 233; 7: Compound 234; 8: Compound 235; 9: Compound 237; 10: Compound 239; 11: Compound 243; 12: MC3; 13: PBS; 14: naive test subjects. [Figure 17]Graph showing hEPO mRNA expression in CD1 mice measured 3 hours (left panel), 6 hours (middle panel), and 24 hours (right panel) after intravenous administration of various nanoparticle compositions. Numbers 1-13 refer to compositions containing hEPO-expressing mRNA and the following: 1: Compound 147, 2: Compound 184, 3: Compound 232; 4: Compound 189; 5: Compound 200; 6: Compound 233; 7: Compound 234; 8: Compound 235; 9: Compound 237; 10: Compound 239; 11: Compound 243; 12: MC3; 13: PBS. [Figure 18] Figure 1 shows the results of luciferase expression measured after intramuscular administration of various nanoparticle compositions at 0.01 mpk to CD-1 mice. (A) Bar graph showing total luminous flux at 6 hours post-administration. Numbers above each bar indicate the expression ratio compared to MC3. (B) Total luminous flux at 3, 6, and 24 hours post-administration. Numbers 1-11 in the figure refer to compositions containing the following: 1: MC3; 2: Compound 143; 3: Compound 49; 4: Compound 113; 5: Compound 61; 6: Compound 72; 7: Compound 75; 8: Compound 71; 9: Compound 128; 10: Compound 156; and 11: Compound 157. [Figure 19] Figure 1 shows the results of luciferase expression measured after subcutaneous administration of various nanoparticle compositions at 0.05 mpk to CD-1 mice. (A) Bar graph showing total luminous flux at 6 hours post-administration. Numbers above each bar indicate the expression ratio compared to MC3. (B) Total luminous flux at 3, 6, and 24 hours post-administration. Numbers 1-12 in the figure refer to compositions containing the following: 1: PBS; 2: MC3; 3: Compound 25; 4: Compound 30; 5: Compound 20; 6: Compound 110; 7: Compound 112; 8: Compound 113; 9: Compound 72; 10: Compound 75; 11: Compound 122; 12: Compound 24. [Figure 20]A series of graphs summarizing ex vivo luciferase expression levels in (A) the spleen, (B) the liver, and (C) the injection site 24 hours after administration of nanoparticle compositions containing compounds of the present disclosure to CD-1 mice. Total luminous flux values were obtained by body luminescence imaging (BLI). PBS (phosphate-buffered saline) was used as a control. Numbers 1-12 in the figures refer to compositions containing the following: 1: PBS; 2: MC3; 3: Compound 25; 4: Compound 30; 5: Compound 20; 6: Compound 110; 7: Compound 112; 8: Compound 113; 9: Compound 72; 10: Compound 75; 11: Compound 122; 12: Compound 24. [Figure 21-1] A series of graphs showing cytokine expression induced by compositions comprising lipids of the present disclosure. A: G-CSF (12); B: IFN-gamma (38); C: MCP-1 (51); D: IFN-alpha (30); E: IL-6 (28); F: IL-12p70 (39); G: IL-10 (22); H: MIP-1 beta (72); I: TNF-alpha (45); J: RANTES (44). Numbers 1-12 in the figures refer to compositions containing the following: 1: PBS; 2: MC3; 3: Compound 25; 4: Compound 30; 5: Compound 20; 6: Compound 110; 7: Compound 112; 8: Compound 113; 9: Compound 72; 10: Compound 75; 11: Compound 122; 12: Compound 24. [Figure 21-2] A series of graphs showing cytokine expression induced by compositions comprising lipids of the present disclosure. A: G-CSF (12); B: IFN-gamma (38); C: MCP-1 (51); D: IFN-alpha (30); E: IL-6 (28); F: IL-12p70 (39); G: IL-10 (22); H: MIP-1 beta (72); I: TNF-alpha (45); J: RANTES (44). Numbers 1-12 in the figures refer to compositions containing the following: 1: PBS; 2: MC3; 3: Compound 25; 4: Compound 30; 5: Compound 20; 6: Compound 110; 7: Compound 112; 8: Compound 113; 9: Compound 72; 10: Compound 75; 11: Compound 122; 12: Compound 24. [Figure 21-3]A series of graphs showing cytokine expression induced by compositions comprising lipids of the present disclosure. A: G-CSF (12); B: IFN-gamma (38); C: MCP-1 (51); D: IFN-alpha (30); E: IL-6 (28); F: IL-12p70 (39); G: IL-10 (22); H: MIP-1 beta (72); I: TNF-alpha (45); J: RANTES (44). Numbers 1-12 in the figures refer to compositions containing the following: 1: PBS; 2: MC3; 3: Compound 25; 4: Compound 30; 5: Compound 20; 6: Compound 110; 7: Compound 112; 8: Compound 113; 9: Compound 72; 10: Compound 75; 11: Compound 122; 12: Compound 24. [Figure 22] A series of graphs summarizing luciferase expression levels in mice (A) 3 hours, (B) 6 hours, and (C) 24 hours after subcutaneous administration of nanoparticle compositions containing compounds of the present disclosure. Total luminous flux values were obtained by body luminescence imaging (BLI). PBS (phosphate-buffered saline) was used as a control. In these figures, numbers 1-12 refer to compositions containing the following, respectively: 1: PBS; 2: MC3; 3: Compound 168; 4: Compound 23; 5: Compound 19; 6: Compound 108; 7: Compound 109; 8: Compound 111; 9: Compound 60; 10: Compound 61; 11: Compound 69; 12: Compound 128. [Figure 23] Figure 1 shows the results of hEPO expression measured at various time points: 3 hours (left block), 6 hours (middle block), and 24 hours (right block) after subcutaneous administration of various nanoparticle compositions containing compounds of the present disclosure at 0.05 mpk to mice, where numbers 1-11 correspond to MC3, PBS, and compounds 18, 25, 48, 49, 111, 60, 168, 207, and 233, respectively. [Figure 24] Figure 1 shows the results of luciferase expression measured at various time points: 3 hours (left panel), 6 hours (middle panel), and 24 hours (right panel) after intramuscular administration of various nanoparticle compositions containing compounds of the present disclosure at 0.01 mpk to mice, where numbers 1-9 correspond to MC3 and compounds 178, 181, 182, 218, 198, 200, 233, and 239, respectively. [Figure 25] Figure 1 shows the results of hEPO expression measured 3, 6, and 24 hours after intravenous administration to CD-1 mice of nanoparticle compositions containing Compound 18 or MC3 at 0.5 mpk and modified mRNA in which each uridine has been replaced with either N1-methylpseudouridine or 5-methoxyuridine. In this figure, numbers 1-4 refer to compositions containing: 1: modified mRNA in which each uridine has been replaced with 5-methoxyuridine and MC3; 2: modified mRNA in which each uridine has been replaced with N1-methylpseudouridine and MC3; 3: modified mRNA in which each uridine has been replaced with 5-methoxyuridine and Compound 18; 4: modified mRNA in which each uridine has been replaced with N1-methylpseudouridine and Compound 18. [Figure 26] This graph shows B cell activation in mouse splenocytes administered nanoparticle compositions containing Compound 18 or MC3 and modified mRNA in which each uridine was replaced with either N1-methylpseudouridine or 5-methoxyuridine. PBS was used as a control. In this figure, numbers 1-5 refer to compositions containing the following: 1: modified mRNA in which each uridine was replaced with 5-methoxyuridine and MC3; 2: modified mRNA in which each uridine was replaced with N1-methylpseudouridine and MC3; 3: modified mRNA in which each uridine was replaced with 5-methoxyuridine and Compound 18; 4: modified mRNA in which each uridine was replaced with N1-methylpseudouridine and Compound 18; 5: PBS. [Figure 27] Graph showing hEPO mRNA expression in CD1 mice measured 3 hours (left panel), 6 hours (middle panel), and 24 hours (right panel) after subcutaneous administration of various nanoparticle compositions at 0.5 mpk. Numbers 1-9 refer to compositions containing hEPO-expressing mRNA and the following: 1: PBS, 2: Compound 18, 3: Compound 30; 4: Compound 96; 5: Compound 151; 6: Compound 98; 7: Compound 163; 8: Compound 164; 9: Compound 165. [Figure 28-1]
[0023] Figure 1 is a series of graphs showing cytokine expression induced by a composition comprising a lipid of the present disclosure and a modified mRNA expressing hEPO in which each uridine has been replaced with N1-methylpseudouridine, measured 6 hours after subcutaneous administration to CD-1 mice. A: G-CSF; B: IFN-gamma; C: IFN-alpha; D: IL-12p70; E: IP-10; F: IL-6; G: MCP-1; H: MIP-1 beta; I: RANTES; J: TNF-alpha. Numbers 1-9 in the figures refer to compositions containing: 1: PBS; 2: Compound 18; 3: Compound 30; 4: Compound 96; 5: Compound 151; 6: Compound 98; 7: Compound 163; 8: Compound 164; and 9: Compound 165. [Figure 28-2]
[0023] Figure 1 is a series of graphs showing cytokine expression induced by a composition comprising a lipid of the present disclosure and a modified mRNA expressing hEPO in which each uridine has been replaced with N1-methylpseudouridine, measured 6 hours after subcutaneous administration to CD-1 mice. A: G-CSF; B: IFN-gamma; C: IFN-alpha; D: IL-12p70; E: IP-10; F: IL-6; G: MCP-1; H: MIP-1 beta; I: RANTES; J: TNF-alpha. Numbers 1-9 in the figures refer to compositions containing: 1: PBS; 2: Compound 18; 3: Compound 30; 4: Compound 96; 5: Compound 151; 6: Compound 98; 7: Compound 163; 8: Compound 164; and 9: Compound 165. [Figure 28-3]
[0023] Figure 1 is a series of graphs showing cytokine expression induced by a composition comprising a lipid of the present disclosure and a modified mRNA expressing hEPO in which each uridine has been replaced with N1-methylpseudouridine, measured 6 hours after subcutaneous administration to CD-1 mice. A: G-CSF; B: IFN-gamma; C: IFN-alpha; D: IL-12p70; E: IP-10; F: IL-6; G: MCP-1; H: MIP-1 beta; I: RANTES; J: TNF-alpha. Numbers 1-9 in the figures refer to compositions containing: 1: PBS; 2: Compound 18; 3: Compound 30; 4: Compound 96; 5: Compound 151; 6: Compound 98; 7: Compound 163; 8: Compound 164; and 9: Compound 165. [Figure 29]A series of graphs showing optimization of aminolipid efficacy and clearance. A. Systemic luciferase bioluminescence of novel LNPs versus MC3 LNPs measured in CD-1 mice (n=6) 6 hours after intravenous administration of 0.5 mg / kg hEPO mRNA in lipid. The graph shows serum hEPO concentrations; error bars indicate standard deviation of the ratio of novel lipid expression to MC3 expression. *p<0.05, **p<0.01, ***p<0.001, ns=not statistically significant. Numbers 1-9 refer to compositions containing the following: 1: Compound 281; 2: Compound 138; 3: Compound 136; 4: Compound 6; 5: Compound 18; 6: Compound 29; 7: Compound 14; 8: Compound 25; and 9: Compound 26. Figure 1B summarizes the levels of Compound 18 and Compound 25 measured in liver tissue from Sprague Dawley rats (n = 3 per time point) administered a 0.2 mg / kg dose of hEPO mRNA-containing LNPs compared to MC3. p < 0.05 for the AUC of Compound 18 and Compound 25 compared to MC3. Figure 1C is a graph showing hEPO expression in Sprague Dawley rats. hEPO serum concentrations were measured after intravenous administration of a 1 mg / kg dose of Compound 18, Compound 25, Compound 26, or MC3 and LNPs (n = 3) containing hEPO mRNA. [Figure 30] A series of graphs showing the pharmacokinetics and expression profile of compound 18 after multiple administration. (A) Comparison of tissue distribution of MC3 and compound 18 after weekly intravenous administration of three bolus doses containing 0.05 mg / kg mRNA to CD-1 mice (n=3 per time point). (B) Serum hEPO concentrations 6 hours after weekly intravenous administration of a bolus dose containing 0.5 mg / kg hEPO mRNA-containing LNPs to CD-1 mice (n=8). (C) Liver tissue clearance of compound 18 and its primary metabolite, compound 166, after weekly administration of a 0.25 mg / kg mRNA-containing dose to CD-1 mice (n=3 per time point). [Figure 31]A series of graphs showing the expression profile of lipid nanoparticles of the present disclosure in a cynomolgus monkey study. A shows hEPO serum concentrations after delivery of 0.01 mg / kg hEPO mRNA in MC3 or Compound 18. Liquid nanoparticles were administered intravenously via a 60-minute infusion (n=3). p<0.05 for Compound 18 AUC compared to MC3. B shows human IgG influenza A antibody serum concentrations after delivery of 0.3 mg / kg MC3 or Compound 18 antibody mRNA in LNP administered intravenously via a 60-minute infusion (n=3). p<0.05 for Compound 18 AUC compared to MC3. C shows hEPO serum concentrations after delivery of 0.2 mg / kg of hEPO mRNA in Compound 18 LNP administered intravenously via a 60-minute infusion (n=4) once weekly. [Figure 32]A series of graphs summarizing the results of a 1-month toxicology evaluation in rats and non-human primates. PBS (phosphate-buffered saline) was used as a control. (A) Serum alanine aminotransferase levels in Sprague-Dawley rats administered intravenously via a 10-minute infusion once weekly for 5 weeks. Serum levels were measured 24 hours after the fifth dose (n=10). No statistical differences were observed between PBS and each dose level. (B) Serum aspartate aminotransferase levels in Sprague-Dawley rats administered intravenously via a 10-minute infusion once weekly for 5 weeks. Serum levels were measured 24 hours after the fifth dose (n=10). *p<0.05, no statistical difference between PBS and the 0.05 and 2.0 mg / kg doses. (C) Serum alanine aminotransferase levels in cynomolgus monkeys administered 1 mg / kg mRNA intravenously via a 60-minute infusion once weekly. Serum levels were measured 24 hours after the fifth dose (n=4). No statistical difference was observed between pre-dose PBS and day 30 levels of Compound 18. D shows serum aspartate aminotransferase levels in cynomolgus monkeys administered 1 mg / kg mRNA intravenously via a 60-minute infusion administered once weekly. Serum levels were measured 24 hours after the fifth dose (n=4). No statistical difference was observed between pre-dose PBS and day 30 levels of Compound 18. [Figure 33] A pair of graphs summarizing the results of a one-month toxicology evaluation in rats and non-human primates. A shows C5b9 serum concentrations on days 1 and 29 in cynomolgus monkeys administered 1 mg / kg of mRNA (n=4). No statistical difference was observed between PBS and Compound 18 at any time point. B shows MCP-1 serum concentrations on days 1 and 29 in cynomolgus monkeys administered 1 mg / kg of mRNA. n=4, *p<0.05, no statistical difference was observed between PBS and Compound 18 at any other time point. [Figure 34]Figure 1 shows a series of fixed cell images of the endosomal escape efficiency of lipid nanoparticles of the present disclosure. HeLa cells were transfected with rhodamine-labeled MC3 and Compound 18 LNPs encapsulating luciferase mRNA. After 4 hours of incubation, unformulated mRNA was processed for single-molecule FISH (smFISH, red) along with electroporated cells. mRNA molecules that exited the endocytic organelle into the cytosol are shown in green (image analysis overlap). Endosomal escape efficiency was assessed by computing the ratio between the number of cytosolic mRNAs and the number of internalized LNPs per cell. (A) Image showing electroporated HeLa cells. (B) Image showing MC3-treated HeLa cells. (C) Image showing Compound 18-treated HeLa cells. [Figure 35] A pair of graphs comparing the tissue distribution of MC3 and Compound 18. A shows the tissue distribution of MC3 and Compound 18 after three intravenous administrations of 0.05 mg / kg mRNA to CD-1 mice (n=3 per time point). B shows the tissue distribution of MC3 and Compound 18 at 12 hours after administration of 0.2 mg / kg mRNA to cynomolgus monkeys (n=2). [Figure 36] Graph showing human IgG expression in cynomolgus monkeys administered 0.1 mg / kg of human IgG mRNA intravenously via a 60-minute infusion in a composition containing MC3 or Compound 18 (n=3). [Figure 37] A series of graphs showing MC3 single-cell necrosis in rat livers and liver enzymes. The top row is a pair of images of the livers of rats administered 0.3 mg / kg of non-mRNA-containing liquid nanoparticles (LNPs) (right) and PBS (phosphate-buffered saline) (left) as a control. The bottom row is a pair of graphs showing the expression of ALT (left) and AST (right) in the liver after administration of 0.3 mg / kg of mRNA-containing MC3-based LNPs. ALT and AST were elevated, and pathology showed evidence of necrosis. [Figure 38] Graph showing mRNA levels in NHPs after repeated dosing over 29 days. [Figure 39] A pair of graphs showing hEPO expression in ApoE knockout mice and LDLr knockout mice administered compound 18-based LNPs. (A) shows hEPO expression in ApoE knockout mice. (B) shows hEPO expression in LDLr knockout mice. DETAILED DESCRIPTION OF THE INVENTION
[0043] The present disclosure relates to novel lipids and lipid nanoparticle compositions comprising the novel lipids. The present disclosure also provides methods for delivering therapeutic and / or prophylactic agents to mammalian cells, particularly methods for delivering therapeutic and / or prophylactic agents to mammalian organs, methods for producing a polypeptide of interest in mammalian cells, and methods for treating a disease or disorder in a mammal in need thereof. For example, a method for producing a polypeptide of interest in a cell can include contacting a nanoparticle composition comprising mRNA with a mammalian cell, whereby the mRNA can be translated to produce the polypeptide of interest. A method for delivering a therapeutic and / or prophylactic agent to a mammalian cell or organ can include administering to a subject a nanoparticle composition comprising the therapeutic and / or prophylactic agent, whereby the administration includes contacting the cell or organ with the composition, whereby the therapeutic and / or prophylactic agent is delivered to the cell or organ.
[0044] lipids The present disclosure provides lipids comprising a central amine moiety and at least one biodegradable group. The lipids described herein can be advantageously used in lipid nanoparticle compositions for the delivery of therapeutic and / or prophylactic agents to mammalian cells or organs. For example, the lipids described herein have little or no immunogenicity. For example, a lipid compound of any of formulas (I), (IA), (IB), (II), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), or (III) has lower immunogenicity compared to a control lipid (e.g., MC3, KC2, or DLinDMA). For example, a formulation comprising a lipid disclosed herein and a therapeutic or prophylactic agent has an increased therapeutic index compared to a corresponding formulation comprising a control lipid (e.g., MC3, KC2, or DLinDMA) and the same therapeutic or prophylactic agent.
[0045] In a first aspect of the present invention, the compounds described herein have the formula (I): [ka] (In the formula: R1 is C 5~30 Alkyl, C 5~20 Alkenyl, -R * selected from the group consisting of -YR", -YR", and -R"M'R'; R2 and R3 are independently H, C 1~14 Alkyl, C 2~14 Alkenyl, -R * YR”, -YR”, and -R * OR”, or R2 and R3 together with the atoms to which they are attached form a heterocycle or a carbocycle; R4 is hydrogen, C 3~6 Carbocyclic ring, -(CH2) n Q, -(CH2) n CHQR, -(CH2) o C(R 10 )2(CH2) n~o Q, -CHQR, -CQ(R)2, and unsubstituted C 1~6alkyl, where Q is a carbocycle, a heterocycle, -OR, -O(CH) n N(R)2, -C(O)OR, -OC(O)R, -CX3, -CX2H, -CXH2, -CN, -N(R)2, -C(O)N(R)2, -N(R)C(O)R , -N(R)S(O)2R, -N(R)C(O)N(R)2, -N(R)C(S)N(R)2, -N(R)R8, -N(R)S(O)2R8, -O(CH2) n OR, -N(R)C(=NR9)N(R)2, -N(R)C(=CHR9)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(OR)C (O)R, -N(OR)S(O)2R, -N(OR)C(O)OR, -N(OR)C(O)N(R)2, -N(OR)C(S)N(R)2, -N(OR)C(= -NR9)N(R), -N(OR)C(=CHR9)N(R), -C(=NR9)N(R), -C(=NR9)R, -C(O)N(R)OR, and -C(R)N(R)C(O)OR, wherein each o is independently selected from 1, 2, 3, and 4, and each n is independently selected from 1, 2, 3, 4, and 5; Each R5 is independently OH, C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; Each R6 is independently OH, C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; M and M′ are independently selected from —C(O)O—, —OC(O)—, —OC(O)—M″—C(O)O—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)—, —SS—, an aryl group, and a heteroaryl group; 1~13 Alkyl or C 2~13 is alkenyl; R7 is C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; R8, C 3~6selected from the group consisting of carbocycles and heterocycles; R9 is H, CN, NO2, C 1~6 Alkyl, -OR, -S(O)2R, -S(O)2N(R)2, C 2~6 Alkenyl, C 3~6 selected from the group consisting of carbocycles and heterocycles; R 10 But H, OH, C 1~3 Alkyl, and C 2~3 alkenyl; Each R is independently C 1~3 Alkyl, C 2~3 Alkenyl, (CH2) q OR * selected from the group consisting of each q is independently selected from 1, 2, and 3; Each R' is independently C 1~18 Alkyl, C 2~18 Alkenyl, -R * selected from the group consisting of Y-R″, -Y-R″, and H; Each R" is independently C 3~15 Alkyl and C 3~15 alkenyl; Each R * But independently, C 1~12 Alkyl and C 2~12 alkenyl; Each Y is independently C 3~6 It is a carbocyclic ring; each X is independently selected from the group consisting of F, Cl, Br, and I; m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13; and wherein R4 is -(CH2) n Q, -(CH2) n When n is 1, 2, 3, 4, or 5, Q is not -N(R) or (ii) when n is 1 or 2, Q is not a 5-, 6-, or 7-membered heterocycloalkyl. or an N-oxide thereof, or a salt or isomer thereof.
[0046] Another aspect of the present disclosure is a compound of formula (III): [ka] (In the formula, R1 is C 5~30 Alkyl, C 5~20 Alkenyl, -R * selected from the group consisting of -YR", -YR", and -R"M'R'; R2 and R3 are independently H, C 1~14 Alkyl, C 2~14 Alkenyl, -R * YR”, -YR”, and -R * OR”, or R2 and R3 together with the atom to which they are attached form a heterocyclic or carbocyclic ring; R4 is hydrogen, C 3~6 Carbocyclic ring, -(CH2) n Q, -(CH2) n CHQR, -(CH2) o C(R 10 )2(CH2) n~o Q, -CHQR, -CQ(R)2, and unsubstituted C 1~6 alkyl, where Q is a carbocycle, a heterocycle, -OR, -O(CH) n N(R)2, -C(O)OR, -OC(O)R, -CX3, -CX2H, -CXH2, -CN, -N(R)2, -C(O)N(R)2, -N(R)C(O) R, -N(R)S(O)2R, -N(R)C(O)N(R)2, -N(R)C(S)N(R)2, N(R)R8, -N(R)S(O)2R8, -O(CH2) nOR, -N(R)C(=NR9)N(R)2, -N(R)C(=CHR9)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(OR)C (O)R, -N(OR)S(O)2R, -N(OR)C(O)OR, -N(OR)C(O)N(R)2, -N(OR)C(S)N(R)2, -N(OR)C(= -NR9)N(R), -N(OR)C(=CHR9)N(R), -C(=NR9)N(R), -C(=NR9)R, -C(O)N(R)OR, and -C(R)N(R)C(O)OR, wherein each o is independently selected from 1, 2, 3, and 4, and each n is independently selected from 1, 2, 3, 4, and 5; R x But C 1~6 Alkyl, C 2~6 Alkenyl, -(CH2) r OH, and -(CH2) r NR2, where r is selected from 1, 2, 3, 4, 5, and 6; Each R5 is independently OH, C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; Each R6 is independently OH, C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; M and M′ are independently selected from —C(O)O—, —OC(O)—, —OC(O)—M″—C(O)O—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)—, —SS—, an aryl group, and a heteroaryl group; 1~13 Alkyl or C 2~13 is alkenyl; R7 is C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl, and H; R8, C 3~6 selected from the group consisting of carbocycles and heterocycles; R9 is H, CN, NO2, C 1~6Alkyl, -OR, -S(O)2R, -S(O)2N(R)2, C 2~6 Alkenyl, C 3~6 selected from the group consisting of carbocycles and heterocycles; R 10 But H, OH, C 1~3 Alkyl, and C 2~3 alkenyl; Each R is independently C 1~3 Alkyl, C 2~3 Alkenyl, (CH2) q OR * and H; each q is independently selected from 1, 2, and 3; Each R' is independently C 1~18 Alkyl, C 2~18 Alkenyl, -R * selected from the group consisting of Y-R", -Y-R", and H; Each R" is independently C 3~15 Alkyl and C 3~15 alkenyl; Each R * But independently, C 1~12 Alkyl and C 2~12 alkenyl; Each Y is independently C 3~6 It is a carbocyclic ring; each X is independently selected from the group consisting of F, Cl, Br, and I; m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13 or an N-oxide thereof, or a salt or isomer thereof.
[0047] In certain embodiments, a subset of compounds of formula (I) is of formula (IA): [ka] (In the formula, l is selected from 1, 2, 3, 4, and 5; m is selected from 5, 6, 7, 8, and 9; M is a bond or M'; R is hydrogen, unsubstituted C1~3 Alkyl, -(CH2) o C(R 10 )2(CH2) n~o Q, or -(CH2) n Q, where Q is OH, —NHC(S)N(R), —NHC(O)N(R), —N(R)C(O)R, —N(R)S(O)R, —N(R)R, —NHC(═NR)N(R), —NHC(═CHR)N(R), —OC(O)N(R), —N(R)C(O)OR, heteroaryl, or heterocycloalkyl; M and M′ are independently selected from —C(O)O—, —OC(O)—, —OC(O)—M″—C(O)O—, —C(O)N(R′)—, —P(O)(OR′)O—, —SS—, an aryl group, and a heteroaryl group; R and R are independently selected from H, C 1~14 Alkyl, and C 2~14 For example, m is 5, 7, or 9. For example, Q is OH, -NHC(S)N(R), or -NHC(O)N(R). For example, Q is -N(R)C(O)R, or -N(R)S(O)R.
[0048] In certain embodiments, a subset of compounds of formula (I) is of formula (IB): [ka] wherein all variables are as defined herein, or an N-oxide thereof, or a salt or isomer thereof. For example, m is selected from 5, 6, 7, 8, and 9; M and M′ are independently selected from —C(O)O—, —OC(O)—, —OC(O)—M″—C(O)O—, —C(O)N(R′)—, —P(O)(OR′)O—, —SS—, an aryl group, and a heteroaryl group; R2 and R3 are independently selected from H, C 1~14 Alkyl, and C 2~14alkenyl. For example, m is 5, 7, or 9. In certain embodiments, a subset of compounds of formula (I) is selected from the group consisting of: [ka] wherein l is selected from 1, 2, 3, 4, and 5; M is a bond or M'; and R is hydrogen, unsubstituted C 1~3 Alkyl, -(CH2) o C(R 10 )2(CH2) n~o Q, or -(CH2) n Q, where n is 2, 3, or 4, and Q is OH, —NHC(S)N(R), —NHC(O)N(R), —N(R)C(O)R, —N(R)S(O)R, —N(R)R, —NHC(═NR)N(R), —NHC(═CHR)N(R), —OC(O)N(R), —N(R)C(O)OR, heteroaryl, or heterocycloalkyl; M and M′ are independently selected from —C(O)O—, —OC(O)—, —OC(O)—M″—C(O)O—, —C(O)N(R′)—, —P(O)(OR′)O—, —SS—, an aryl group, and a heteroaryl group; R and R are independently selected from H, C 1~14 Alkyl, and C 2~14 alkenyl) or an N-oxide thereof, or a salt or isomer thereof.
[0049] Compounds of any one of formula (I) or (IA) include one or more of the following features, as applicable: In some embodiments, M1 is M'.
[0050] In certain embodiments, M and M' are independently -C(O)O- or -OC(O)-. In certain embodiments, at least one of M and M' is -C(O)O- or -OC(O)-.
[0051] In certain embodiments, at least one of M and M' is -OC(O)-.
[0052] In certain embodiments, M is -OC(O)- and M' is -C(O)O-. In some embodiments, M is -C(O)O- and M' is -OC(O)-. In certain embodiments, M and M' are each -OC(O)-. In some embodiments, M and M' are each -C(O)O-.
[0053] In certain embodiments, at least one of M and M' is -OC(O)-M"-C(O)O-.
[0054] In some embodiments, M and M' are independently -SS-.
[0055] In certain embodiments, at least one of M and M' is -SS.
[0056] In some embodiments, one of M and M' is -C(O)O- or -OC(O)- and the other is -SS-. For example, M is -C(O)O- or -OC(O)- and M' is -SS-, or M' is -C(O)O- or -OC(O)- and M is -SS-.
[0057] In certain embodiments, one of M and M′ is —OC(O)—M″—C(O)O—, where M″ is a bond, C 1~13 Alkyl or C 2~13 In another embodiment, M" is C 1~6 Alkyl or C 2~6 In certain embodiments, M" is C 1~4 Alkyl or C 2~4 It is alkenyl.
[0058] In certain embodiments, 1 is 1, 3, or 5.
[0059] In some embodiments, R4 is hydrogen.
[0060] In some embodiments, R4 is not hydrogen.
[0061] In certain embodiments, R4 is unsubstituted methyl or -(CH2) n Q, where Q is OH, —NHC(S)N(R)2, —NHC(O)N(R)2, —N(R)C(O)R, or —N(R)S(O)2R.
[0062] In some embodiments, Q is OH.
[0063] In some embodiments, Q is —NHC(S)N(R) 2 .
[0064] In some embodiments, Q is —NHC(O)N(R) 2 .
[0065] In certain embodiments, Q is —N(R)C(O)R.
[0066] In certain embodiments, Q is —N(R)S(O)R.
[0067] In one embodiment, Q is —O(CH) n N(R)2.
[0068] In one embodiment, Q is —O(CH) n It is OR.
[0069] In some embodiments, Q is —N(R)R 8 .
[0070] In some embodiments, Q is —NHC(═NR 9 )N(R) 2 .
[0071] In some embodiments, Q is —NHC(═CHR 9 )N(R) 2 .
[0072] In some embodiments, Q is —OC(O)N(R) 2 .
[0073] In certain embodiments, Q is —N(R)C(O)OR.
[0074] In some embodiments, n is 2.
[0075] In some embodiments, n is 3.
[0076] In some embodiments, n is 4.
[0077] In one embodiment, M1 is absent.
[0078] In some embodiments, at least one R5 is hydroxyl, e.g., one R5 is hydroxyl.
[0079] In some embodiments, at least one R6 is hydroxyl, e.g., one R6 is hydroxyl.
[0080] In some embodiments, one of R5 and R6 is hydroxyl. For example, one R5 is hydroxyl and each R6 is hydrogen. For example, one R6 is hydroxyl and each R5 is hydrogen.
[0081] In one embodiment, R x C 1~6 In one embodiment, R x But C 1~3 alkyl. For example, R x is methyl. For example, R x is ethyl. For example, R x is propyl.
[0082] In one embodiment, R x -(CH2) r OH and r is 1, 2 or 3. For example, R x is methanoyl. For example, R x is ethanoyl. For example, R xis propanoyl.
[0083] In one embodiment, R x Ga-(CH2) r NR2, where r is 1, 2, or 3, and each R is H or methyl. For example, R x is methaneamino, methylmethaneamino, or dimethylmethaneamino. For example, R x is aminomethanil, methylaminomethanil, or dimethylaminomethanil. For example, R x is aminoethanyl, methylaminoethanyl, or dimethylaminoethanyl. For example, R x is aminopropanyl, methylaminopropanyl, or dimethylaminopropanyl.
[0084] In some embodiments, R' is C 1~18 Alkyl, C 2~18 Alkenyl, -R * YR”, or -YR”.
[0085] In one embodiment, R2 and R3 are independently selected from the group consisting of C 3~14 Alkyl or C 3~14 It is alkenyl.
[0086] In one embodiment, the compound of formula (I) has the formula (IIa) [ka] or an N-oxide thereof, or a salt or isomer thereof, wherein R4 is as described herein.
[0087] In another embodiment, the compound of formula (I) has the formula (IIb) [ka] or an N-oxide thereof, or a salt or isomer thereof, wherein R4 is as described herein.
[0088] In another embodiment, the compound of formula (I) has formula (IIc) or (IIe): [ka] or an N-oxide thereof, or a salt or isomer thereof, wherein R4 is as described herein.
[0089] In another embodiment, the compound of formula (I) has the formula (IIf): [ka] (Wherein M is —C(O)O— or —OC(O)—, M″ is C 1~6 Alkyl or C 2~6 alkenyl, and R and R are independently selected from the group consisting of C 5~14 Alkyl and C 5~14 alkenyl, and n is selected from 2, 3, and 4), or an N-oxide thereof, or a salt or isomer thereof.
[0090] In a further embodiment, the compound of formula (I) has the formula (IId) [ka] wherein n is 2, 3, or 4; m, R′, R″, and R2-R6 are as described herein, or an N-oxide thereof, or a salt or isomer thereof. For example, each of R2 and R3 is independently selected from the group consisting of C 5~14 Alkyl and C 5~14 alkenyl.
[0091] In a further embodiment, the compound of formula (I) has the formula (IIg) [ka] wherein l is selected from 1, 2, 3, 4, and 5; m is selected from 5, 6, 7, 8, and 9; M is a bond or M′; M and M′ are independently selected from —C(O)O—, —OC(O)—, —OC(O)—M″—C(O)O—, —C(O)N(R′)—, —P(O)(OR′)O—, —SS—, an aryl group, and a heteroaryl group; R and R are independently selected from H, C 1~14 Alkyl, and C 2~14 alkenyl) or its N-oxide, or a salt or isomer thereof. For example, M" is a compound of C 1~6 Alkyl (e.g., C 1~4 alkyl) or C 2~6 Alkenyl (e.g., C 2~4 alkenyl). For example, R2 and R3 are independently C 5~14 Alkyl and C 5~14 alkenyl.
[0092] A compound of any one of formulas (I), (IA), (IB), (II), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), and (III) comprises one or more of the following features, if applicable:
[0093] In one embodiment, R4 is C 3~6 Carbocyclic ring, -(CH2) n Q, -(CH2) n CHQR, -(CH2) o C(R 10 )2(CH2) n~o -Q, -CHQR, and -CQ(R), wherein Q is selected from the group consisting of C 3~6 Carbocycles, N, O, S, and P, -OR, -O(CH2) nand a 5- to 14-membered aromatic or non-aromatic heterocycle having one or more heteroatoms selected from N(R), -C(O)OR, -OC(O)R, -CX, -CXH, -CXH, -CN, -N(R), -N(R)S(O)R, -C(O)N(R), -N(R)C(O)R, -N(R)S(O)R, -N(R)C(O)N(R), -N(R)C(S)N(R), and -C(R)N(R)C(O)OR; wherein each o is independently selected from 1, 2, 3, and 4; and each n is independently selected from 1, 2, 3, 4, and 5.
[0094] In another embodiment, R4 is C 3~6 Carbocyclic ring, -(CH2) n Q, -(CH2) n CHQR, -(CH2) o C(R 10 )2(CH2) n~o -Q, -CHQR, and -CQ(R)2, wherein Q is C 3~6 Carbocycles, N, O, and S, -OR, -O(CH2) n 5- to 14-membered heteroaryl having one or more heteroatoms selected from N(R)2, -C(O)OR, -OC(O)R, -CX3, -CX2H, -CXH2, -CN, -C(O)N(R)2, -N(R)S(O)2R8, -N(R)C(O)R, -N(R)S(O)2R, -N(R)C(O)N(R)2, -N(R)C(S)N(R)2, -C(R)N(R)2C(O)OR, and oxo (=O), OH, amino, and C 1~3 and 5- to 14-membered heterocycloalkyl having one or more heteroatoms selected from N, O, and S substituted with one or more substituents selected from alkyl, wherein each o is independently selected from 1, 2, 3, and 4, and each n is independently selected from 1, 2, 3, 4, and 5.
[0095] In another embodiment, R4 is C 3~6 Carbocyclic ring, -(CH2) n Q, -(CH2) n CHQR, -(CH2) o C(R 10 )2(CH2)n~o -Q, -CHQR, and -CQ(R)2, wherein Q is C 3~6 Carbocycles, N, O, and S, -OR, -O(CH2) n and (i) R is -(CH) n Q, where n is 1 or 2, or (ii) R4 is -(CH2) n (iii) when R4 is -CHQR, and -CQ(R)2, Q is either a 5- to 14-membered heteroaryl or an 8- to 14-membered heterocycloalkyl;
[0096] In another embodiment, R4 is C 3~6 Carbocyclic ring, -(CH2) n Q, -(CH2) n CHQR, -(CH2) o C(R 10 )2(CH2) n~o -Q, -CHQR, and -CQ(R)2, wherein Q is C 3~6 Carbocycles, N, O, and S, -OR, -O(CH2) n and 5-14 membered heteroaryl having one or more heteroatoms selected from N(R), -C(O)OR, -OC(O)R, -CX, -CXH, -CXH, -CN, -C(O)N(R), -N(R)S(O)R, -N(R)C(O)R, -N(R)S(O)R, -N(R)C(O)N(R), -N(R)C(S)N(R), -C(R)N(R)C(O)OR; each o is independently selected from 1, 2, 3, and 4; and each n is independently selected from 1, 2, 3, 4, and 5.
[0097] In another embodiment, R4 is -(CH2) n Q, where Q is —N(R)S(O)R and n is selected from 1, 2, 3, 4, and 5. In a further embodiment, R is —(CH) n Q, where Q is -N(R)S(O)R, where R is C 3~6 C such as cycloalkyl 3~6 is a carbocyclic ring, and n is selected from 1, 2, 3, 4, and 5. For example, R4 is -(CH2)3NHS(O)2R8, and R8 is cyclopropyl.
[0098] In another embodiment, R4 is -(CH2) o C(R 10 )2(CH2) n~o Q, where Q is —N(R)C(O)R, n is selected from 1, 2, 3, 4, and 5, and o is selected from 1, 2, 3, and 4. In a further embodiment, R is —(CH) o C(R 10 )2(CH2) n~o Q, where Q is —N(R)C(O)R, where R is C1-C3 alkyl, n is selected from 1, 2, 3, 4, and 5, and o is selected from 1, 2, 3, and 4. In another embodiment, R4 is —(CH2) o C(R 10 )2(CH2) n~o Q, where Q is —N(R)C(O)R, where R is C1-C3 alkyl, n is 3, and o is 1. In one embodiment, R 10 But H, OH, C 1~3 Alkyl, or C 2~3 For example, R4 is 3-acetamido-2,2-dimethylpropyl.
[0099] In one embodiment, one R 10 is H and one R 10 But C 1~3 Alkyl or C2~3 In another embodiment, each R 10 But C 1~3 Alkyl or C 2~3 In another embodiment, each R 10 But C 1~3 alkyl (e.g., methyl, ethyl, or propyl). For example, one R 10 is methyl and one R 10 is ethyl or propyl. For example, one R 10 is ethyl and one R 10 is methyl or propyl. For example, one R 10 is propyl and one R 10 is methyl or ethyl. For example, each R 10 is methyl. For example, each R 10 is ethyl. For example, each R 10 is propyl.
[0100] In one embodiment, one R 10 is H and one R 10 is OH. In another embodiment, each R 10 is OH.
[0101] In another embodiment, R4 is unsubstituted C 1~4 Alkyl, for example, unsubstituted methyl.
[0102] In another embodiment, R4 is hydrogen.
[0103] In certain embodiments, the present disclosure provides a compound of formula (I) wherein R4 is -(CH2) n Q or -(CH2) n CHQR, where Q is —N(R) 2 and n is selected from 3, 4, and 5.
[0104] In certain embodiments, the present disclosure provides a compound of formula (I) wherein R4 is -(CH2) n Q, -(CH2) nand n is selected from the group consisting of -CHQR, -CHQR, and -CQ(R)2, where Q is -N(R)2 and n is selected from 1, 2, 3, 4, and 5.
[0105] In certain embodiments, the present disclosure provides a compound of formula (I), wherein R and R are independently selected from the group consisting of: 2~14 Alkyl, C 2~14 Alkenyl, -R * YR”, -YR”, and -R * OR" or R2 and R3 together with the atoms to which they are attached form a heterocycle or a carbocycle and R4 is selected from the group consisting of -(CH2) n Q or -(CH2) n CHQR, where Q is —N(R) 2 and n is selected from 3, 4, and 5.
[0106] In certain embodiments, R2 and R3 are independently C 2~14 Alkyl, C 2~14 Alkenyl, -R * YR”, -YR”, and -R * OR”, or R2 and R3 together with the atoms to which they are attached form a heterocyclic or carbocyclic ring.
[0107] In one embodiment, R is C 5~20 Alkyl and C 5~20 alkenyl. In other embodiments, R1 is -R * -YR", -YR", and -R"M'R'.
[0108] In certain embodiments, R is -R * In some embodiments, Y is a cyclopropyl group. In some embodiments, R * is C alkyl or C alkenyl. In certain embodiments, R" is C 3~12For example, R" can be a C alkyl. For example, R" can be a C 4~8 It can be alkyl (e.g., C4, C5, C6, C7, or C8 alkyl).
[0109] In some embodiments, R is (CH) q OR * and q is selected from 1, 2, and 3; and R * is substituted with one or more substituents selected from the group consisting of amino, C1-C6 alkylamino, and C1-C6 dialkylamino 1~12 For example, R is (CH2) q OR * and q is selected from 1, 2, and 3; and R * is substituted with C1-C6 dialkylamino 1~12 For example, R is (CH2) q OR * and q is selected from 1, 2, and 3; and R * is substituted with C1-C6 dialkylamino 1~3 For example, R is (CH2) q OR * and q is selected from 1, 2, and 3; and R * is substituted with dimethylamino (e.g., dimethylaminoethanyl) 1~3 It is alkyl.
[0110] In one embodiment, R is C 5~20 In certain embodiments, R1 is C6 alkyl. In certain embodiments, R1 is C8 alkyl. In other embodiments, R1 is C9 alkyl. In certain embodiments, R1 is C 14 In another embodiment, R is C 18 It is alkyl.
[0111] In one embodiment, R is C 21~30 In one embodiment, R is C 26In one embodiment, R is C 28 In certain embodiments, R is alkyl. [ka] is.
[0112] In one embodiment, R is C 5~20 In certain embodiments, R is C 18 alkenyl. In some embodiments, R1 is linoleyl.
[0113] In certain embodiments, R1 is branched (e.g., decan-2-yl, undecan-3-yl, dodecan-4-yl, tridecan-5-yl, tetradecan-6-yl, 2-methylundecan-3-yl, 2-methyldecan-2-yl, 3-methylundecan-3-yl, 4-methyldodecan-4-yl, or heptadec-9-yl). [ka] is.
[0114] In certain embodiments, R is an unsubstituted C 5~20 Alkyl or C 5~20 In certain embodiments, R' is a substituted C 5~20 Alkyl or C 5~20 Alkenyl (e.g., C such as 1-cyclopropylnonyl) 3~6 substituted with a carbocyclic ring or substituted with OH or alkoxy). For example, [ka] is.
[0115] In other embodiments, R1 is -R"M'R'. In certain embodiments, M' is -OC(O)-M"-C(O)O-. For example, R1 is [ka] where x is an integer from 1 to 13 (e.g., selected from 3, 4, 5, and 6), s is an integer from 1 to 13 (e.g., selected from 1, 2, and 3), and t is an integer from 2 to 14 (e.g., selected from 4, 5, and 6). For example, x is selected from 3, 4, 5, and 6, s is selected from 1, 2, and 3, and t is selected from 4, 5, and 6.
[0116] In other embodiments, R1 is -(CHR5R6) m -Different from M-CR2R3R7.
[0117] In some embodiments, R' is -R * In some embodiments, Y is selected from -YR" and -YR". 3~8 In one embodiment, Y is C 6~10 In certain embodiments, Y is aryl. In certain embodiments, Y is a cyclopropyl group. In certain embodiments, Y is a cyclohexyl group. In certain embodiments, R * is a C1 alkyl.
[0118] In one embodiment, R″ is C 3~12 Alkyl and C 3~12 In some embodiments, R″ adjacent to Y is C alkyl. In some embodiments, R″ adjacent to Y is C 4~9 alkyl (e.g., C4, C5, C6, C7 or C8 or C9 alkyl).
[0119] In one embodiment, R″ is a substituted C 3~12 (e.g., C substituted with hydroxyl 3~12 alkyl). For example, R" is [ka] is.
[0120] In certain embodiments, R' is selected from C4 alkyl and C4 alkenyl. In certain embodiments, R' is selected from C5 alkyl and C5 alkenyl. In certain embodiments, R' is selected from C6 alkyl and C6 alkenyl. In certain embodiments, R' is selected from C7 alkyl and C7 alkenyl. In certain embodiments, R' is selected from C9 alkyl and C9 alkenyl.
[0121] In some embodiments, R' is [ka] In some embodiments, R' is [ka] and M' is -OC(O)-. In other embodiments, R' is [ka] and M' is -C(O)O-.
[0122] In other embodiments, R' is C 11 Alkyl and C 11 In another embodiment, R' is selected from C 12 Alkyl, C 12 Alkenyl, C 13 Alkyl, C 13 Alkenyl, C 14 Alkyl, C 14 Alkenyl, C 15 Alkyl, C 15 Alkenyl, C 16 Alkyl, C 16 Alkenyl, C 17 Alkyl, C 17 Alkenyl, C 18 Alkyl, and C18 In certain embodiments, R' is selected from straight chain C 4~18 Alkyl or C 4~18 In certain embodiments, R' is branched (e.g., decan-2-yl, undecan-3-yl, dodecan-4-yl, tridecan-5-yl, tetradecan-6-yl, 2-methylundecan-3-yl, 2-methyldecan-2-yl, 3-methylundecan-3-yl, 4-methyldodecan-4-yl, or heptadec-9-yl). In certain embodiments, R' is [ka] is.
[0123] In certain embodiments, R' is unsubstituted C 1~18 In certain embodiments, R' is a substituted C 1~18 alkyl (e.g., alkoxy, such as methoxy, or C 1-cyclopropylnonyl, such as 1-cyclopropylnonyl) 3~6 Carbocyclic or C(O)O-alkyl or OC(O)-alkyl substituted C(O)OCH3 or OC(O)CH3 1~15 alkyl). For example, R' is [ka] is.
[0124] In certain embodiments, R′ is a branched C 1~18 For example, R' is [ka] is.
[0125] In one embodiment, R″ is C 3~15 Alkyl and C 3~15In some embodiments, R" is selected from the group consisting of C alkyl, C alkyl, C alkyl, C alkyl, C alkyl, or C alkyl. In some embodiments, R" is selected from the group consisting of C alkyl, C 10 Alkyl, C 11 Alkyl, C 12 Alkyl, C 13 Alkyl, C 14 Alkyl, or C 15 It is alkyl.
[0126] In some embodiments, M' is -C(O)O-. In some embodiments, M' is -OC(O)-. In some embodiments, M' is -OC(O)-M"-C(O)O-.
[0127] In other embodiments, M' is an aryl or heteroaryl group. For example, M' may be selected from the group consisting of phenyl, oxazole, and thiazole.
[0128] In some embodiments, M is -C(O)O-. In some embodiments, M is -OC(O)-. In some embodiments, M is -C(O)N(R')-. In some embodiments, M is -P(O)(OR')O-. In some embodiments, M is -OC(O)-M"-C(O)O-.
[0129] In other embodiments, M is an aryl or heteroaryl group. For example, M can be selected from the group consisting of phenyl, oxazole, and thiazole.
[0130] In some embodiments, M is the same as M'. In other embodiments, M is different from M'.
[0131] In some embodiments, M" is a bond. In some embodiments, M" is C 1~13 Alkyl or C 2~13 In one embodiment, M" is C 1~6 Alkyl or C 2~6In certain embodiments, M" is a straight chain alkyl or alkenyl. In certain embodiments, M" is branched, for example, -CH(CH3)CH2-.
[0132] In certain embodiments, each R5 is H. In some such embodiments, each R6 is also H.
[0133] In some embodiments, R7 is H. In other embodiments, R7 is C 1~3 alkyl (for example, methyl, ethyl, propyl, or i-propyl).
[0134] In one embodiment, R2 and R3 are independently selected from the group consisting of C 5~14 Alkyl or C 5~14 It is alkenyl.
[0135] In some embodiments, R2 and R3 are the same. In some embodiments, R2 and R3 are C8 alkyl. In certain embodiments, R2 and R3 are C2 alkyl. In other embodiments, R2 and R3 are C3 alkyl. In some embodiments, R2 and R3 are C4 alkyl. In certain embodiments, R2 and R3 are C5 alkyl. In other embodiments, R2 and R3 are C6 alkyl. In some embodiments, R2 and R3 are C7 alkyl.
[0136] In other embodiments, R2 and R3 are different. In certain embodiments, R2 is C8 alkyl. In certain embodiments, R3 is C 1~7 (e.g., C1, C2, C3, C4, C5, C6, or C7 alkyl) or C9 alkyl.
[0137] In some embodiments, R7 and R3 are H.
[0138] In certain embodiments, R2 is H.
[0139] In certain embodiments, m is 5, 7, or 9.
[0140] In one embodiment, R4 is -(CH2) n Q and -(CH2) n Selected from CHQR.
[0141] In some embodiments, Q is -OR, -OH, -O(CH2) n and -C(O)R, -CX, -CN, -N(R)C(O)R, -N(H)C(O)R, -N(R)S(O)R, -N(H)S(O)R, -N(R)C(O)N(R), -N(H)C(O)N(R), -N(H)C(O)N(R), -N(R)C(S)N(R), -N(H)C(S)N(R), -N(H)C(S)N(H)(R), -C(R)N(R)C(O)OR, -N(R)S(O)R, carbocycle, and heterocycle.
[0142] In certain embodiments, Q is —N(R)R 8 , —N(R)S(O) 2 R 8 , —O(CH 2 ) n -OR, -N(R)C(=NR9)N(R)2, -N(R)C(=CHR9)N(R)2, -OC(O)N(R)2, or -N(R)C(O)OR.
[0143] In certain embodiments, Q is -N(OR)C(O)R, -N(OR)S(O)R, -N(OR)C(O)OR, -N(OR)C(O)N(R), -N(OR)C(S)N(R), -N(OR)C(=NR)N(R), or -N(OR)C(=CHR)N(R).
[0144] In certain embodiments, Q is thiourea or an isostere thereof, such as [ka] Or -NHC(=NR9)N(R)2.
[0145] In certain embodiments, Q is -C(=NR9)N(R). For example, when Q is -C(=NR9)N(R), n is 4 or 5. For example, R is -S(O)2N(R).
[0146] In certain embodiments, Q is -C(=NR9)R or -C(O)N(R)OR, such as -CH(=N-OCH3), -C(O)NH-OH, -C(O)NH-OCH3, -C(O)N(CH3)-OH, or -C(O)N(CH3)-OCH3.
[0147] In certain embodiments, Q is —OH.
[0148] In certain embodiments, Q is a substituted or unsubstituted 5- to 10-membered heteroaryl, e.g., Q is triazole, imidazole, pyrimidine, purine, 2-amino-1,9-dihydro-6H-purin-6-on-9-yl (or guanin-9-yl), adenin-9-yl, cytosin-1-yl, or uracil-1-yl, each of which is optionally substituted with one or more substituents selected from alkyl, OH, alkoxy, -alkyl-OH, -alkyl-O-alkyl, which may be further substituted. In certain embodiments, Q is, for example, oxo (=O), OH, amino, mono- or dialkylamino, and C 1~3 and substituted 5- to 14-membered heterocycloalkyl, substituted with one or more substituents selected from alkyl, for example, Q is 4-methylpiperazinyl, 4-(4-methoxybenzyl)piperazinyl, isoindolin-2-yl-1,3-dione, pyrrolidin-1-yl-2,5-dione, or imidazolidin-3-yl-2,4-dione.
[0149] In certain embodiments, Q is —NHR 8 , where R 8 is oxo (═O), amino (NH 2 ), mono- or dialkylamino, C 1~3 C optionally substituted with one or more substituents selected from alkyl and halo 3~6For example, R is cyclobutenyl, such as 3-(dimethylamino)-cyclobut-3-en-4-yl-1,2-dione. In a further embodiment, R is oxo (=O), thio (=S), amino (NH), mono- or di-alkylamino, C 1~3 C optionally substituted with one or more substituents selected from alkyl, heterocycloalkyl, and halo 3~6 cycloalkyl, where mono- or di-alkylamino, C 1~3 Alkyl and heterocycloalkyl are further substituted, for example, R is cyclobutenyl substituted with one or more of oxo, amino, and alkylamino, where alkylamino is, for example, C 1~3It is further substituted with one or more of alkoxy, amino, mono- or di-alkylamino, and halo. For example, R8 is 3-(((dimethylamino)ethyl)amino)cyclobut-3-enyl-1,2-dione. For example, R8 is cyclobutenyl substituted with one or more of oxo and alkylamino. For example, R8 is 3-(ethylamino)cyclobut-3-ene-1,2-dione. For example, R8 is cyclobutenyl substituted with one or more of oxo, thio, and alkylamino. For example, R8 is 3-(ethylamino)-4-thioxocyclobut-2-en-1-one or 2-(ethylamino)-4-thioxocyclobut-2-en-1-one. For example, R8 is cyclobutenyl substituted with one or more of thio and alkylamino. For example, R8 is 3-(ethylamino)cyclobut-3-ene-1,2-dithione. For example, R8 is cyclobutenyl substituted with one or more of oxo and dialkylamino. For example, R8 is 3-(diethylamino)cyclobut-3-ene-1,2-dione. For example, R8 is cyclobutenyl substituted with one or more of oxo, thio, and dialkylamino. For example, R8 is 2-(diethylamino)-4-thioxocyclobut-2-en-1-one or 3-(diethylamino)-4-thioxocyclobut-2-en-1-one. For example, R8 is cyclobutenyl substituted with one or more of thio and dialkylamino. For example, R8 is 3-(diethylamino)cyclobut-3-ene-1,2-dithione. For example, R8 is cyclobutenyl substituted with one or more of oxo and alkylamino or dialkylamino, where the alkylamino or dialkylamino is further substituted, for example, with one or more alkoxy. For example, R8 is 3-(bis(2-methoxyethyl)amino)cyclobut-3-ene-1,2-dione. For example, R8 is cyclobutenyl substituted with one or more of oxo and heterocycloalkyl. For example, R8 is cyclobutenyl substituted with one or more of oxo and piperidinyl, piperazinyl, or morpholinyl.For example, R8 is cyclobutenyl substituted with one or more of oxo and heterocycloalkyl, where heterocycloalkyl is, for example, one or more C. 1~3 For example, R is cyclobutenyl substituted with one or more of oxo and heterocycloalkyl, where the heterocycloalkyl (e.g., piperidinyl, piperazinyl, or morpholinyl) is further substituted with methyl.
[0150] In certain embodiments, Q is —NHR 8 , where R 8 is amino (NH 2 ), mono- or dialkylamino, C 1~3 Heteroaryl optionally substituted with one or more substituents selected from alkyl and halo, for example, R8 is thiazole or imidazole.
[0151] In certain embodiments, Q is —NHC(═NR)N(R), where R is CN, C 1~6 alkyl, NO, -S(O)N(R), -OR, -S(O)R, or H. For example, Q is -NHC(=NR)N(CH), -NHC(=NR)NHCH, -NHC(=NR)NH. In some embodiments, Q is -NHC(=NR)N(R), where R is CN and R is a C substituted with mono- or di-alkylamino. 1~3 In some embodiments, Q is -NHC(=NR9)N(R)2, where R9 is C 1~6 alkyl, NO, -S(O)N(R), -OR, -S(O)R, or H, where R is substituted with mono- or di-alkylamino. 1~3 alkyl, for example, R is ((dimethylamino)ethyl)amino.
[0152] In certain embodiments, Q is —NHC(═CHR 9 )N(R) 2 , where R 9 is NO 2 , CN, C 1~6Alkyl, -S(O)2N(R)2, -OR, -S(O)2R, or H. For example, Q is -NHC(=CHR9)N(CH3)2, -NHC(=CHR9)NHCH3, or -NHC(=CHR9)NH2.
[0153] In certain embodiments, Q is -OC(O)N(R)2, -N(R)C(O)OR, -N(OR)C(O)OR, e.g., -OC(O)NHCH3, -N(OH)C(O)OCH3, -N(OH)C(O)CH3, -N(OCH3)C(O)OCH3, -N(OCH3)C(O)CH3, -N(OH)S(O)2CH3, or -NHC(O)OCH3.
[0154] In certain embodiments, Q is —N(R)C(O)R, where R is C 1~3 Alkoxyl or S(O) t C 1~3 alkyl optionally substituted with alkyl, where t is 0, 1, or 2;
[0155] In certain embodiments, Q is unsubstituted or substituted C 6~10 Aryl (e.g., phenyl) or C 3~6 It is cycloalkyl.
[0156] In some embodiments, n is 1. In other embodiments, n is 2. In further embodiments, n is 3. In some other embodiments, n is 4. For example, R4 can be -(CH2)2OH. For example, R4 can be -(CH2)3OH. For example, R4 can be -(CH2)4OH. For example, R4 can be benzyl. For example, R4 can be 4-methoxybenzyl.
[0157] In one embodiment, R4 is C 3~6 In one embodiment, R4 is C 3~6 For example, R4 is cycloalkyl, for example, OH, halo, C 1~6It can be cyclohexyl optionally substituted with alkyl, etc. For example, R4 can be 2-hydroxycyclohexyl.
[0158] In some embodiments, R is H.
[0159] In one embodiment, R is C substituted with mono- or di-alkylamino. 1~3 alkyl, for example, R is ((dimethylamino)ethyl)amino.
[0160] In one embodiment, R is C 1~3 C substituted with one or more substituents selected from the group consisting of alkoxyl, amino, and C1-C3 dialkylamino 1~6 It is alkyl.
[0161] In some embodiments, R is unsubstituted C 1~3 Alkyl or unsubstituted C 2~3 For example, R4 can be -CH2CH(OH)CH3, -CH(CH3)CH2OH, or -CH2CH(OH)CH2CH3.
[0162] In one embodiment, R is substituted C 1~3 and alkyl, such as CHOH. For example, R can be —CHCH(OH)CHOH, —(CH)NHC(O)CHOH, —(CH)NHC(O)CHOBn, —(CH)O(CH)OH, —(CH)NHCHOCH, —(CH)NHCHOCHCH, CHSCH, CHS(O)CH, CHS(O)CH, or —CH(CHOH).
[0163] In one embodiment, R4 is one of the following groups: [ka] [ka] [ka] The value is selected from either:
[0164] In one embodiment, R4 is one of the following groups: [ka] [ka] The value is selected from either:
[0165] In some embodiments, the compound of formula (III) further comprises an anion. As described herein, the anion can be any anion capable of reacting with an amine to form an ammonium salt. Examples include, but are not limited to, chloride, bromide, iodide, fluoride, acetate, formate, trifluoroacetate, difluoroacetate, trichloroacetate, and phosphate.
[0166] In certain embodiments, compounds of any of the formulae described herein are suitable for making nanoparticle compositions for intramuscular administration.
[0167] In some embodiments, R2 and R3, together with the atoms to which they are attached, form a heterocyclic or carbocyclic ring. In some embodiments, R2 and R3, together with the atoms to which they are attached, form a 5- to 14-membered aromatic or non-aromatic heterocyclic ring having one or more heteroatoms selected from N, O, S, and P. In some embodiments, R2 and R3, together with the atoms to which they are attached, form an optionally substituted C ring, either aromatic or non-aromatic. 3~20 Carbocyclic rings (e.g., C 3~18 carbocycle, C 3~15 carbocycle, C 3~12 Carbocyclic, or C 3~10In some embodiments, R2 and R3, together with the atoms to which they are attached, form a C 3~6 In other embodiments, R2 and R3 together with the atoms to which they are attached form a C6 carbocyclic ring, such as a cyclohexyl or phenyl group. In certain embodiments, a heterocyclic or C 3~6 The carbocycle may be substituted with one or more alkyl groups (e.g., on the same ring atom or adjacent or non-adjacent ring atoms). For example, R2 and R3, together with the atom to which they are attached, may form a cyclohexyl or phenyl group having one or more C5 alkyl substitutions. In certain embodiments, the heterocycle or C5 alkyl group formed by R2 and R3 may be substituted with one or more C5 alkyl groups. 3~6 A carbocycle is substituted with a carbocyclic group. For example, R2 and R3, together with the atom to which they are attached, can form a cyclohexyl or phenyl group substituted with cyclohexyl. In some embodiments, R2 and R3, together with the atom to which they are attached, form a C 7~15 It forms a carbocyclic ring, for example a cycloheptyl, cyclopentadecanyl, or naphthyl group.
[0168] In one embodiment, R4 is -(CH2) n Q and -(CH2) n In some embodiments, Q is selected from -OR, -OH, -O(CH) n In another embodiment, Q is selected from the group consisting of imidazole, pyrimidine, and purine.
[0169] In some embodiments, R2 and R3, together with the atoms to which they are attached, form a heterocycle or a carbocycle. In some embodiments, R2 and R3, together with the atoms to which they are attached, form a C 3~6 In certain embodiments, a heterocycle or C 3~6 The carbocycle may be substituted with one or more alkyl groups (e.g., on the same ring atom or adjacent or non-adjacent ring atoms). For example, R2 and R3, together with the atom to which they are attached, may form a phenyl group having one or more C5 alkyl substitutions.
[0170] In some embodiments, at least one occurrence of R5 and R6 is C 1~3 In some embodiments, one of R5 and R6 adjacent to M is C 1~3 alkyl, e.g., methyl, and the other is H. In some embodiments, one of R5 and R6 adjacent to M is C 1~3 One is alkyl, for example, methyl, and the other is H, and M is -OC(O)- or -C(O)O-.
[0171] In some embodiments, at most one occurrence of R5 and R6 is C 1~3 In some embodiments, one of R5 and R6 adjacent to M is C 1~3 alkyl, e.g., methyl, and the other is H. In some embodiments, one of R5 and R6 adjacent to M is C 1~3 alkyl, for example, methyl, and the other is H, and M is -OC(O)- or -C(O)O-.
[0172] In certain embodiments, each occurrence of R5 and R6 is H.
[0173] In certain embodiments, the compound of formula (I) is [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] is selected from the group consisting of:
[0174] In a further embodiment, the compound of formula (I) is [ka] is selected from the group consisting of:
[0175] In certain embodiments, the compound of formula (I) is [ka] [ka] [ka] [ka] [ka]
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
[0176] In one embodiment, the lipid of the present disclosure is compound 340: [ka] Includes.
[0177] The central amine moiety of the lipid represented by formula (I), (IA), (IB), (II), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), or (III) can be protonated at physiological pH. Thus, the lipid can have a positive charge or partial positive charge at physiological pH. Such lipids can be called cationic or ionic (amino) lipids. The lipid can also be zwitterionic, i.e., a neutral molecule with both positive and negative charges.
[0178] As used herein, the term "alkyl" or "alkyl group" means a straight- or branched-chain saturated hydrocarbon containing one or more carbon atoms (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more carbon atoms), which is optionally substituted. 1~14The term "alkyl" means an optionally substituted, straight or branched chain saturated hydrocarbon containing from 1 to 14 carbon atoms. Unless otherwise specified, alkyl groups described herein refer to both unsubstituted and substituted alkyl groups.
[0179] As used herein, the term "alkenyl" or "alkenyl group" means an optionally substituted, straight- or branched-chain hydrocarbon containing two or more carbon atoms (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more carbon atoms) and at least one double bond. 2~14 The term "alkenyl" refers to an optionally substituted straight or branched chain hydrocarbon containing 2 to 14 carbon atoms and at least one carbon-carbon double bond. Alkenyl groups can contain one, two, three, four, or more carbon-carbon double bonds. For example, C 18 Alkenyl may contain one or more double bonds. C containing two double bonds 18 The alkenyl group may be a linoleyl group. Unless otherwise specified, the alkenyl groups described herein refer to both unsubstituted and substituted alkenyl groups.
[0180] As used herein, the term "alkynyl" or "alkynyl group" means an optionally substituted, straight- or branched-chain hydrocarbon containing two or more carbon atoms (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more carbon atoms) and at least one carbon-carbon triple bond. 2~14 The term "alkynyl" refers to an optionally substituted straight or branched chain hydrocarbon containing 2 to 14 carbon atoms and at least one carbon-carbon triple bond. An alkynyl group can contain one, two, three, four, or more carbon-carbon triple bonds. For example, C 18An alkynyl may contain one or more carbon-carbon triple bonds. Unless otherwise specified, alkynyl groups described herein refer to both unsubstituted and substituted alkynyl groups.
[0181] As used herein, the term "carbocycle" or "carbocyclic group" means an optionally substituted monocyclic or polycyclic ring system containing one or more rings of carbon atoms. The rings can be 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11-, 12-, 13-, 14-, 15-, 16-, 17-, 18-, 19-, or 20-membered rings. 3~6 The term "carbocycle" refers to a carbocycle containing a single ring having 3 to 6 carbon atoms. A carbocycle may contain one or more carbon-carbon double or triple bonds and may be non-aromatic or aromatic (e.g., a cycloalkyl or aryl group). Examples of carbocycles include cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, and 1,2-dihydronaphthyl groups. The term "cycloalkyl," as used herein, refers to a non-aromatic carbocycle, which may or may not contain any double or triple bonds. Unless otherwise specified, carbocycles described herein refer to both unsubstituted and substituted carbocyclic groups, i.e., optionally substituted carbocycles.
[0182] As used herein, the term "heterocycle" or "heterocyclic group" refers to an optionally substituted monocyclic or polycyclic ring system containing one or more rings, wherein at least one ring contains at least one heteroatom. The heteroatom may be, for example, a nitrogen, oxygen, or sulfur atom. The ring may be a 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11-, 12-, 13-, or 14-membered ring. The heterocycle may contain one or more double or triple bonds and may be non-aromatic or aromatic (e.g., a heterocycloalkyl or heteroaryl group). Examples of heterocyclic rings include imidazolyl, imidazolidinyl, oxazolyl, oxazolidinyl, thiazolyl, thiazolidinyl, pyrazolidinyl, pyrazolyl, isoxazolidinyl, isoxazolyl, isothiazolidinyl, isothiazolyl, morpholinyl, pyrrolyl, pyrrolidinyl, furyl, tetrahydrofuryl, thiophenyl, pyridinyl, piperidinyl, quinolyl, and isoquinolyl groups.As used herein, the term "heterocycloalkyl" refers to a non-aromatic heterocyclic ring, and may or may not contain any double or triple bond.Unless otherwise specified, the heterocyclic ring described herein refers to both unsubstituted and substituted heterocyclic rings, i.e., optionally substituted heterocyclic rings.
[0183] As used herein, a "biodegradable group" is a group that can promote faster metabolism of lipids in mammalian organisms. The biodegradable group may be selected from the group consisting of, but not limited to, -C(O)O-, -OC(O)-, -C(O)N(R')-, -N(R')C(O)-, -C(O)-, -C(S)-, -C(S)S-, -SC(S)-, -CH(OH)-, -P(O)(OR')O-, -S(O)-, an aryl group, and a heteroaryl group. As used herein, an "aryl group" is an optionally substituted carbocyclic group containing one or more aromatic rings. Examples of aryl groups include phenyl and naphthyl groups. As used herein, a "heteroaryl group" is an optionally substituted heterocyclic group containing one or more aromatic rings. Examples of heteroaryl groups include pyrrolyl, furyl, thiophenyl, imidazolyl, oxazolyl, and thiazolyl. Both aryl and heteroaryl groups can be optionally substituted. For example, M and M' can be selected from the non-limiting group consisting of optionally substituted phenyl, oxazole, and thiazole. In the formulas herein, M and M' can be independently selected from the list of biodegradable groups above. Unless otherwise specified, the aryl or heteroaryl groups described herein refer to both unsubstituted and substituted groups, i.e., optionally substituted aryl or heteroaryl groups.
[0184] Alkyl, alkenyl, and cyclyl (eg, carbocyclyl and heterocyclyl) groups may be optionally substituted, unless otherwise specified. Optional substituents include, but are not limited to, halogen atoms (e.g., chloride, bromide, fluoride, or iodide groups), carboxylic acids (e.g., —C(O)OH), alcohols (e.g., hydroxyl, —OH), esters (e.g., —C(O)OR or —OC(O)R), aldehydes (e.g., —C(O)H), carbonyls (e.g., represented by —C(O)R, or alternatively, C═O), acyl halides (e.g., —C(O)X, where X is a halide selected from bromide, fluoride, chloride, and iodide), carbonates (e.g., —OC(O)OR), alkoxy (e.g., —OR), acetals (e.g., —C(OR)R″″, where each OR is an alkoxy group, which may be the same or different, and R″″ is an alkyl or alkenyl group), phosphates (e.g., P(O) 3- ), thiol (e.g., -SH), sulfoxide (e.g., -S(O)R), sulfinic acid (e.g., -S(O)OH), sulfonic acid (e.g., -S(O)2OH), thial (e.g., -C(S)H), sulfate (e.g., S(O)4 2-), sulfonyl (e.g., -S(O)2-), amido (e.g., -C(O)NR2, or -N(R)C(O)R), azido (e.g., -N3), nitro (e.g., -NO2), cyano (e.g., -CN), isocyano (e.g., -NC), acyloxy (e.g., -OC(O)R), amino (e.g., -NR2, -NRH, or -NH2), carbamoyl (e.g., -OC(O)NR2 , -OC(O)NRH, or -OC(O)NH), sulfonamide (e.g., -S(O)NR, -S(O)NRH, -S(O)NH, -N(R)S(O)R, -N(H)S(O)R, -N(R)S(O)H, or -N(H)S(O)H), alkyl, alkenyl, and cyclyl (e.g., carbocyclyl or heterocyclyl) groups. In any of the above, R is an alkyl or alkenyl group, as defined herein. In certain embodiments, the substituents themselves can be further substituted, for example, with 1, 2, 3, 4, 5, or 6 substituents as defined herein. For example, C 1~6 Alkyl groups may be further substituted with 1, 2, 3, 4, 5, or 6 substituents as defined herein.
[0185] Nitrogen-containing compounds of the present disclosure can be converted to N-oxides by treatment with an oxidizing agent (e.g., 3-chloroperoxybenzoic acid (mCPBA) and / or hydrogen peroxide) to provide other compounds of the present disclosure. Thus, all nitrogen-containing compounds shown and claimed, when permitted by valency and structure, include the compounds as shown and their N-oxide derivatives (which may be N→O or N + -O -(which may be depicted as N-hydroxy or N-alkoxy). Additionally, in other cases, nitrogen in the compounds of the present disclosure can be converted to N-hydroxy or N-alkoxy compounds. For example, N-hydroxy compounds can be prepared by oxidation of the parent amine with an oxidizing agent such as m-CPBA. All depicted and claimed nitrogen-containing compounds, when permitted by valency and structure, are also considered to cover both the compound as depicted and its N-hydroxy (i.e., N—OH) and N-alkoxy (i.e., N—OR, where R is substituted or unsubstituted C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, 3- to 14-membered carbocyclic or 3- to 14-membered heterocyclic) derivatives.
[0186] About, Approximately: As used herein, the terms "and" and "about" when applied to one or more values of interest refer to values similar to the stated reference value. In certain embodiments, the term "approximately" or "about" refers to a range in either direction (greater or less than) 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less of the stated reference value, unless otherwise specified or the context clearly indicates otherwise (except when such value exceeds 100% of the possible value). For example, when used in reference to the amount of a given compound in the lipid component of a nanoparticle composition, "about" can mean + / - 10% of the stated value. For example, a nanoparticle composition comprising a lipid component having about 40% of a given compound may contain 30-50% of the compound.
[0187] As used herein, the term "compound" is intended to include all isomers and isotopes of the structure shown. "Isotopes" refer to atoms with the same atomic number but different mass numbers due to the different number of neutrons in the nucleus. For example, isotopes of hydrogen include tritium and deuterium. Furthermore, the compounds, salts, or complexes of the present disclosure can be prepared by conventional methods in combination with solvents or water molecules to form solvates and hydrates.
[0188] As used herein, the term "contacting" means establishing a physical connection between two or more entities. For example, contacting a mammalian cell with a nanoparticle composition means that the mammalian cell and the nanoparticle share a physical connection. Methods for contacting cells with external entities both in vivo and ex vivo are well known in the field of biology. For example, contacting a nanoparticle composition and a mammalian cell placed within a mammal may be performed by various administration routes (e.g., intravenous, intramuscular, intradermal, and subcutaneous) and may involve various amounts of the nanoparticle composition. Furthermore, two or more mammalian cells may be contacted by the nanoparticle composition.
[0189] As used herein, the term "deliver" means providing an entity to a destination. For example, delivering a therapeutic and / or prophylactic agent to a subject can include administering a nanoparticle composition comprising the therapeutic and / or prophylactic agent to the subject (e.g., by intravenous, intramuscular, intradermal, or subcutaneous routes). Administering a nanoparticle composition to a mammal or mammalian cells can include contacting one or more cells with the nanoparticle composition.
[0190] As used herein, the term "enhanced delivery" refers to greater (e.g., at least 1.5-fold greater, at least 2-fold greater, at least 3-fold greater, at least 4-fold greater, at least 5-fold greater, at least 6-fold greater, at least 7-fold greater, at least 8-fold greater, at least 9-fold greater, at least 10-fold greater) delivery of a therapeutic and / or prophylactic agent by a nanoparticle to a target tissue of interest (e.g., the liver of a mammal) compared to the level of delivery of a therapeutic and / or prophylactic agent by a control nanoparticle to a target tissue of interest (e.g., MC3, KC2, or DLinDMA). The level of nanoparticle delivery to a particular tissue can be measured by comparing the amount of protein produced in the tissue to the weight of the tissue, the amount of therapeutic and / or prophylactic agent in the tissue to the weight of the tissue, the amount of protein produced in the tissue to the total amount of protein in the tissue, or the amount of therapeutic and / or prophylactic agent in the tissue to the total amount of therapeutic and / or prophylactic agent in the tissue. It will be understood that enhanced delivery of nanoparticles to target tissues need not be determined in the subject being treated, but can be determined in surrogate animal models (e.g., rat models), etc. In certain embodiments, nanoparticle compositions comprising a compound of Formula (I), (IA), (IB), (II), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), or (III) have substantially the same level of enhanced delivery regardless of the route of administration. For example, certain compounds disclosed herein exhibit similar enhanced delivery when used to deliver therapeutic and / or prophylactic agents either intravenously or intramuscularly. In other embodiments, certain compounds disclosed herein (e.g., compounds of Formula (IA) or (II), e.g., compounds 18, 25, 30, 60, 108-112, or 122) exhibit higher levels of enhanced delivery when used to deliver therapeutic and / or prophylactic agents intramuscularly than intravenously.
[0191] As used herein, the terms "specific delivery," "specifically deliver," or "specifically delivering" refer to greater (e.g., at least 1.5-fold greater, at least 2-fold greater, at least 3-fold greater, at least 4-fold greater, at least 5-fold greater, at least 6-fold greater, at least 7-fold greater, at least 8-fold greater, at least 9-fold greater, at least 10-fold greater) delivery of a therapeutic and / or prophylactic agent by a nanoparticle to a target tissue of interest (e.g., the liver of a mammal) compared to a non-target tissue (e.g., the spleen of a mammal). The level of nanoparticle delivery to a particular tissue can be measured by comparing the amount of protein produced in the tissue to the weight of the tissue, the amount of therapeutic and / or prophylactic agent in the tissue to the weight of the tissue, the amount of protein produced in the tissue to the total amount of protein in the tissue, or the amount of therapeutic and / or prophylactic agent in the tissue to the total therapeutic and / or prophylactic agent in the tissue. For example, for renal vascular targeting, a therapeutic and / or prophylactic agent is specifically delivered to the kidney of a mammal compared to the liver and spleen if 1.5, 2, 3, 5, 10, 15, or 20 times more therapeutic and / or prophylactic agent is delivered to the kidney per gram of tissue compared to that delivered to the liver or spleen following systemic administration of the therapeutic and / or prophylactic agent. It will be understood that the ability of a nanoparticle to specifically deliver to a target tissue need not be determined in the subject being treated, but can be determined in a surrogate such as an animal model (e.g., a rat model).
[0192] As used herein, "encapsulation efficiency" refers to the amount of a therapeutic and / or prophylactic agent that becomes part of a nanoparticle composition relative to the initial total amount of the therapeutic and / or prophylactic agent used to prepare the nanoparticle composition. For example, if 97 mg of a therapeutic and / or prophylactic agent is encapsulated in the nanoparticle composition out of a total of 100 mg of the therapeutic and / or prophylactic agent initially provided in the composition, the encapsulation efficiency may be expressed as 97%. As used herein, "encapsulation" may refer to complete, substantial, or partial enclosure, confinement, surrounding, or encasement.
[0193] As used herein, "expression" of a nucleic acid sequence refers to translation of mRNA into a polypeptide or protein and / or post-translational modification of the polypeptide or protein.
[0194] As used herein, the term "in vitro" refers to events that take place not within a living organism (e.g., an animal, plant, or microorganism), but in an artificial environment, e.g., a test tube or reaction vessel, cell culture, petri dish, etc.
[0195] As used herein, the term "in vivo" refers to events that take place within an organism (e.g., an animal, plant, or microorganism, or cells or tissues thereof). As used herein, the term "ex vivo" refers to an event that occurs outside of an organism (e.g., an animal, plant, or microorganism, or cells or tissues thereof). An ex vivo event can occur in an environment that is minimally altered from the natural (e.g., in vivo) environment.
[0196] As used herein, the term "isomer" refers to any geometric isomer, tautomer, zwitterion, stereoisomer, enantiomer, or diastereomer of a compound. A compound may contain one or more chiral centers and / or double bonds and, therefore, can exist as stereoisomers, e.g., double bond isomers (i.e., geometric E / Z isomers) or diastereomers (e.g., enantiomers (i.e., (+) or (-)) or cis / trans isomers). The present disclosure encompasses all isomers of the compounds described herein, including stereomerically pure forms (e.g., geometrically pure, enantiomerically pure, or diastereomerically pure) and enantiomeric and stereoisomeric mixtures, e.g., racemates. Enantiomeric and stereoisomeric mixtures of compounds and means for resolving them into their component enantiomers or stereoisomers are well known.
[0197] A "tautomer" is one of two or more structural isomers that exist in equilibrium and are readily converted from one isomeric form to another. This conversion results in the formal migration of a hydrogen atom accompanied by the switching of adjacent conjugated double bonds. Tautomers exist as mixtures of tautomeric sets in solution. In solutions where tautomerization is possible, a chemical equilibrium of the tautomers will be achieved. The exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH. The concept of tautomers that are interconvertible by tautomerization is called tautomerism.
[0198] Of the various types of tautomerism possible, two are commonly observed: keto-enol tautomerism, in which the simultaneous migration of an electron and a hydrogen atom occurs; and ring-chain tautomerism, which occurs when an aldehyde group (-CHO) in a sugar molecule reacts with one of the hydroxyl groups (-OH) in the same molecule to give a cyclic (ring-shaped) form, such as that exhibited by glucose.
[0199] Common tautomeric pairs are ketone-enol, amide-nitrile, lactam-lactim, amide-imidic acid tautomers in heterocyclic rings (e.g., in nucleobases such as guanine, thymine, and cytosine), imine-enamine, and enamine-enamine. An example of tautomerism in a disubstituted guanidine is shown below. [ka]
[0200] It should be understood that the compounds of the present disclosure may be depicted as various tautomeric forms. It should also be understood that where the compounds have tautomeric forms, all tautomeric forms are intended to be included within the scope of the present disclosure, and the naming of the compounds does not exclude any tautomeric form.
[0201] As used herein, "lipid component" refers to a component of a nanoparticle composition that comprises one or more lipids.For example, the lipid component can comprise one or more cationic / ionic lipids, PEGylated lipids, structured lipids, or other lipids, such as phospholipids.
[0202] As used herein, a "linker" refers to a moiety that connects two moieties, such as the bond between two nucleosides of a capping species. The linker may contain one or more groups, including, but not limited to, a phosphate group (e.g., phosphate, boranophosphate, thiophosphate, selenophosphate, and phosphonate), an alkyl group, an amidate, or glycerol. For example, the two nucleosides of a capping analog may be linked at their 5' positions by a chain containing a triphosphate group or two phosphate moieties and a boranophosphate moiety.
[0203] As used herein, "method of administration" can include intravenous, intramuscular, intradermal, subcutaneous, or other methods of delivering a composition to a subject. The method of administration can be selected to target delivery (e.g., specifically deliver) to a particular area or system of the body.
[0204] As used herein, "modified" means non-natural. For example, RNA can be modified RNA. That is, RNA can contain one or more non-natural nucleic acid bases, nucleosides, nucleotides, or linkers. "Modified" species can also be referred to herein as "altered" species. Species can be chemically, structurally, or functionally modified or altered. For example, modified nucleic acid base species can contain one or more non-natural substitutions.
[0205] As used herein, "N:P ratio" refers to the molar ratio of ionic (in the physiological pH range) nitrogen atoms in the lipid to phosphate groups in the RNA, for example, in a nanoparticle composition comprising a lipid component and RNA.
[0206] As used herein, a "nanoparticle composition" refers to a composition containing one or more lipids. Nanoparticle compositions are typically on the order of micrometers or smaller in size and may contain a lipid bilayer. Nanoparticle compositions include lipid nanoparticles (LNPs), liposomes (e.g., lipid vesicles), and lipoplexes. For example, a nanoparticle composition may be a liposome having a lipid bilayer with a diameter of 500 nm or less.
[0207] As used herein, "naturally occurring" means existing in nature without artificial assistance. As used herein, "patient" refers to a subject who is seeking or may need treatment, who needs treatment, who is undergoing treatment, who is to receive treatment, or who is receiving professional medical care for a particular disease or condition.
[0208] As used herein, "PEG lipid" or "PEGylated lipid" refers to a lipid that includes a polyethylene glycol moiety. The phrase "pharmaceutically acceptable" is used herein to refer to compounds, materials, compositions, and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable risk-benefit ratio.
[0209] As used herein, the phrase "pharmaceutically acceptable excipient" refers to any ingredient other than the compounds described herein (e.g., a vehicle capable of suspending, complexing, or dissolving an active compound) that has substantially non-toxic and non-inflammatory properties in patients. Excipients include, for example, anti-caking agents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (pigments), emollients, emulsifiers, fillers (diluents), film-forming agents or coatings, flavors, fragrances, glidants (glidants), lubricants, preservatives, printing inks, adsorbents, suspending or dispersing agents, sweeteners, and water for hydration. Exemplary excipients include, but are not limited to: butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dibasic), calcium stearate, croscarmellose, cross-linked polyvinylpyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropylmethylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methylparaben, microcrystalline cellulose, polyethylene glycol, polyvinylpyrrolidone, povidone-iodine, pregelatinized starch, propylparaben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethylcellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E (α-tocopherol), vitamin C, xylitol, and other species disclosed herein.
[0210] In this specification, for convenience, the structural formula of a compound represents a specific isomer in some cases, but the present disclosure includes all isomers, such as geometric isomers, optical isomers based on asymmetric carbons, stereoisomers, tautomers, etc., and it is understood that not all isomers may have the same level of activity.In addition, for compounds represented by formula, crystalline polymorphism may exist.It is noted that any crystalline form, crystalline mixture, or its anhydride or hydrate is included in the scope of the present disclosure.
[0211] The terms "crystalline polymorph," "polymorph," or "crystalline form" refer to a compound (or a salt or solvate thereof) that has different crystal packing arrangements, all having the same elemental composition. Polymorphism refers to a crystalline structure that can crystallize in a variety of different packing arrangements. Different crystalline forms typically have different X-ray diffraction patterns, infrared spectra, melting points, densities, hardness, crystal shapes, optical and electrical properties, stability, and solubility. Depending on the recrystallization solvent, crystallization rate, storage temperature, and other factors, one crystalline form may predominate. Crystal polymorphs of a compound can be prepared by crystallization under various conditions.
[0212] The composition can also include one or more salts of compounds.Salt can be pharmaceutically acceptable salt.As used herein, " pharmaceutically acceptable salt " refers to the derivative of the disclosed compound, in which the parent compound is modified by converting existing acid or base moiety into its salt form (for example, by reacting free base group with suitable organic acid).Examples of pharmaceutically acceptable salt include, but are not limited to, inorganic or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids. Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, and 2-hydroxyethanesulfonate. Representative alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like, as well as non-toxic ammonium, quaternary ammonium, and amine cations, including, but not limited to, ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. Pharmaceutically acceptable salts of the present disclosure include conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present disclosure can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or an organic solvent, or in a mixture of both; generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts can be found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418; Pharmaceutical Salts: Properties, Selection, and Use, P.H. Stahl and C.G. Wermuth (eds.), Wiley-VCH, 2008; and Berge et al., Journal of Pharmaceutical Science, 66, 1-19 (1977), each of which is incorporated herein by reference in its entirety.
[0213] As used herein, a "phospholipid" is a lipid that contains a phosphate moiety and one or more carbon chains, for example, unsaturated fatty acid chains. A phospholipid may contain one or more multiple (e.g., double or triple) bonds (e.g., one or more unsaturated). Certain phospholipids can promote fusion with membranes. For example, cationic phospholipids can interact with one or more negatively charged phospholipids in a membrane (e.g., a cell membrane or an intracellular membrane). The fusion of a phospholipid with a membrane allows one or more components of a lipid-containing composition to pass through the membrane, for example, allowing the one or more components to be delivered to a cell.
[0214] As used herein, "polydispersity index" is a ratio that describes the uniformity of the particle size distribution of a system. For example, a small value less than 0.3 indicates a narrow particle size distribution. As used herein, the term "polypeptide" or "polypeptide of interest" refers to a polymer of amino acid residues typically joined by peptide bonds, which may be naturally or synthetically produced (e.g., isolated or purified).
[0215] As used herein, "RNA" refers to naturally occurring or non-naturally occurring ribonucleic acid. For example, RNA may contain modified and / or non-naturally occurring components, such as one or more nucleobases, nucleosides, nucleotides, or linkers. RNA may contain a cap structure, a chain-terminating nucleoside, a stem-loop, a polyA sequence, and / or a polyadenylation signal. RNA may have a nucleotide sequence encoding a polypeptide of interest. For example, RNA may be messenger RNA (mRNA). Translation of an mRNA encoding a specific polypeptide, for example, in vivo translation of an mRNA in a mammalian cell, can produce the encoded polypeptide. The RNA may be selected from the non-limiting group consisting of small interfering RNA (siRNA), asymmetric interfering RNA (aiRNA), microRNA (miRNA), Dicer substrate RNA (dsRNA), small hairpin RNA (shRNA), mRNA, single guide RNA (sgRNA), cas9 mRNA, and mixtures thereof.
[0216] As used herein, a "single unit dose" is a dose of any therapeutic agent administered in one dose / one time / single route / single point of contact, i.e., a single administration event. As used herein, a "split dose" is the division of a single unit dose or total daily dose into two or more doses.
[0217] As used herein, a "total daily dose" is the amount administered or prescribed in a 24-hour period. It may be administered as a single unit dose. As used herein, "size" or "average size" with respect to a nanoparticle composition refers to the average diameter of the nanoparticle composition.
[0218] As used herein, the term "subject" or "patient" refers to any living organism to which a composition according to the present disclosure can be administered, for example, for experimental, diagnostic, prophylactic, and / or therapeutic purposes. Typical subjects include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and humans) and / or plants.
[0219] As used herein, "target cell" refers to any one or more cells of interest. The cells may be found in vitro, in vivo, in situ, or in the tissue or organ of an organism. The organism may be an animal, preferably a mammal, more preferably a human, and most preferably a patient.
[0220] As used herein, "target tissue" refers to any one or more tissue types of interest where delivery of a therapeutic and / or prophylactic agent may result in a desired biological and / or pharmacological effect. Examples of target tissues of interest include specific tissues, organs, and systems or groups thereof. In particular applications, the target tissue may be the kidney, lung, spleen, the vascular endothelium of a blood vessel (e.g., in a coronary artery or femur), or tumor tissue (e.g., by intratumoral administration). "Non-target tissue" refers to any one or more tissue types where expression of the encoded protein does not result in a desired biological and / or pharmacological effect. In particular applications, non-target tissues may include the liver and spleen.
[0221] The terms "therapeutic agent" or "prophylactic agent" refer to any agent that has a therapeutic, diagnostic, and / or prophylactic effect and / or induces a desired biological and / or pharmacological effect when administered to a subject. A therapeutic agent may also be referred to as an "active" or "agent." Such agents include, but are not limited to, cytotoxins, radioactive ions, chemotherapeutic agents, small molecule drugs, proteins, and nucleic acids.
[0222] As used herein, the term "therapeutically effective amount" means the amount of delivered agent (e.g., nucleic acid, drug, composition, therapeutic agent, diagnostic agent, prophylactic agent, etc.) that, when administered to a subject suffering from or susceptible to an infection, disease, disorder, and / or condition, is sufficient to treat, ameliorate the symptoms of, diagnose, prevent, and / or delay the onset of the infection, disease, disorder, and / or condition.
[0223] As used herein, "transfection" refers to the introduction of a species (e.g., RNA) into a cell. Transfection can be performed, for example, in vitro, ex vivo, or in vivo.
[0224] As used herein, the term "treating" refers to the partial or complete alleviation, remission, improvement, relief, delay in onset, inhibition of progression, reduction in severity, and / or reduction in incidence of one or more symptoms or characteristics of a particular infection, disease, disorder, and / or condition. For example, "treating" cancer can refer to the inhibition of tumor survival, growth, and / or spread. Treatment can be administered to subjects who do not show signs of the disease, disorder, and / or condition and / or who show only early signs of the disease, disorder, and / or condition, with the intent of reducing the risk of developing pathologies associated with the disease, disorder, and / or condition.
[0225] As used herein, "zeta potential" is the kinetic potential of, for example, lipids in a particle composition.
[0226] Nanoparticle Composition The present disclosure also features nanoparticle compositions that include a lipid component that includes a compound represented by formula (I), (IA), (IB), (II), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), or (III), as described herein.
[0227] In some embodiments, the largest dimension of the nanoparticle composition is 1 μm or less (e.g., 1 μm, 900 nm, 800 nm, 700 nm, 600 nm, 500 nm, 400 nm, 300 nm, 200 nm, 175 nm, 150 nm, 125 nm, 100 nm, 75 nm, 50 nm, or less), as measured, for example, by dynamic light scattering (DLS), transmission electron microscopy, scanning electron microscopy, or another method. Nanoparticle compositions include, for example, lipid nanoparticles (LNPs), liposomes, lipid vesicles, and lipoplexes. In some embodiments, the nanoparticle composition is a vesicle comprising one or more lipid bilayers. In certain embodiments, the nanoparticle composition comprises two or more concentric bilayers separated by an aqueous compartment. The lipid bilayers can be functionalized and / or crosslinked to each other. The lipid bilayer can comprise one or more ligands, proteins, or channels.
[0228] The nanoparticle composition includes a lipid component comprising at least one compound represented by Formula (I), (IA), (IB), (II), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), or (III). For example, the lipid component of the nanoparticle composition can include one or more of Compounds 1-280. The nanoparticle composition can also include various other components. For example, the lipid component of the nanoparticle composition can include one or more other lipids in addition to a lipid represented by Formula (I), (IA), (IB), (II), (II), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), or (III).
[0229] Cationic / Ionic Lipids The nanoparticle composition can include, in addition to a lipid represented by formula (I), (IA), (IB), (II), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), or (III), one or more cationic and / or ionic lipids (e.g., lipids that can have a positive charge or partial positive charge at physiological pH). Cationic and / or ionic lipids include 3-(didodecylamino)-N1,N1,4-tridodecyl-1-piperazineethanamine (KL10), N1-[2-(didodecylamino)ethyl]-N1,N4,N4-tridodecyl-1,4-piperazinediethanamine (KL22), 14,25-ditridecyl-15,18,21,24-tetraaza-octatriacontane (KL25), 1,2-dilinoleyloxy-N,N-dimethylaminopropanol (KL26), and 1,2-dilinoleyloxy-N,N-dimethylaminopropanol (KL27). DLin-DMA), 2,2-Dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA), Heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (DLin-MC3-DMA), 2,2-Dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLin-KC2-DMA), 1,2-Dioleyl Oxy-N,N-dimethylaminepropane (DODMA), 2-({8-[(3β)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-1-amine (octyl-CLinDMA), (2R)-2-({8-[(3β)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z
[0039] In addition to these, the cationic lipid may also be selected from the non-limiting group consisting of (2S)-2-({8-[(3β)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-1-amine (octyl-CLinDMA(2S)).
[0230] PEG lipids The lipid component of the nanoparticle composition may contain one or more PEG or PEG-modified lipids. Such species are alternatively referred to as PEGylated lipids. PEG lipids are lipids modified with polyethylene glycol. The PEG lipids may be selected from the non-limiting group consisting of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide (PEG-CER), PEG-modified dialkylamine, PEG-modified diacylglycerol (PEG-DEG), PEG-modified dialkylglycerol, and mixtures thereof. For example, the PEG lipid may be PEG-c-DOMG, PEG-DMG, PEG-DLPE, PEG-DMPE, PEG-DPPC, or PEG-DSPE lipid.
[0231] structured lipids The lipid component of the nanoparticle composition may comprise one or more structured lipids. The structured lipid may be selected from the group consisting of, but not limited to, cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, tomatine, ursolic acid, α-tocopherol, and mixtures thereof. In some embodiments, the structured lipid is cholesterol. In some embodiments, the structured lipid includes cholesterol and a corticosteroid (such as prednisolone, dexamethasone, prednisone, and hydrocortisone), or a combination thereof.
[0232] phospholipids The lipid component of the nanoparticle composition may comprise one or more phospholipids, such as one or more (poly)unsaturated lipids. The phospholipids may be assembled into one or more lipid bilayers. Generally, the phospholipid may comprise a phospholipid moiety and one or more fatty acid moieties. For example, the phospholipid may be represented by the formula (IV): [ka] (In the formula, R pwherein R represents a phospholipid moiety, and R and R represent fatty acid moieties with or without unsaturation, which may be the same or different. The phospholipid moiety may be selected from the non-limiting group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylserine, phosphatidic acid, 2-lysophosphatidylcholine, and sphingomyelin. The fatty acid moiety may be selected from the non-limiting group consisting of lauric acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, α-linolenic acid, erucic acid, phytanic acid, arachidic acid, arachidonic acid, eicosapentaenoic acid, behenic acid, docosapentaenoic acid, and docosahexaenoic acid. Non-naturally occurring species are also contemplated, including naturally occurring species with modifications and substitutions, including branching, oxidation, cyclization, and alkynes. For example, phospholipids can be functionalized or crosslinked with one or more alkynes (e.g., alkenyl groups in which one or more double bonds are replaced with triple bonds). Under appropriate reaction conditions, the alkyne groups can undergo copper-catalyzed cycloaddition when exposed to azides. Such reactions can be useful for functionalizing the lipid bilayer of nanoparticle compositions to facilitate membrane penetration or cellular recognition, or for linking nanoparticle compositions to useful components such as targeting or imaging moieties (e.g., dyes).
[0233] Phospholipids useful in the compositions and methods of the present invention include 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), and 1,2-dioleoyl-sn-glycero-3-phosphocholine (DLPC). ro-3-phosphocholine), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn -glycero-3-phosphocholine (POPC: 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 diether PC), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), 1,2-dilinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16).0 PE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), dipalmitoylphosphatidylglycerol (DPPG), palmitoyloleoylphosphatidylethanolamine (POPE), distearoyl- ... The nanoparticle composition may be selected from the non-limiting group consisting of phosphatidylethanolamine (DSPE), dipalmitoylphosphatidylethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), 1-stearoyl-2-oleoyl-phosphatidiethanolamine (SOPE), 1-stearoyl-2-oleoyl-phosphatidylcholine (SOPC), sphingomyelin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyloleoylphosphatidylcholine, lysophosphatidylcholine, lysophosphatidylethanolamine (LPE), and mixtures thereof. In some embodiments, the nanoparticle composition comprises DSPC. In certain embodiments, the nanoparticle composition comprises DOPE. In some embodiments, the nanoparticle composition comprises both DSPC and DOPE.
[0234] adjuvants In certain embodiments, nanoparticle compositions comprising one or more lipids described herein may further comprise one or more adjuvants, such as glucopyranosyl lipid adjuvant (GLA), CpG oligodeoxynucleotides (e.g., class A or B), poly(I:C), aluminum hydroxide, and Pam3CSK4.
[0235] therapeutic agent The nanoparticle composition can include one or more therapeutic and / or prophylactic agents. The disclosure features methods for delivering a therapeutic and / or prophylactic agent to a mammalian cell or organ, producing a polypeptide of interest in the mammalian cell, and treating a disease or disorder in a mammal in need thereof, comprising administering to the mammal a nanoparticle composition including the therapeutic and / or prophylactic agent and / or contacting mammalian cells with a nanoparticle composition including the therapeutic and / or prophylactic agent.
[0236] Therapeutic and / or prophylactic agents include biologically active substances, or alternatively referred to as "active agents." Therapeutic and / or prophylactic agents can be substances that, when delivered to a cell or organ, effect a desired change in the cell, organ, or other body tissue or system. Such species can be useful in treating one or more diseases, disorders, or conditions. In certain embodiments, the therapeutic and / or prophylactic agents are small molecule drugs useful in treating a particular disease, disorder, or condition. Examples of drugs useful in nanoparticle compositions include, but are not limited to, antitumor drugs (e.g., vincristine, doxorubicin, mitoxantrone, camptothecin, cisplatin, bleomycin, cyclophosphamide, methotrexate, and streptozotocin), anti-tumor agents (e.g., actinomycin D, vincristine, vinblastine, cytosine arabinoside, anthracyclines, alkylating agents, platinum compounds, antimetabolites, and nucleoside analogs, such as methotrexate and purine and pyrimidine analogs), anti-infectives, local anesthetics (e.g., dibucaine and chlorpromazine), beta-adrenergic blockers (e.g., propranolol, timolol, and labetalol), antihypertensives ( antihistamines (e.g., diphenylhydramine, chlorpheniramine, and promethazine), antibiotics / antibacterials (e.g., gentamicin, ciprofloxacin, and cefoxitin), antifungals (e.g., miconazole, terconazole, econazole, isoconazole, butoconazole, clotrimazole, itraconazole, nystatin, naftifine, and amphotericin B), antiparasitic agents, hormones, hormone antagonists, immunomodulators, neurotransmitter antagonists, antiglaucoma agents, vitamins, anesthetics, and imaging agents.
[0237] In certain embodiments, the therapeutic and / or prophylactic agent is a cytotoxin, a radioactive ion, a chemotherapeutic agent, a vaccine, a compound that elicits an immune response, and / or another therapeutic and / or prophylactic agent. A cytotoxin or cytotoxic agent includes any agent that can be harmful to cells. Examples include, but are not limited to, taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, teniposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, dihydroxyanthracenedione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, maytansinoids, such as maytansinol, rachelmycin (CC-1065), and analogs or congeners thereof. Radioactive ions include, but are not limited to, iodine (e.g., iodine-125 or iodine-131), strontium-89, phosphorus, palladium, cesium, iridium, sulfate, cobalt, yttrium-90, samarium-153, and praseodymium. Vaccines include compounds and preparations capable of conferring immunization against one or more conditions associated with infectious diseases, such as influenza, measles, human papillomavirus (HPV), rabies, meningitis, whooping cough, tetanus, plague, hepatitis, and tuberculosis, and may include mRNA encoding antigens and / or epitopes derived from infectious diseases. Vaccines also include compounds and preparations that direct an immune response against cancer cells and may include mRNA encoding antigens, epitopes, and / or neoepitopes derived from tumor cells. Compounds that elicit an immune response may include vaccines, corticosteroids (e.g., dexamethasone), and other species. In one embodiment, the vaccine and / or compound capable of eliciting an immune response is administered intramuscularly via a composition comprising a compound of Formula (I), (IA), (IB), (II), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), or (III) (e.g., compounds 3, 18, 20, 25, 26, 29, 30, 60, 108-112, or 122).Other therapeutic and / or prophylactic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil dacarbazine), alkylating agents (e.g., mechlorethamine, thiotepa chlorambucil, rachelmycin (CC-1065), melphalan, carmustine (BSNU), lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, These include tocine, mitomycin C, and cis-dichlorodiamineplatinum(II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and antimitotic agents (e.g., vincristine, vinblastine, taxol, and maytansinoids).
[0238] In other embodiments, the therapeutic and / or prophylactic agent is a protein. Therapeutic proteins useful in the nanoparticles of the present disclosure include, but are not limited to, gentamicin, amikacin, insulin, erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), factor VIR, luteinizing hormone-releasing hormone (LHRH) analogs, interferon, heparin, hepatitis B surface antigen, typhoid vaccine, and cholera vaccine.
[0239] Polynucleotides and Nucleic Acids In certain embodiments, the therapeutic agent is a polynucleotide or nucleic acid (e.g., ribonucleic acid or deoxyribonucleic acid). The term "polynucleotide," in its broadest sense, includes any compound and / or substance that is or can be incorporated into an oligonucleotide strand. Exemplary polynucleotides for use in accordance with the present disclosure include, but are not limited to, one or more of deoxyribonucleic acid (DNA), ribonucleic acid (RNA), including messenger mRNA (mRNA), hybrids thereof, RNAi-inducing agents, RNAi agents, siRNA, shRNA, miRNA, antisense RNA, ribozymes, catalytic DNA, RNA that induces triple helix formation, aptamers, vectors, and the like. In certain embodiments, the therapeutic and / or prophylactic agent is RNA. RNA useful in the compositions and methods described herein may be selected from the group consisting of, but not limited to, shortmers, antagomirs, antisense, ribozymes, small interfering RNAs (siRNAs), asymmetric interfering RNAs (aiRNAs), microRNAs (miRNAs), dicer substrate RNAs (dsRNAs), small hairpin RNAs (shRNAs), transfer RNAs (tRNAs), messenger RNAs (mRNAs), and mixtures thereof. In certain embodiments, the RNA is mRNA.
[0240] In certain embodiments, the therapeutic and / or prophylactic agent is an mRNA. The mRNA can encode any polypeptide of interest, including any natural or non-natural or modified polypeptide. The polypeptide encoded by the mRNA can be of any size and have any secondary structure or activity. In certain embodiments, the polypeptide encoded by the mRNA can have a therapeutic effect when expressed in a cell.
[0241] In other embodiments, the therapeutic and / or prophylactic agent is an siRNA. The siRNA may be capable of selectively knocking down or downregulating the expression of a gene of interest. For example, the siRNA may be selected so that, when a nanoparticle composition containing the siRNA is administered to a subject in need thereof, it silences a gene associated with a particular disease, disorder, or pathological condition. The siRNA may comprise a sequence complementary to the mRNA sequence encoding the gene or protein of interest. In some embodiments, the siRNA may be an immunomodulatory siRNA.
[0242] In certain embodiments, the therapeutic and / or prophylactic agent is sgRNA and / or cas9 mRNA. sgRNA and / or cas9 mRNA can be used as a gene editing tool. For example, sgRNA-cas9 complex can affect the mRNA translation of cellular genes.
[0243] In some embodiments, the therapeutic agent and / or prophylactic agent is shRNA or its encoding vector or plasmid.When appropriate construct is delivered to nucleus, shRNA can be produced inside target cell.The construct and mechanism related to shRNA are well known in the art.
[0244] Nucleic acids and polynucleotides useful in the present disclosure typically include a first region of linked nucleosides encoding a polypeptide of interest (e.g., a coding region), a first flanking region (e.g., a 5'-UTR) located at the 5' end of the first region, a second flanking region (e.g., a 3'-UTR) located at the 3' end of the first region, at least one 5'-cap region, and a 3'-stabilizing region. In certain embodiments, the nucleic acid or polynucleotide further includes a poly-A region or a Kozak sequence (e.g., in the 5'-UTR). In some cases, the polynucleotide may contain one or more intronic nucleotide sequences that can be excised from the polynucleotide. In certain embodiments, the polynucleotide or nucleic acid (e.g., mRNA) may include a 5'-cap structure, a chain-terminating nucleotide, a stem-loop, a polyA sequence, and / or a polyadenylation signal. Any one of the regions of the nucleic acid may include one or more modified components (e.g., modified nucleosides). For example, the 3'-stabilizing region may contain modified nucleosides, such as L-nucleosides, reverse thymidines, or 2'-O-methyl nucleosides, and / or the coding region, 5'-UTR, 3'-UTR, or cap region may include modified nucleosides, such as 5-substituted uridines (e.g., 5-methoxyuridine), 1-substituted pseudouridines (e.g., 1-methyl-pseudouridine or 1-ethyl-pseudouridine), and / or 5-substituted cytidines (e.g., 5-methyl-cytidine).
[0245] In general, the shortest length of a polynucleotide may be a length of polynucleotide sequence sufficient to encode a dipeptide. In another embodiment, the length of the polynucleotide sequence is sufficient to encode a tripeptide. In another embodiment, the length of the polynucleotide sequence is sufficient to encode a tetrapeptide. In another embodiment, the length of the polynucleotide sequence is sufficient to encode a pentapeptide. In another embodiment, the length of the polynucleotide sequence is sufficient to encode a hexapeptide. In another embodiment, the length of the polynucleotide sequence is sufficient to encode a heptapeptide. In another embodiment, the length of the polynucleotide sequence is sufficient to encode an octapeptide. In another embodiment, the length of the polynucleotide sequence is sufficient to encode a nonapeptide. In another embodiment, the length of the polynucleotide sequence is sufficient to encode a decapeptide.
[0246] Examples of dipeptides that the modified polynucleotide sequences can encode include, but are not limited to, carnosine and anserine. In some embodiments, the polynucleotide is greater than 30 nucleotides in length. In another embodiment, the polynucleotide molecule is greater than 35 nucleotides in length. In another embodiment, the length is at least 40 nucleotides. In another embodiment, the length is at least 45 nucleotides. In another embodiment, the length is at least 55 nucleotides. In another embodiment, the length is at least 50 nucleotides. In another embodiment, the length is at least 60 nucleotides. In another embodiment, the length is at least 80 nucleotides. In another embodiment, the length is at least 90 nucleotides. In another embodiment, the length is at least 100 nucleotides. In another embodiment, the length is at least 120 nucleotides. In another embodiment, the length is at least 140 nucleotides. In another embodiment, the length is at least 160 nucleotides. In another embodiment, the length is at least 180 nucleotides. In another embodiment, the length is at least 200 nucleotides. In another embodiment, the length is at least 250 nucleotides. In another embodiment, the length is at least 300 nucleotides. In another embodiment, the length is at least 350 nucleotides. In another embodiment, the length is at least 400 nucleotides. In another embodiment, the length is at least 450 nucleotides. In another embodiment, the length is at least 500 nucleotides. In another embodiment, the length is at least 600 nucleotides. In another embodiment, the length is at least 700 nucleotides. In another embodiment, the length is at least 800 nucleotides. In another embodiment, the length is at least 900 nucleotides. In another embodiment, the length is at least 1000 nucleotides. In another embodiment, the length is at least 1100 nucleotides. In another embodiment, the length is at least 1200 nucleotides. In another embodiment, the length is at least 1300 nucleotides. In another embodiment, the length is at least 1400 nucleotides.In another embodiment, the length is at least 1500 nucleotides. In another embodiment, the length is at least 1600 nucleotides. In another embodiment, the length is at least 1800 nucleotides. In another embodiment, the length is at least 2000 nucleotides. In another embodiment, the length is at least 2500 nucleotides. In another embodiment, the length is at least 3000 nucleotides. In another embodiment, the length is at least 4000 nucleotides. In another embodiment, the length is at least 5000 nucleotides or more than 5000 nucleotides.
[0247] Nucleic acids and polynucleotides may contain one or more naturally occurring nucleotides, including any of the standard nucleotides A (adenosine), G (guanosine), C (cytosine), U (uridine), or T (thymidine). In one embodiment, all or substantially all of the nucleotides comprising (a) the 5'-UTR, (b) the open reading frame (ORF), (c) the 3'-UTR, (d) the poly-A tail, and any combination of (a, b, c, or d above) contain the naturally occurring standard nucleotides A (adenosine), G (guanosine), C (cytosine), U (uridine), or T (thymidine).
[0248] Nucleic acids and polynucleotides can contain one or more modified components described herein that confer useful properties, including improved stability and / or substantially no induction of an innate immune response in cells into which the polynucleotide is introduced. For example, modified polynucleotides or nucleic acids exhibit reduced degradation in cells into which the polynucleotide or nucleic acid is introduced, compared to corresponding unmodified polynucleotides or nucleic acids. These modified species can improve the efficiency of protein production, intracellular retention of the polynucleotide, and / or viability of contacted cells, as well as have reduced immunogenicity.
[0249] Polynucleotides and nucleic acids can be natural or non-natural. Polynucleotides and nucleic acids can contain one or more modified (e.g., altered or alternative) nucleobases, nucleosides, nucleotides, or combinations thereof. Nucleic acids and polynucleotides useful in nanoparticle compositions can contain any useful modification or alteration, such as those to the nucleobase, sugar, or internucleoside linkage (e.g., linking phosphate / phosphodiester bond / phosphodiester backbone). In certain embodiments, modifications (e.g., one or more modifications) are present in each of the nucleobase, sugar, and internucleoside linkage. Modifications according to the present disclosure can be modifications of ribonucleic acid (RNA) to deoxyribonucleic acid (DNA) (e.g., replacement of 2'-OH with 2'-H in a ribofuranosyl ring), threose nucleic acid (TNA), glycol nucleic acid (GNA), peptide nucleic acid (PNA), locked nucleic acid (LNA), or hybrids thereof. Additional modifications are described herein.
[0250] Polynucleotides and nucleic acids may or may not be uniformly modified along the entire length of the molecule. For example, one or more or all types of nucleotides (e.g., purines or pyrimidines, or one or more or all of A, G, U, C) may or may not be uniformly modified in a polynucleotide or nucleic acid, or in a given, predetermined sequence region thereof. In some cases, every nucleotide X in a polynucleotide (or in a given sequence region thereof) is modified, where X can be any one of the nucleotides A, G, U, C, or any one of the combinations A+G, A+U, A+C, G+U, G+C, U+C, A+G+U, A+G+C, G+U+C, or A+G+C.
[0251] Different sugar modifications and / or internucleoside linkages (e.g., backbone structures) can be present at various positions in a polynucleotide. It will be understood by those skilled in the art that nucleotide analogs or other modifications can be placed at any position in a polynucleotide so that the function of the polynucleotide is not substantially impaired. Modifications can also be 5'- or 3'-terminal modifications. In certain embodiments, a polynucleotide contains a modification at the 3'-terminus. Polynucleotides may contain from about 1% to about 100% modified nucleotides (relative to the total nucleotide content, or relative to one or more types of nucleotides, i.e., any one or more of A, G, U, or C), or any percentage therebetween (e.g., 1%-20%, 1%-25%, 1%-50%, 1%-60%, 1%-70%, 1%-80%, 1%-90%, 1%-95%, 10%-20%, 10%-25%, 10%-50%, 10%-60%, 10%-70%, 10%-80%, 10%-90%, It may contain 10% to 95%, 10% to 100%, 20% to 25%, 20% to 50%, 20% to 60%, 20% to 70%, 20% to 80%, 20% to 90%, 20% to 95%, 20% to 100%, 50% to 60%, 50% to 70%, 50% to 80%, 50% to 90%, 50% to 95%, 50% to 100%, 70% to 80%, 70% to 90%, 70% to 95%, 70% to 100%, 80% to 90%, 80% to 95%, 80% to 100%, 90% to 95%, 90% to 100%, and 95% to 100%). It will be understood that occurrences of standard nucleotides (eg, A, G, U, or C) may account for any remaining percentages.
[0252] A polynucleotide can contain a minimum of 0% and a maximum of 100% modified nucleotides, or any percentage therebetween, for example, at least 5% modified nucleotides, at least 10% modified nucleotides, at least 25% modified nucleotides, at least 50% modified nucleotides, at least 80% modified nucleotides, or at least 90% modified nucleotides. For example, a polynucleotide can contain modified pyrimidines, such as modified uracil or cytosine. In some embodiments, at least 5%, at least 10%, at least 25%, at least 50%, at least 80%, at least 90%, or 100% of the uracils in a polynucleotide are substituted with modified uracils (e.g., 5-substituted uracils). The modified uracils can be substituted with a compound having a single unique structure, or with multiple compounds having different structures (e.g., two, three, four, or more unique structures). In some cases, at least 5%, at least 10%, at least 25%, at least 50%, at least 80%, at least 90%, or 100% of the cytosines in a polynucleotide are substituted with modified cytosines (e.g., 5-substituted cytosines). The modified cytosines may be substituted with a compound having a single unique structure, or may be substituted with multiple compounds having different structures (e.g., two, three, four, or more unique structures).
[0253] In some cases, the nucleic acid does not substantially induce an innate immune response in a cell into which the polynucleotide (e.g., mRNA) has been introduced, characterized by 1) increased expression of pro-inflammatory cytokines, 2) activation of intracellular PRRs (e.g., RIG-I, MDA5, etc.), and / or 3) termination or reduction of protein translation.
[0254] The nucleic acid may optionally include other agents (e.g., RNAi-inducing agents, RNAi agents, siRNA, shRNA, miRNA, antisense RNA, ribozymes, catalytic DNA, tRNA, RNA that induces triple helix formation, aptamers, and vectors). In certain embodiments, the nucleic acid may include one or more messenger RNAs (mRNAs) with one or more modified nucleosides or nucleotides (i.e., modified mRNA molecules).
[0255] In certain embodiments, the nucleic acid (e.g., mRNA) molecules, formulas, compositions, or methods related thereto are disclosed in WO 2002 / 098443, WO 2003 / 051401, WO 2008 / 052770, WO 2009127230, WO 2006122828, WO 2008 / 083949, WO 2010088927, WO 2010 / 037539, WO 2004 / 00 No. 4743, International Publication No. 2005 / 016376, International Publication No. 2006 / 024518, International Publication No. 2007 / 095976, International Publication No. 2008 / 014979, International Publication No. 2008 / 077592, International Publication No. 2009 / 030481, International Publication No. 2009 / 095226, International Publication No. 2011069586, International Publication No. 2011026641, International Publication No. 2011 / 144358 Lett., International Publication No. 2012019780, International Publication No. 2012013326, International Publication No. 2012089338, International Publication No. 2012113513, International Publication No. 2012116811, International Publication No. 2012116810, International Publication No. 2013113502, International Publication No. 2013113501, International Publication No. 2013113736, International Publication No. 2013143698, International Publication No. 201314 3699 pamphlet, International Publication No. 2013143700 pamphlet, International Publication No. 2013 / 120626 pamphlet, International Publication No. 2013120627 pamphlet, International Publication No. 2013120628 pamphlet, International Publication No. 2013120629 pamphlet, International Publication No. 2013174409 pamphlet, International Publication No. 2014127917 pamphlet, International Publication No. 2015 / 024669 pamphlet, International Publication No. 2015 / 024668 pamphlet, International Publication No. 2015 / 024667 pamphlet,The present invention also includes one or more polynucleotides comprising the features described in WO 2015 / 024665, WO 2015 / 024666, WO 2015 / 024664, WO 2015101415, WO 2015101414, WO 2015024667, WO 2015062738, WO 2015101416 (all of which are incorporated herein by reference).
[0256] Nucleobase Modification Modified nucleosides and nucleotides may contain modified nucleobases. The nucleobases of nucleic acids are organic bases, such as purines or pyrimidines, or derivatives thereof. The nucleobases may be standard bases (e.g., adenine, guanine, uracil, thymine, and cytosine). These nucleobases may be modified or completely replaced to provide polynucleotide molecules with improved properties, such as improved stability, such as resistance to nucleases. Non-standard or modified bases may contain one or more substitutions or modifications, including, but not limited to, alkyl, aryl, halo, oxo, hydroxyl, alkyloxy, and / or thio substitutions; one or more fused or open rings; oxidation; and / or reduction.
[0257] Modified nucleotide base pairing encompasses not only standard adenine-thymine, adenine-uracil, or guanine-cytosine base pairs, but also base pairs formed between nucleotides and / or modified nucleotides containing non-standard or modified bases, where the configuration of hydrogen bond donors and hydrogen bond acceptors allows for hydrogen bonding between the non-standard base and a standard base or between two complementary non-standard base structures. One example of such non-standard base pairing is base pairing between the modified nucleotide inosine and adenine, cytosine, or uracil.
[0258] In some embodiments, the nucleobase is a modified uracil. Exemplary nucleobases and nucleosides having modified uracil include pseudouridine (ψ), pyridin-4-one ribonucleoside, 5-aza-uracil, 6-aza-uracil, 2-thio-5-aza-uracil, 2-thio-uracil (s 2 U), 4-thio-uracil (s 4 U), 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxy-uracil (ho 5 U), 5-aminoallyl-uracil, 5-halo-uracil (e.g., 5-iodo-uracil or 5-bromo-uracil), 3-methyl-uracil (m 3 U), 5-methoxy-uracil (mo 5 U), uracil 5-hydroxyacetic acid (cmo 5 U), uracil 5-hydroxyacetic acid methyl ester (mcmo 5 U), 5-carboxymethyl-uracil (cm 5 U), 1-carboxymethyl-pseudouridine, 5-carboxyhydroxymethyl-uracil (chm 5 U), 5-carboxyhydroxymethyl-uracil methyl ester (mchm 5 U), 5-methoxycarbonylmethyl-uracil (mcm 5 U), 5-methoxycarbonylmethyl-2-thiouracil (mcm 5 s 2 U), 5-aminomethyl-2-thio-uracil (nm 5 s 2 U), 5-methylaminomethyl-uracil (mnm 5 U), 5-methylaminomethyl-2-thiouracil (mnm 5 s 2 U), 5-methylaminomethyl-2-seleno-uracil (mnm 5 se 2 U), 5-carbamoylmethyl-uracil (ncm 5 U), 5-carboxymethylaminomethyl-uracil (cmnm 5 U), 5-carboxymethylaminomethyl-2-thiouracil (cmnm 5 s 2U), 5-propynyl-uracil, 1-propynyl-pseudouracil, 5-taurinomethyl-uracil (τm 5 U), 1-taurinomethyl-pseudouridine, 5-taurinomethyl-2-thio-uracil (τm 5 s 2 U), 1-taurinomethyl-4-thio-pseudouridine, 5-methyl-uracil (m 5 U, i.e., having the nucleobase deoxythymine), 1-methyl-pseudouridine (m 1 ψ), 1-ethyl-pseudouridine (Et 1 ψ), 5-methyl-2-thiouracil (m 5 s 2 U), 1-methyl-4-thio-pseudouridine (m 1 s 4 ψ), 4-thio-1-methyl-pseudouridine, 3-methyl-pseudouridine (m 3 ψ), 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydrouracil (D), dihydropseudouridine, 5,6-dihydrouracil, 5-methyl-dihydrouracil (m 5 D), 2-thio-dihydrouracil, 2-thio-dihydropseudouridine, 2-methoxy-uracil, 2-methoxy-4-thio-uracil, 4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine, N1-methyl-pseudouridine, 3-(3-amino-3-carboxypropyl)uracil (acp 3 U), 1-methyl-3-(3-amino-3-carboxypropyl)pseudouridine (acp 3 ψ), 5-(isopentenylaminomethyl)uracil (inm 5 U), 5-(isopentenylaminomethyl)-2-thiouracil (inm 5 s 2 U), 5,2'-O-dimethyl-uridine (m 5 Um), 2-thio-2'-O_methyl-uridine (s 2 Um), 5-methoxycarbonylmethyl-2'-O-methyl-uridine (mcm 5Um), 5-carbamoylmethyl-2'-O-methyl-uridine (ncm 5 Um), 5-carboxymethylaminomethyl-2'-O-methyl-uridine (cmnm 5 Um), 3,2'-O-dimethyl-uridine (m 3 Um), and 5-(isopentenylaminomethyl)-2'-O-methyl-uridine (inm 5 Um), 1-thio-uracil, deoxythymidine, 5-(2-carbomethoxyvinyl)-uracil, 5-(carbamoylhydroxymethyl)-uracil, 5-carbamoylmethyl-2-thio-uracil, 5-carboxymethyl-2-thio-uracil, 5-cyanomethyl-uracil, 5-methoxy-2-thio-uracil, and 5-[3-(1-E-propenylamino)]uracil.
[0259] In some embodiments, the nucleobase is a modified cytosine. Exemplary nucleobases and nucleosides having modified cytosines include 5-aza-cytosine, 6-aza-cytosine, pseudoisocytidine, 3-methyl-cytosine (m3C), N4-acetyl-cytosine (ac4C), 5-formyl-cytosine (f5C), N4-methyl-cytosine (m4C), 5-methyl-cytosine (m5C), 5-halo-cytosine (e.g., 5-iodo-cytosine), 5-hydroxymethyl-cytosine (hm5C), 1-methyl-pseudoisocytidine, pyrrolo-cytosine, pyrrolo-pseudoisocytidine, 2-thio-cytosine (s2C), 2-thio-5-methyl-cytosine, 4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine Idoisocytidine, Zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytosine, 2-methoxy-5-methyl-cytosine, 4-methoxy-pseudoisocytidine, 4-methoxy-1-methyl-pseudoisocytidine, Lysidine (k2C), 5,2'-O-dimethyl-cytidine (m5Cm), N4- These include acetyl-2'-O-methyl-cytidine (ac4Cm), N4,2'-O-dimethyl-cytidine (m4Cm), 5-formyl-2'-O-methyl-cytidine (f5Cm), N4,N4,2'-O-trimethyl-cytidine (m42Cm), 1-thio-cytosine, 5-hydroxy-cytosine, 5-(3-azidopropyl)-cytosine, and 5-(2-azidoethyl)-cytosine.
[0260] In some embodiments, the nucleobase is a modified adenine. Exemplary nucleobases and nucleosides having modified adenines include 2-amino-purine, 2,6-diaminopurine, 2-amino-6-halo-purine (e.g., 2-amino-6-chloro-purine), 6-halo-purine (e.g., 6-chloro-purine), 2-amino-6-methyl-purine, 8-azido-adenine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-amino-purine, 7-deaza-8-aza-2-amino-purine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza- 2,6-Diaminopurine, 1-methyl-adenine (m1A), 2-methyl-adenine (m2A), N6-methyl-adenine (m6A), 2-methylthio-N6-methyl-adenine (ms2m6A), N6-isopentenyl-adenine (i6A), 2-methylthio-N6-isopentenyl-adenine (ms2i6A), N6-(cis-hydroxyisopentenyl)adenine (io6A), 2-methylthio-N6-(cis-hydroxyisopentenyl)adenine (ms2io6A), N6-glycinylcarbamoyl-adenine (g6A), N6-threonylcarbamoyl-adenine (t6A), N6-methyl-N6-threonylcarbamoyl-adenine (m6t6A), 2-methylthio-N6-threonylcarbamoyl-adenine (ms2g6A), N6,N6-dimethyl-adenine (m62A), N6-hydroxynorvalylcarbamoyl-adenine (hn6A), 2-methylthio-N6-hydroxynorvalylcarbamoyl-adenine (ms2hn6A), N6-acetyl-adenine (ac6A), 7-methyl-adenine, 2-methylthio- These include adenine, 2-methoxy-adenine, N6,2'-O-dimethyl-adenosine (m6Am), N6,N6,2'-O-trimethyl-adenosine (m62Am), 1,2'-O-dimethyl-adenosine (m1Am), 2-amino-N6-methyl-purine, 1-thio-adenine, 8-azido-adenine, N6-(19-amino-pentaoxanonadecyl)-adenine, 2,8-dimethyl-adenine, N6-formyl-adenine, and N6-hydroxymethyl-adenine.
[0261] In some embodiments, the nucleobase is a modified guanine. Exemplary nucleobases and nucleosides having modified guanines include inosine (I), 1-methyl-inosine (m1I), wyosine (imG), methylwyosine (mimG), 4-demethyl-wyosine (imG-14), isowyosine (imG2), wybutosine (yW), peroxywybutosine (o2yW), hydroxywybutosine (OHyW), undermodified hydroxywybutosine (OHyW), and hydroxywybutosine (OHyW). * ), 7-deaza-guanine, queuosine (Q), epoxyqueuosine (oQ), galactosyl-queuosine (galQ), mannosyl-queuosine (manQ), 7-cyano-7-deaza-guanine (preQ0), 7-aminomethyl-7-deaza-guanine (preQ1), archaeosine (G+), 7-deaza-8-aza-guanine, 6-thio-guanine, 6-thio-7-deaza-guanine, 6-thio-7-deaza-8-aza-guanine, 7-methyl-guanine (m7G), 6-thio-7-methyl-guanine, 7-methyl-inosine, 6-methoxy-guanine, 1-methyl-guanine (m1G), N2-methyl-guanine (m2G), N2,N2-dimethyl-guanine (m22G), N2,7- Dimethyl-guanine (m2,7G), N2,N2,7-dimethyl-guanine (m2,2,7G), 8-oxo-guanine, 7-methyl-8-oxo-guanine, 1-methyl-6-thio-guanine, N2-methyl-6-thio-guanine, N2,N2-dimethyl-6-thio-guanine, N2-methyl-2'-O-methyl-guanosine (m2Gm), N2,N2-dimethyl-2'-O-methyl-guanosine (m22Gm), 1-methyl-2'-O-methyl-guanosine (m1Gm), N2,7-dimethyl-2'-O-methyl-guanosine (m2,7Gm), 2'-O-methyl-inosine (Im), 1,2'-O-dimethyl-inosine (m1Im), 1-thio-guanine, and O-6-methyl-guanine.
[0262] The modified nucleobase of a nucleotide can independently be a purine, a pyrimidine, a purine or pyrimidine analog. For example, the nucleobase can be a modified adenine, cytosine, guanine, uracil, or hypoxanthine. In another embodiment, the nucleobases can also include, for example, natural and synthetic derivatives of bases, such as pyrazolo[3,4-d]pyrimidine, 5-methylcytosine (5-me-C), 5-hydroxymethylcytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-propynyluracil and cytosine, 6-azouracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo (e.g., 8-bromo), 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxy and other 8-substituted adenines and guanines, 5-halo, especially 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, deazaguanine, 7-deazaguanine, 3-deazaguanine, deazaadenine, 7-deazaadenine, 3-deazaadenine, pyrazolo[3,4-d]pyrimidine, imidazo[1,5-a]1,3,5 triazinone, 9-deazapurine, imidazo[4,5-d]pyrazine, thiazolo[4,5-d]pyrimidine, pyrazin-2-one, 1,2,4-triazine, pyridazine; or 1,3,5 triazine. When nucleotides are designated using the abbreviations A, G, C, T, or U, each letter refers to a representative base and / or its derivatives, e.g., A includes adenine or an adenine analog, e.g., 7-deazaadenine.
[0263] Modifications in sugars Nucleosides comprise a sugar molecule (e.g., a 5-carbon or 6-carbon sugar, such as pentose, ribose, arabinose, xylose, glucose, galactose, or deoxy derivatives thereof) in combination with a nucleobase, while nucleotides are nucleosides containing a phosphate group or modified group (e.g., boranophosphate, thiophosphate, selenophosphate, phosphonate, alkyl group, amidate, and glycerol). The nucleoside or nucleotide can be a standard species, e.g., a nucleoside or nucleotide containing a standard nucleobase, sugar, and, in the case of a nucleotide, a phosphate group, or a modified nucleoside or nucleotide containing one or more modified moieties. For example, modified nucleosides and nucleotides can be modified in the sugar of the nucleoside or nucleotide. In certain embodiments, modified nucleosides or nucleotides have the structure: [ka] Includes.
[0264] In each of Formulas IV, V, VI and VII: m and n are each independently an integer of 0 to 5; Each of U and U' is independently O, S, N(R U ) nu , or C(R U ) nu where nu is an integer from 0 to 2, and each R U is independently H, halo, or optionally substituted alkyl; R 1’ , R 2’ , R 1” , R 2” , R 1 , R 2 , R 3 , R 4 , and R 5each, if present, is independently H, halo, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, or absent; 3 and R 1’ , R 1” , R 2’ , R 2” , or R 5 (e.g., R 1’ and R 3 Combination of R 1” and R 3 Combination of R 2’ and R 3 Combination of R 2” and R 3 combination, or R 5 and R 3 (combinations of) can be joined together to form an optionally substituted alkylene or an optionally substituted heteroalkylene, which, together with the carbons to which they are attached, provide an optionally substituted heterocyclyl (e.g., a bicyclic, tricyclic, or tetracyclic heterocyclyl); where R 5 and R 1’ , R 1” , R 2’ , or R 2” (e.g., R 1’ and R 5 Combination of R 1” and R 5 Combination of R 2’ and R 5 combination, or R 2” and R 5(combinations of) can be joined together to form an optionally substituted alkylene or an optionally substituted heteroalkylene, which, together with the carbons to which they are attached, provide an optionally substituted heterocyclyl (e.g., a bicyclic, tricyclic, or tetracyclic heterocyclyl); where R 4 and R 1’ , R 1” , R 2’ , R 2” , R 3 , or R 5 can be joined together to form an optionally substituted alkylene or an optionally substituted heteroalkylene, which, together with the carbons to which they are attached, provide an optionally substituted heterocyclyl (e.g., a bicyclic, tricyclic, or tetracyclic heterocyclyl); each of m' and m" is independently an integer from 0 to 3 (e.g., 0 to 2, 0 to 1, 1 to 3, or 1 to 2); Y 1 , Y 2 , and Y 3 each independently represents O, S, Se, -NR N1 -, optionally substituted alkylene, or optionally substituted heteroalkylene, where R N1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or absent; Each Y 4 are independently H, hydroxy, thiol, boranyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted thioalkoxy, optionally substituted alkoxyalkoxy, or optionally substituted amino; Each Y 5 is independently O, S, Se, optionally substituted alkylene (e.g., methylene), or optionally substituted heteroalkylene; B is a nucleobase, either modified or unmodified. In some embodiments, the 2'-hydroxy group (OH) can be modified or substituted with several different substituents. Exemplary substitutions at the 2'-position include, but are not limited to, H, azido, halo (e.g., fluoro), optionally substituted C 1~6 alkyl (e.g., methyl); optionally substituted C 1~6 Alkoxy (e.g., methoxy or ethoxy); optionally substituted C 6~10 Aryloxy; optionally substituted C 3~8 Cycloalkyl; optionally substituted C 6~10 Aryl-C 1~6 Alkoxy, optionally substituted C 1~12 (heterocyclyl)oxy; sugars (e.g., ribose, pentose, or any described herein); polyethylene glycol (PEG), -O(CH2CH2O) n CH2CH2OR (wherein R is H or optionally substituted alkyl and n is an integer from 0 to 20 (e.g., 0 to 4, 0 to 8, 0 to 10, 0 to 16, 1 to 4, 1 to 8, 1 to 10, 1 to 16, 1 to 20, 2 to 4, 2 to 8, 2 to 10, 2 to 16, 2 to 20, 4 to 8, 4 to 10, 4 to 16, and 4 to 20); "locked" nucleic acids (LNAs) (wherein the 2'-hydroxy is 1~6 Alkylene or C 1~6a heteroalkylene bridge linked to the 4'-carbon of the same ribose sugar; exemplary bridges included methylene, propylene, ether, or amino bridges; aminoalkyl, as defined herein; aminoalkoxy, as defined herein; amino, as defined herein; and amino acid, as defined herein. Generally, RNA contains the sugar group ribose, which is a five-membered ring bearing an oxygen atom. Exemplary, non-limiting modified nucleotides include substitution of an oxygen atom in the ribose (e.g., with S, Se, or an alkylene such as methylene or ethylene); addition of a double bond (e.g., to replace ribose with cyclopentenyl or cyclohexenyl); ring contraction of ribose (e.g., to form a four-membered cyclobutane or oxetane ring); ring expansion of ribose (e.g., to add additional carbons or heteroatoms, such as anhydrohexitol, altritol, mannitol, cyclohexanyl, cyclohexenyl, and morpholino (also having a phosphoramidate backbone)). to form 6- or 7-membered rings with 2 atoms; polycyclic forms (e.g., tricyclic and "unlocked" forms such as glycol nucleic acids (GNAs) (e.g., R-GNA or S-GNA, in which the ribose is replaced by a glycol unit linked to a phosphodiester bond), threose nucleic acids (TNA, in which the ribose is replaced by α-L-threofuranosyl-(3'→2')), and peptide nucleic acids (PNA, in which a 2-amino-ethyl-glycine bond replaces the ribose and phosphodiester backbone).
[0265] In certain embodiments, the sugar group contains one or more carbons that have the opposite stereochemical configuration as the corresponding carbon in ribose. Thus, a polynucleotide molecule can include nucleotides that contain, for example, arabinose or L-ribose as the sugar.
[0266] In certain embodiments, a polynucleotide comprises at least one nucleoside where the sugar is L-ribose, 2'-O-methyl-ribose, 2'-fluoro-ribose, arabinose, hexitol, LNA, or PNA.
[0267] Modifications in internucleoside linkages Modified nucleotides can be modified in the internucleoside linkage (e.g., the phosphate backbone). As used herein, the terms "phosphate" and "phosphodiester" are used interchangeably with respect to the polynucleotide backbone. The backbone phosphate group can be modified by replacing one or more of the oxygen atoms with different substituents.
[0268] Modified nucleotides may include wholesale substitution of unmodified phosphate moieties with alternative internucleoside linkages as described herein. Examples of modified phosphate groups include, but are not limited to, phosphorothioates, phosphoroselenates, boranophosphates, boranophosphate esters, hydrogen phosphonates, phosphoramidates, phosphorodiamidates, alkyl or aryl phosphonates, and phosphotriesters. Phosphorodithioates have both non-linked oxygens replaced by sulfur. Phosphate linkers can also be modified by replacing the linking oxygen with nitrogen (bridged phosphoramidates), sulfur (bridged phosphorothioates), and carbon (bridged methylene-phosphonates).
[0269] Modified nucleosides and nucleotides can include substitution of one or more non-bridging oxygens with a borane moiety (BH3), sulfur (thio), methyl, ethyl, and / or methoxy. As a non-limiting example, two non-bridging oxygens at the same position (e.g., the alpha (α), beta (β), or gamma (γ) position) can be substituted with sulfur (thio) and methoxy.
[0270] Substitution of one or more oxygen atoms at the α-position of a phosphate moiety (e.g., α-phosphate thiolate) provides for the non-natural phosphorothioate backbone linkages to confer stability (e.g., against exonucleases and endonucleases) to RNA and DNA. Phosphorothioate DNA and RNA have increased nuclease resistance and therefore a longer half-life in the cellular environment.
[0271] Other internucleoside linkages that can be used in accordance with the present disclosure are described herein, including internucleoside linkages that do not contain a phosphorus atom. Internal ribosome entry site A polynucleotide may contain an internal ribosome entry site (IRES). An IRES may act as the sole ribosome binding site or as one of multiple ribosome binding sites of an mRNA. A polynucleotide containing more than one functional ribosome binding site may encode several peptides or polypeptides that are independently translated by the ribosome (e.g., a polycistronic mRNA). When a polynucleotide comprises an IRES, a second translatable region is optionally further provided. Examples of IRES sequences that may be used in accordance with the present disclosure include, but are not limited to, those from picornaviruses (e.g., picornavirus (FMDV)), plague virus (CFFV), polio virus (PV), encephalomyocarditis virus (ECMV), foot-and-mouth disease virus (FMDV), hepatitis C virus (HCV), classical swine fever virus (CSFV), and the like. Examples include those derived from swine fever virus, murine leukemia virus (MLV), simian immune deficiency virus (SIV) or cricket paralysis virus (CrPV).
[0272] 5'-cap structure A polynucleotide (e.g., mRNA) can contain a 5'-cap structure. The 5'-cap structure of a polynucleotide is involved in nuclear export, enhances polynucleotide stability, and binds to mRNA cap-binding protein (CBP), which is involved in intracellular polynucleotide stability and translational competence via the binding of CBP to poly-A binding protein to form mature circular mRNA species. The cap also assists in the removal of 5'-proximal introns during mRNA splicing.
[0273] Endogenous polynucleotide molecules can be capped at the 5' end to form a 5'-ppp-5'-triphosphate linkage between the terminal guanosine cap residue of the polynucleotide and the 5'-terminal transcribed sense nucleotide. This 5'-guanylate cap can then be methylated to generate an N7-methyl-guanylate residue. The ribose sugar of the terminal and / or anteterminal transcribed nucleotide at the 5' end of the polynucleotide can also optionally be 2'-O-methylated. 5'-cap removal by hydrolysis and cleavage of the guanylate cap structure can target polynucleotide molecules, such as mRNA molecules, for degradation.
[0274] Modifications to polynucleotides can generate non-hydrolyzable cap structures to prevent cap removal and thereby increase polynucleotide half-life. Because cap structure hydrolysis requires cleavage of the 5'-ppp-5' phosphorodiester bond, modified nucleotides can be used during the capping reaction. For example, Vaccinia Capping Enzyme from New England Biolabs (Ipswich, MA) can be used with α-thio-guanosine nucleotides according to the manufacturer's instructions to form phosphorothioate bonds within the 5'-ppp-5' cap. Additional modified guanosine nucleotides, such as α-methyl-phosphonate and seleno-phosphate nucleotides, can be used.
[0275] Further modifications include, but are not limited to, 2'-O-methylation (described above) of the ribose sugar of the 5'-terminus and / or penultimate nucleotide of the polynucleotide at the 2'-hydroxy group of the sugar. Several different 5'-cap structures can be used to generate the 5'-cap of a polynucleotide, such as an mRNA molecule.
[0276] 5'-cap structures include those described in International Patent Publication Nos. WO2008127688, WO2008016473, and WO2011015347, each of which is incorporated herein by reference.
[0277] A cap analog, also referred to herein as a synthetic cap analog, chemical cap, chemical cap analog, or structural or functional cap analog, differs in its chemical structure from the natural (i.e., endogenous, wild-type, or physiological) 5'-cap while retaining cap function. Cap analogs can be synthesized / linked to a polynucleotide chemically (i.e., non-enzymatically) or enzymatically.
[0278] For example, an anti-reverse cap analog (ARCA) cap contains two guanosines linked by a 5'-5'-triphosphate group, where one guanosine has an N7-methyl group as well as a 3'-O-methyl group (i.e., N7,3'-O-dimethyl-guanosine-5'-triphosphate-5'-guanosine, m 7 The N7- and 3'-O-methylated guanosine contains the N7- and 3'-O-methylated guanosine (which may also be referred to as 3'O-Me-m7G(5')ppp(5')G). The 3'-O atom of the other unmodified guanosine is linked to the 5'-terminal nucleotide of the capped polynucleotide (e.g., mRNA). The N7- and 3'-O-methylated guanosine provides the terminal portion of the capped polynucleotide (e.g., mRNA).
[0279] Another exemplary cap is mCAP, which is similar to ARCA but has a 2'-O-methyl group on the guanosine (i.e., N7,2'-O-dimethyl-guanosine-5'-triphosphate-5'-guanosine, mCAP). 7 Gm-ppp-G).
[0280] The cap can be a dinucleotide cap analog. As a non-limiting example, dinucleotide cap analogs, such as those described in U.S. Pat. No. 8,519,110 (the cap structures of which are incorporated herein by reference), can be modified with boranophosphate or phosphoroselenoate groups at various phosphate positions.
[0281] Alternatively, the cap analog can be an N7-(4-chlorophenoxyethyl)-substituted dinucleotide cap analog known in the art and / or described herein. Non-limiting examples of N7-(4-chlorophenoxyethyl)-substituted dinucleotide cap analogs include N7-(4-chlorophenoxyethyl)-G(5')ppp(5')G and N7-(4-chlorophenoxyethyl)-m3'-OG(5')ppp(5')G cap analogs (see, e.g., the various cap analogs and methods for synthesizing cap analogs described in Kore et al., Bioorganic & Medicinal Chemistry 2013 21:4570-4574, the cap structures of which are incorporated herein by reference). In other cases, cap analogs useful with polynucleotides of the present disclosure are 4-chloro / bromophenoxyethyl analogs.
[0282] Although cap analogs allow for the simultaneous capping of polynucleotides in in vitro transcription reactions, up to 20% of transcripts remain uncapped. This, along with structural differences between the cap analog and the endogenous 5'-cap structure of polynucleotides produced by the endogenous cellular transcription machinery, can result in reduced translational efficiency and reduced cellular stability.
[0283] Modified polynucleotides can also be post-transcriptionally capped using enzymes to generate more authentic 5'-cap structures. As used herein, the phrase "more authentic" refers to features that structurally or functionally resemble or mimic endogenous or wild-type features. That is, a "more authentic" feature better represents endogenous, wild-type, native, or physiological cellular function and / or structure compared to prior art synthetic features or analogs, or outperforms the corresponding endogenous, wild-type, native, or physiological features in one or more respects. Non-limiting examples of more authentic 5'-cap structures useful for polynucleotides of the present disclosure are those that have, among other things, increased binding of cap-binding proteins, increased half-life, reduced susceptibility to 5'-endonucleases, and / or decreased 5'-cap removal compared to synthetic 5'-cap structures (or wild-type, native, or physiological 5'-cap structures) known in the art. For example, recombinant vaccinia virus capping enzyme and recombinant 2'-O-methyltransferase enzyme can form a standard 5'-5'-triphosphate linkage between the 5'-terminal nucleotide of a polynucleotide and a guanosine cap nucleotide, where the cap guanosine contains an N7-methylation and the 5'-terminal nucleotide of the polynucleotide contains a 2'-O-methyl. Such a structure is called a Cap 1 structure. This cap results in higher translational capacity, cellular stability, and reduced activation of cellular pro-inflammatory cytokines, for example, compared to other 5'-cap analog structures known in the art. Other exemplary cap structures include 7mG(5')ppp(5')N,pN2p (cap 0), 7mG(5')ppp(5')NlmpNp (cap 1), 7mG(5')-ppp(5')NlmpN2mp (cap 2), and m(7)Gpppm(3)(6,6,2')Apm(2')Apm(2')Cpm(2)(3,2')Up (cap 4).
[0284] Because the modified polynucleotides can be capped after transcription, and because this process is more efficient, nearly 100% of the modified polynucleotides can be capped, as opposed to about 80% when a cap analog is attached to the polynucleotide during the in vitro transcription reaction.
[0285] The 5'-end cap can comprise an endogenous cap or a cap analog. The 5'-end can comprise a guanosine analog. Useful guanosine analogs include inosine, N1-methyl-guanosine, 2'-fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, and 2-azido-guanosine.
[0286] In some cases, the polynucleotide contains a modified 5'-cap. Modifications at the 5'-cap can increase the stability of the polynucleotide, increase the half-life of the polynucleotide, and increase the translation efficiency of the polynucleotide. Modified 5'-caps include, but are not limited to, one or more of the following modifications: a modification at the 2' and / or 3' position of the capped guanosine triphosphate (GTP), a sugar ring oxygen replacement with a methylene moiety (CH2) (thus creating a carbocyclic ring), a modification at the triphosphate bridge portion of the cap structure, or a modification at the nucleobase (G) portion.
[0287] 5'-UTR A 5'-UTR can be provided as a flanking region of a polynucleotide (e.g., mRNA). The 5'-UTR can be homologous or heterologous to the coding region found in the polynucleotide. Multiple 5'-UTRs can be included in a flanking region and can be of the same or different sequence. Any portion (including none) of a flanking region can be codon-optimized and, independently, can contain one or more different structural or chemical modifications before and / or after codon optimization.
[0288] Table 21 of U.S. Provisional Patent Application No. 61 / 775,509 and Tables 21 and 22 of U.S. Provisional Patent Application No. 61 / 829,372, which are incorporated herein by reference, provide lists of start and stop sites for modified polynucleotides (e.g., mRNAs). In Table 21, each 5'-UTR (5'-UTR-005 to 5'-UTR 68511) is identified by its start and stop sites relative to its native or wild-type (homologous) transcript (the identification number used in the ENST; ENSEMBL database).
[0289] A 5'-UTR heterologous to the coding region of a modified polynucleotide (e.g., mRNA) can be engineered to modify one or more properties of the polynucleotide (e.g., mRNA). The polynucleotide (e.g., mRNA) can then be administered to a cell, tissue, or organism, and results such as protein levels, localization, and / or half-life can be measured to assess the beneficial effect the heterologous 5'-UTR may have on the modified polynucleotide (mRNA). Variants of the 5'-UTR can be used in which one or more nucleotides, including A, T, C, or G, have been added to or removed from the end. The 5'-UTR can also be codon-optimized or modified by any of the methods described herein.
[0290] 5'-UTR, 3'-UTR, and translation enhancer element (TEE) The 5'-UTR of a polynucleotide (e.g., mRNA) may contain at least one translational enhancer element. The term "translational enhancer element" refers to a sequence that increases the amount of a polypeptide or protein produced from a polynucleotide. As a non-limiting example, a TEE may be located between the transcription promoter and the start codon. A polynucleotide (e.g., mRNA) having at least one TEE in its 5'-UTR may include a cap in the 5'-UTR. Furthermore, at least one TEE may be located in the 5'-UTR of a polynucleotide (e.g., mRNA) to effect cap-dependent or cap-independent translation.
[0291] In one embodiment, TEEs are conserved elements in UTRs that can facilitate translational activity of a polynucleotide, including, but not limited to, cap-dependent or cap-independent translation. The conservation of these sequences has been previously demonstrated by Panek et al. (Nucleic Acids Research, 2013, 1-10) for 14 species, including humans.
[0292] In one non-limiting example, a known TEE can be found in the 5'-leader of the Gtx homeodomain protein (Chappell et al., Proc. Natl. Acad. Sci. USA 101:9590-9594, 2004, which TEE is incorporated herein by reference).
[0293] In another non-limiting example, TEEs are disclosed in U.S. Patent Application Publication Nos. 2009 / 0226470 and 2013 / 0177581, as well as International Patent Publication Nos. WO 2009 / 075886, WO 2012 / 009644, and WO 1999 / 024595, and U.S. Pat. Nos. 6,310,197 and 6,849,405, the respective TEE sequences of which are incorporated herein by reference.
[0294] In yet another non-limiting example, the TEE can be an internal ribosome entry site (IRES), HCV-IRES, or IRES element, such as, but not limited to, those described in U.S. Pat. No. 7,468,275, U.S. Patent Application Publication Nos. 2007 / 0048776 and 2011 / 0124100, and International Patent Publication Nos. WO 2007 / 025008 and WO 2001 / 055369 (the respective IRES sequences of which are incorporated herein by reference). IRES elements include, but are not limited to, the Gtx sequences (e.g., Gtx9-nt, Gtx8-nt, Gtx7-nt) described by Chappell et al. (Proc. Natl. Acad. Sci. USA 101:9590-9594, 2004) and by Zhou et al. (PNAS 102:6273-6278, 2005), and in U.S. Patent Application Publication Nos. 2007 / 0048776 and 2011 / 0124100 and International Patent Publication No. WO 2007 / 025008, the IRES sequences of each of which are incorporated herein by reference.
[0295] "Translation enhancer polynucleotides" are exemplified herein and / or disclosed in the art (e.g., U.S. Pat. Nos. 6,310,197, 6,849,405, 7,456,273, 7,183,395, U.S. Patent Application Publication Nos. 20090 / 226470, 2007 / 0048776, 2011 / 0124100, 2009 / 0093049, etc.). See International Patent Publication Nos. WO 2009 / 075886, WO 2007 / 025008, WO 2012 / 009644, WO 2001 / 055371, WO 1999 / 024595, and European Patent Nos. 2610341 and 2610340 (each of which is a reference to a TEE arrangement). A sequence is a polynucleotide that includes one or more of the specific TEEs (incorporated herein by reference) or their variants, homologs, or functional derivatives. One or more copies of a specific TEE may be present in a polynucleotide (e.g., mRNA). A TEE in a translation enhancer polynucleotide may be organized in one or more sequence segments. A sequence segment can possess one or more of the specific TEEs exemplified herein, with each TEE being present in one or more copies. When multiple sequence segments are present in a translation enhancer polynucleotide, they may be homologous or heterologous. Thus, multiple sequence segments in a translation enhancer polynucleotide may possess the same or different types of the specific TEEs exemplified herein, the same or different numbers of copies of each of the specific TEEs, and / or the same or different configurations of TEEs within each sequence segment.
[0296] Polynucleotides (e.g., mRNA) can be prepared using methods described in International Patent Publication Nos. WO 1999 / 024595, WO 2012 / 009644, WO 2009 / 075886, WO 2007 / 025008, WO 1999 / 024595, European Patent Application Publication Nos. 2610341 and 2610340, U.S. Pat. No. 6,310,197 ... The polynucleotide may comprise at least one TEE described in U.S. Patent Publication Nos. 849,405, 7,456,273, 7,183,395, and U.S. Patent Application Publication Nos. 2009 / 0226470, 2011 / 0124100, 2007 / 0048776, 2009 / 0093049, and 2013 / 0177581 (the TEE sequences of each of which are incorporated herein by reference). The TEE may be located in the 5'-UTR of a polynucleotide (e.g., an mRNA).
[0297] Polynucleotides (e.g., mRNA) may be prepared using methods described in U.S. Patent Application Publication Nos. 2009 / 0226470, 2007 / 0048776, 2013 / 0177581, and 2011 / 0124100, International Patent Publication Nos. WO 1999 / 024595, WO 2012 / 009644, WO 2009 / 075886, and WO 2007 / 025008, European Patent Application Publication Nos. 2610341 and 261034 Nos. 6,310,197, 6,849,405, 7,456,273, and 7,183,395 (the TEE sequences of each of which are incorporated herein by reference).
[0298] The 5'-UTR of a polynucleotide (e.g., mRNA) may contain at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, or more than 60 TEE sequences. The TEE sequences in the 5'-UTR of a polynucleotide (e.g., mRNA) may be the same or different TEE sequences. The TEE sequences may be in a pattern such as ABABAB, AABBAABBAABB, or ABCABCABC, or variations thereof, repeated once, twice, or more than three times. In these patterns, each letter A, B, or C represents a different TEE sequence at the nucleotide level.
[0299] In some cases, the 5'-UTR can include a spacer separating the two TEE sequences. As a non-limiting example, the spacer can be a 15-nucleotide spacer and / or other spacers known in the art. As another non-limiting example, the 5'-UTR can include a TEE sequence-spacer module that is repeated at least once, at least twice, at least three times, at least four times, at least five times, at least six times, at least seven times, at least eight times, at least nine times, or ten or more times in the 5'-UTR.
[0300] In other cases, the spacer separating the two TEE sequences may include other sequences known in the art that can regulate translation of a polynucleotide (e.g., an mRNA) of the present disclosure, such as, but not limited to, an miR sequence (e.g., an miR binding site and an miR seed). As a non-limiting example, each spacer used to separate the two TEE sequences may include a different miR sequence or component of an miR sequence (e.g., an miR seed sequence).
[0301] In some cases, the TEE in the 5'-UTR of a polynucleotide (e.g., mRNA) can be selected from the group consisting of those described in U.S. Patent Application Publication Nos. 2009 / 0226470, 2007 / 0048776, 2013 / 0177581, and 2011 / 0124100, International Patent Publication Nos. WO 1999 / 024595, WO 2012 / 009644, WO 2009 / 075886, and WO 2007 / 025008, European Patent Application Publication Nos. 2610341 and 2610340, and U.S. Pat. No. 6,310,197. Nos. 6,849,405, 6,849,405, 7,456,273, and 7,183,395 (each of which TEE sequences are incorporated herein by reference) may comprise at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or more than 99% of the TEE sequences disclosed in the specification of US Pat. Nos. 6,849,405, 6,849,405, 7,456,273, and 7,183,395 (each of which TEE sequences are incorporated herein by reference).In another embodiment, the TEE in the 5'-UTR of a polynucleotide (e.g., mRNA) of the present disclosure is selected from the group consisting of those described in U.S. Patent Application Publication Nos. 2009 / 0226470, 2007 / 0048776, 2013 / 0177581, and 2011 / 0124100, International Patent Publication Nos. WO 1999 / 024595, WO 2012 / 009644, WO 2009 / 075886, and WO 2007 / 02500. The TEE sequences may include 5-30 nucleotide fragments, 5-25 nucleotide fragments, 5-20 nucleotide fragments, 5-15 nucleotide fragments, 5-10 nucleotide fragments of the TEE sequences disclosed in European Patent Application Publication No. 8, European Patent Application Publication Nos. 2610341 and 2610340, and U.S. Patent Nos. 6,310,197, 6,849,405, 7,456,273, and 7,183,395 (the TEE sequences of each of which are incorporated herein by reference).
[0302] In some cases, the TEE in the 5'-UTR of a polynucleotide (e.g., mRNA) of the present disclosure may be a TEE as described by Chappell et al. (Proc. Natl. Acad. Sci. USA 101:9590-9594, 2004) and Zhou et al. (PNAS 102:6273-6278, 2005), Wellensiek et al. ("Genome-wide profiling of human cap-independent translation-enhancing elements," Nature Methods, 2006), and Zhou et al. (PNAS 102:6273-6278, 2005). The TEE sequences disclosed in Supplementary Table 1 and Supplementary Table 2 of the present application (NMETH.org Methods, 2013; DOI:10.1038 / NMETH.2522), each of which is incorporated herein by reference, may comprise at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or more than 99% of the TEE sequences disclosed in Supplementary Table 1 and Supplementary Table 2 of the present application (NMETH.org Methods, 2013; DOI:10.1038 / NMETH.2522), each of which TEE sequences is incorporated herein by reference.In another embodiment, the TEE in the 5'-UTR of a polynucleotide (e.g., mRNA) of the present disclosure is selected from the group consisting of those described by Chappell et al. (Proc. Natl. Acad. Sci. USA 101:9590-9594, 2004) and Zhou et al. (PNAS 102:6273-6278, 2005), Wellensiek et al. ("Genome-wide profiling of human cap-independent translation-enhancing elements," Nature Methods, 2006), and Zhou et al. (PNAS 102:6273-6278, 2005). The TEE sequences may include a 5-30 nucleotide fragment, a 5-25 nucleotide fragment, a 5-20 nucleotide fragment, a 5-15 nucleotide fragment, or a 5-10 nucleotide fragment of the TEE sequences disclosed in Supplementary Table 1 and Supplementary Table 2 disclosed by the National Institute of Standards and Technology (NIS), 2013; DOI: 10.1038 / NMETH.2522 (each of which TEE sequences is incorporated herein by reference).
[0303] In some cases, the TEE used in the 5'-UTR of a polynucleotide (e.g., mRNA) is an IRES sequence, such as, but not limited to, those described in U.S. Pat. No. 7,468,275 and International Patent Publication No. WO 2001 / 055369 (the TEE sequences of each of which are incorporated herein by reference).
[0304] In some cases, TEEs used in the 5'-UTR of a polynucleotide (e.g., an mRNA) can be identified by the methods described in U.S. Patent Application Publication Nos. 2007 / 0048776 and 2011 / 0124100 and International Patent Publication Nos. WO 2007 / 025008 and WO 2012 / 009644, each of which is incorporated herein by reference.
[0305] In some cases, the TEE used in the 5'-UTR of a polynucleotide (e.g., mRNA) of the present disclosure may be a transcriptional regulatory element described in U.S. Patent Nos. 7,456,273 and 7,183,395, U.S. Patent Application Publication No. 2009 / 0093049, and International Publication No. WO 2001 / 055371 (each of which TEE sequences are incorporated herein by reference). Transcriptional regulatory elements may be identified by methods known in the art, such as, but not limited to, the methods described in U.S. Patent Nos. 7,456,273 and 7,183,395, U.S. Patent Application Publication No. 2009 / 0093049, and International Publication No. WO 2001 / 055371 (each of which methods are incorporated herein by reference).
[0306] In still other cases, the TEE used in the 5'-UTR of a polynucleotide (e.g., an mRNA) is a polynucleotide or portion thereof described in U.S. Pat. Nos. 7,456,273 and 7,183,395, U.S. Patent Application Publication No. 2009 / 0093049, and International Publication No. WO 2001 / 055371, the TEE sequences of each of which are incorporated herein by reference.
[0307] A 5'-UTR comprising at least one TEE described herein can be incorporated into a monocistronic sequence, such as, but not limited to, a vector system or a polynucleotide vector. By way of non-limiting example, vector systems and polynucleotide vectors can include those described in U.S. Patent Nos. 7,456,273 and 7,183,395, U.S. Patent Application Publication Nos. 2007 / 0048776, 2009 / 0093049, and 2011 / 0124100, and International Patent Publication Nos. WO 2007 / 025008 and WO 2001 / 055371 (the TEE sequences of each of which are incorporated herein by reference).
[0308] The TEEs described herein can be located in the 5'-UTR and / or 3'-UTR of a polynucleotide (e.g., mRNA). A TEE located in the 3'-UTR can be the same and / or different from a TEE located in the 5'-UTR and / or described for incorporation into the 5'-UTR.
[0309] In some cases, the 3'-UTR of a polynucleotide (e.g., mRNA) may contain at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, or more than 60 TEE sequences. The TEE sequences in the 3'-UTR of a polynucleotide (e.g., mRNA) of the present disclosure may be the same or different TEE sequences. The TEE sequences may be in a pattern such as ABABAB, AABBAABBAABB, or ABCABCABC, or variations thereof, repeated once, twice, or more than three times. In these patterns, each letter A, B, or C represents a different TEE sequence at the nucleotide level.
[0310] In some cases, the 3'-UTR can include a spacer separating the two TEE sequences. As a non-limiting example, the spacer can be a 15-nucleotide spacer and / or other spacers known in the art. As another non-limiting example, the 3'-UTR can include a TEE sequence-spacer module that is repeated at least once, at least twice, at least three times, at least four times, at least five times, at least six times, at least seven times, at least eight times, at least nine times, or ten or more times in the 3'-UTR.
[0311] In other cases, the spacer separating the two TEE sequences can include other sequences known in the art that can regulate translation of a polynucleotide (e.g., an mRNA) of the present disclosure, such as, but not limited to, the miR sequences described herein (e.g., miR binding sites and miR seeds). As a non-limiting example, each spacer used to separate the two TEE sequences can include a different miR sequence or component of a miR sequence (e.g., a miR seed sequence).
[0312] In still other cases, incorporation of miR and / or TEE sequences alters the shape of the stem-loop region, which can increase and / or decrease translation (see, e.g., Kedde et al., "A Pumilio-induced RNA structure switch in p27-3'UTR controls miR-221 and miR-22 accessibility," Nature Cell Biology, 2010).
[0313] stem loop A polynucleotide (e.g., mRNA) can include a stem loop, such as, but not limited to, a histone stem loop. The stem loop can be a nucleotide sequence of about 25 or about 26 nucleotides in length, such as, but not limited to, those described in International Patent Publication No. WO 2013 / 103659 (incorporated herein by reference). The histone stem loop can be located 3' to the coding region (e.g., at the 3' end of the coding region). As a non-limiting example, the stem loop can be located at the 3' end of a polynucleotide described herein. In some cases, a polynucleotide (e.g., mRNA) includes two or more stem loops (e.g., two stem loops). Examples of stem loop sequences are described in International Patent Publication Nos. WO 2012 / 019780 and WO 201502667 (these stem loop sequences are incorporated herein by reference). In some cases, the polynucleotide comprises the stem-loop sequence CAAAGGCTCTTTTCAGAGCCACCA (SEQ ID NO: 1). In other cases, the polynucleotide comprises the stem-loop sequence CAAAGGCUCUUUUCAGAGCCACCA (SEQ ID NO: 2).
[0314] The stem loop may be located in the second terminal region of the polynucleotide. As a non-limiting example, the stem loop may be located in the untranslated region (e.g., 3'-UTR) of the second terminal region.
[0315] In some cases, polynucleotides, such as, but not limited to, mRNAs containing histone stem loops, can be stabilized by the addition of a 3'-stabilizing region (e.g., a 3'-stabilizing region comprising at least one chain-terminating nucleoside). Without intending to be bound by theory, the addition of at least one chain-terminating nucleoside can slow down the degradation of the polynucleotide, thereby increasing the half-life of the polynucleotide.
[0316] In other cases, polynucleotides, such as, but not limited to, mRNAs containing histone stem loops, can be stabilized by modifications to the 3'-region of the polynucleotide that can prevent and / or inhibit the addition of oligo(U) (see, e.g., International Patent Publication No. WO 2013 / 103659).
[0317] In still other cases, polynucleotides such as, but not limited to, mRNAs containing histone stem loops can be stabilized by the addition of oligonucleotides terminating in 3'-deoxynucleosides, 2',3'-dideoxynucleosides, 3'-O-methylnucleosides, 3'-O-ethylnucleosides, 3'-arabinosides, and other modified nucleosides known in the art and / or described herein.
[0318] In some cases, polynucleotides of the present disclosure can include a histone stem loop, a poly-A tract, and / or a 5'-cap structure. The histone stem loop can precede and / or follow the poly-A tract. Polynucleotides comprising histone stem loop and poly-A tract sequences can include chain-terminating nucleosides as described herein.
[0319] In other cases, polynucleotides of the present disclosure may comprise histone stem loop and 5'-cap structures, which may include, but are not limited to, those described herein and / or known in the art.
[0320] In some cases, the conserved stem-loop region can include a miR sequence described herein. As a non-limiting example, the stem-loop region can include a seed sequence of a miR sequence described herein. In another non-limiting example, the stem-loop region can include a miR-122 seed sequence.
[0321] In some cases, the conserved stem-loop region may comprise a miR sequence described herein and may also comprise a TEE sequence. In some cases, incorporation of miR and / or TEE sequences alters the shape of the stem-loop region, which can increase and / or decrease translation (see, e.g., Kedde et al., "A Pumilio-induced RNA structure switch in p27-3'UTR controls miR-221 and miR-22 accessibility," Nature Cell Biology, 2010, incorporated herein by reference in its entirety).
[0322] The polynucleotide may comprise at least one histone stem loop and poly-A region or polyadenylation signal. Non-limiting examples of polynucleotide sequences encoding at least one histone stem loop and poly-A region or polyadenylation signal are described in International Patent Publication Nos. WO 2013 / 120497, WO 2013 / 120629, WO 2013 / 120500, WO 2013 / 120627, WO 2013 / 120498, WO 2013 / 120626, WO 2013 / 120499 and WO 2013 / 120628 (the sequences of each of which are incorporated herein by reference). In some cases, the polynucleotide encoding the histone stem loop and poly-A region or polyadenylation signal may encode a pathogen antigen or fragment thereof, such as the polynucleotide sequences set forth in International Patent Publication Nos. WO 2013 / 120499 and WO 2013 / 120628 (both of which sequences are incorporated herein by reference). In other cases, the polynucleotide encoding the histone stem loop and poly-A region or polyadenylation signal may encode a therapeutic protein, such as the polynucleotide sequences set forth in International Patent Publication Nos. WO 2013 / 120497 and WO 2013 / 120629 (both of which sequences are incorporated herein by reference). In some cases, the polynucleotide encoding the histone stem loop and poly-A region or polyadenylation signal may encode a tumor antigen or a fragment thereof, such as the polynucleotide sequences set forth in International Patent Publication Nos. WO 2013 / 120500 and WO 2013 / 120627 (both of which sequences are incorporated herein by reference).In other cases, the polynucleotide encoding the histone stem loop and poly-A region or polyadenylation signal may encode an allergenic antigen or an autoimmune autoantigen, such as the polynucleotide sequences set forth in International Patent Publication Nos. WO 2013 / 120498 and WO 2013 / 120626 (both of which sequences are incorporated herein by reference).
[0323] Poly-A region A polynucleotide or nucleic acid (e.g., mRNA) can contain a polyA sequence and / or a polyadenylation signal. The polyA sequence can be composed entirely or predominantly of adenine nucleotides or their analogs or derivatives. The polyA sequence can be a tail located adjacent to the 3' untranslated region of the nucleic acid.
[0324] During RNA processing, long chains of adenosine nucleotides (poly-A tracts) are typically added to messenger RNA (mRNA) molecules to increase the molecule's stability. Shortly after transcription, the 3' end of the transcript is cleaved, releasing a 3'-hydroxyl group. Poly-A polymerase then adds chains of adenosine nucleotides to the RNA. This process, called polyadenylation, adds poly-A tracts that are 100 to 250 residues in length.
[0325] The length of the unique poly-A region may confer several advantages to the modified polynucleotides of the present disclosure. Generally, the length of a poly-A region of the present disclosure is at least 30 nucleotides. In another embodiment, the poly-A region is at least 35 nucleotides. In another embodiment, the length is at least 40 nucleotides. In another embodiment, the length is at least 45 nucleotides. In another embodiment, the length is at least 55 nucleotides. In another embodiment, the length is at least 60 nucleotides. In another embodiment, the length is at least 70 nucleotides. In another embodiment, the length is at least 80 nucleotides. In another embodiment, the length is at least 90 nucleotides. In another embodiment, the length is at least 100 nucleotides. In another embodiment, the length is at least 120 nucleotides. In another embodiment, the length is at least 140 nucleotides. In another embodiment, the length is at least 160 nucleotides. In another embodiment, the length is at least 180 nucleotides. In another embodiment, the length is at least 200 nucleotides. In another embodiment, the length is at least 250 nucleotides. In another embodiment, the length is at least 300 nucleotides. In another embodiment, the length is at least 350 nucleotides. In another embodiment, the length is at least 400 nucleotides. In another embodiment, the length is at least 450 nucleotides. In another embodiment, the length is at least 500 nucleotides. In another embodiment, the length is at least 600 nucleotides. In another embodiment, the length is at least 700 nucleotides. In another embodiment, the length is at least 800 nucleotides. In another embodiment, the length is at least 900 nucleotides. In another embodiment, the length is at least 1000 nucleotides. In another embodiment, the length is at least 1100 nucleotides. In another embodiment, the length is at least 1200 nucleotides. In another embodiment, the length is at least 1300 nucleotides. In another embodiment, the length is at least 1400 nucleotides.In another embodiment, the length is at least 1500 nucleotides. In another embodiment, the length is at least 1600 nucleotides. In another embodiment, the length is at least 1700 nucleotides. In another embodiment, the length is at least 1800 nucleotides. In another embodiment, the length is at least 1900 nucleotides. In another embodiment, the length is at least 2000 nucleotides. In another embodiment, the length is at least 2500 nucleotides. In another embodiment, the length is at least 3000 nucleotides.
[0326] In some cases, the poly-A region can be 80 nucleotides, 120 nucleotides, 160 nucleotides in length in the modified polynucleotide molecules described herein. In other cases, the poly-A region can be 20, 40, 80, 100, 120, 140, or 160 nucleotides in length in the modified polynucleotide molecules described herein.
[0327] In some cases, the poly-A region is designed for the entire length of the modified polynucleotide. This design can be based on the length of the coding region of the modified polynucleotide, the length of a particular feature or region of the modified polynucleotide (such as mRNA), or the length of the final product expressed from the modified polynucleotide. Compared to any feature of the modified polynucleotide (e.g., other than the mRNA portion containing the poly-A region), the poly-A region can be 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100% longer in length than the additional feature. The poly-A region can also be designed as part of the modified polynucleotide to which it belongs. In this regard, the poly-A region can be 10, 20, 30, 40, 50, 60, 70, 80, or 90% or more of the total length of the construct or the total length of the construct minus the poly-A region.
[0328] In some cases, engineered binding sites and / or conjugation of polynucleotides (e.g., mRNA) for poly-A binding protein can be used to enhance expression. The engineered binding site can be a sensor sequence that can act as a binding site for a ligand in the local microenvironment of the polynucleotide (e.g., mRNA). As a non-limiting example, a polynucleotide (e.g., mRNA) can include at least one engineered binding site to modify the binding affinity of poly-A binding protein (PABP) and its analogs. Incorporation of at least one engineered binding site can increase the binding affinity of PABP and its analogs.
[0329] Furthermore, multiple different polynucleotides (e.g., mRNAs) can be linked together via their 3' ends to PABP (poly-A binding protein) using modified nucleotides at the 3' end of the poly-A region. Transfection experiments can be performed in relevant cell lines, and protein production can be assayed by ELISA at 12 hours, 24 hours, 48 hours, 72 hours, and 7 days after transfection. As a non-limiting example, transfection experiments can be used to assess the effect on the binding affinity of PABP or its analogs as a result of the addition of at least one engineered binding site.
[0330] In some cases, poly-A regions may be used to regulate translation initiation. Without intending to be bound by theory, poly-A regions may be essential for protein synthesis because they recruit PABP, which can then interact with the translation initiation complex.
[0331] In some cases, poly-A regions may also be used in the present disclosure to protect against 3'-5'-exonuclease digestion. In some cases, a polynucleotide (e.g., mRNA) can contain a poly-AG quartet. A G-quartet is a cyclic hydrogen-bonded array of four guanosine nucleotides that can be formed by G-rich sequences in both DNA and RNA. In this embodiment, a G-quartet is incorporated at the end of a poly-A tract. The resulting polynucleotide (e.g., mRNA) can be assayed at various time points for stability, protein production, and other parameters, including half-life. It has been discovered that poly-AG quartets result in protein production that is at least 75% of that seen using only a 120-nucleotide poly-A tract.
[0332] In some cases, a polynucleotide (e.g., mRNA) may contain a poly-A region and be stabilized by the addition of a 3'-stabilizing region. A polynucleotide (e.g., mRNA) that contains a poly-A region may further contain a 5'-cap structure.
[0333] In other cases, a polynucleotide (e.g., an mRNA) may comprise a poly-AG quartet. A polynucleotide (e.g., an mRNA) that comprises a poly-AG quartet may further comprise a 5'-cap structure.
[0334] In some cases, 3'-stabilizing regions that can be used to stabilize polynucleotides (e.g., mRNA) that contain poly-A regions or poly-AG quartets can be, but are not limited to, those described in International Patent Publication No. WO 2013 / 103659, the poly-A regions and poly-AG quartets of which are incorporated herein by reference. In other cases, 3'-stabilizing regions that can be used in the present disclosure include chain-terminating nucleosides such as 3'-deoxyadenosine (cordycepin), 3'-deoxyuridine, 3'-deoxycytosine, 3'-deoxyguanosine, 3'-deoxythymine, 2',3'-dideoxynucleosides, e.g., 2',3'-dideoxyadenosine, 2',3'-dideoxyuridine, 2',3'-dideoxycytosine, 2',3'-dideoxyguanosine, 2',3'-dideoxythymine, 2'-deoxynucleosides, or O-methylnucleosides.
[0335] In other cases, polynucleotides, such as, but not limited to, mRNAs containing polyA tracts or poly-AG quartets, can be stabilized by modifications to the 3'-region of the polynucleotide that can prevent and / or inhibit the addition of oligo(U) (see, e.g., International Patent Publication No. WO 2013 / 103659).
[0336] In still other cases, polynucleotides such as, but not limited to, mRNAs containing poly-A tracts or poly-AG quartets can be stabilized by the addition of oligonucleotides terminating in 3'-deoxynucleosides, 2',3'-dideoxynucleosides, 3'-O-methylnucleosides, 3'-O-ethylnucleosides, 3'-arabinosides, and other modified nucleosides known in the art and / or described herein.
[0337] Chain-terminating nucleosides Nucleic acids can include chain-terminating nucleosides. For example, chain-terminating nucleosides can include nucleosides deoxygenated at the 2' and / or 3' positions of their sugar groups. Such species include 3'-deoxyadenosine (cordycepin), 3'-deoxyuridine, 3'-deoxycytosine, 3'-deoxyguanosine, 3'-deoxythymine, and 2',3'-dideoxynucleosides, such as 2',3'-dideoxyadenosine, 2',3'-dideoxyuridine, 2',3'-dideoxycytosine, 2',3'-dideoxyguanosine, and 2',3'-dideoxythymine.
[0338] Other ingredients The nanoparticle composition may include one or more ingredients in addition to those described in the previous section. For example, the nanoparticle composition may include one or more hydrophobic small molecules, such as vitamins (e.g., vitamin A or vitamin E) or sterols.
[0339] The nanoparticle compositions may also include one or more permeability enhancer molecules, carbohydrates, polymers, surface altering agents, or other components. Permeability enhancer molecules may be, for example, molecules described in U.S. Patent Application Publication No. 2005 / 0222064. Carbohydrates may include monosaccharides (e.g., glucose) and polysaccharides (e.g., glycogen and its derivatives and analogs).
[0340] A polymer may be included in the nanoparticle composition and / or used to encapsulate or partially encapsulate the nanoparticle composition. The polymer may be biodegradable and / or biocompatible. The polymer may be selected from, but is not limited to, polyamines, polyethers, polyamides, polyesters, polycarbamates, polyureas, polycarbonates, polystyrenes, polyimides, polysulfones, polyurethanes, polyacetylenes, polyethylenes, polyethyleneimines, polyisocyanates, polyacrylates, polymethacrylates, polyacrylonitriles, and polyarylates. For example, polymers include poly(caprolactone) (PCL), ethylene vinyl acetate polymer (EVA), poly(lactic acid) (PLA), poly(L-lactic acid) (PLLA), poly(glycolic acid) (PGA), poly(lactic-co-glycolic acid) (PLGA), poly(L-lactic-co-glycolic acid) (PLLGA), poly(D,L-lactide) (PDLA), poly(L-lactide) (PLLA), poly(D,L-lactide-co-caprolactone), poly(D,L-lactide-co-caprolactone-co-glycolide), poly(D,L-lactide-co-PEO-co-D,L-lactide), poly(D,L-lactide-co-PPO-co-D,L-lactide), and poly(D,L-lactide-co-PPO-co-D,L-lactide).L-lactide), polyalkyl cyanoacrylates, polyurethanes, poly-L-lysine (PLL), hydroxypropyl methacrylate (HPMA), polyethylene glycol, poly-L-glutamic acid, poly(hydroxy acids), polyanhydrides, polyorthoesters, poly(ester amides), polyamides, poly(ester ethers), polycarbonates, polyalkylenes such as polyethylene and polypropylene, polyalkylene glycols such as poly(ethylene glycol) (PEG), polyalkylene oxides (PEO), polyalkylene terephthalates such as poly(ethylene terephthalate), polyvinyl alcohol (PVA), polyvinyl ethers, polyvinyl esters such as poly(vinyl acetate), polyvinyl halides such as poly(vinyl chloride) (PVC), polyvinylpyrrolidone (PVP), polysiloxanes, polystyrene (PS), polyurethanes, derivatized celluloses such as alkyl celluloses, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitrocellulose, hydroxypropyl cellulose, cellulose esters ... carboxymethylcellulose, polymers of acrylic acid, such as poly(methyl(meth)acrylate) (PMMA), poly(ethyl(meth)acrylate), poly(butyl(meth)acrylate), poly(isobutyl(meth)acrylate), poly(hexyl(meth)acrylate), poly(isodecyl(meth)acrylate), poly(lauryl(meth)acrylate), poly(phenyl(meth)acrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecyl acrylate), acrylates) and their copolymers and blends, polydioxanone and its copolymers, polyhydroxyalkanoates, polypropylene fumarates, polyoxymethylene, poloxamers, polyoxamines, poly(ortho)esters, poly(butyric acid), poly(valeric acid), poly(lactide-co-caprolactone), trimethylene carbonate, poly(N-acryloylmorpholine) (PAcM), poly(2-methyl-2-oxazoline) (PMOX), poly(2-ethyl-2-oxazoline) (PEOZ), and polyglycerol.
[0341] Surface modifiers include, but are not limited to, anionic proteins (e.g., bovine serum albumin), surfactants (e.g., cationic surfactants such as dimethyldioctadecyl-ammonium bromide), sugars or sugar derivatives (e.g., cyclodextrin), nucleic acids, polymers (e.g., heparin, polyethylene glycol, and poloxamer), mucolytic agents (e.g., acetylcysteine, artemisia princeps, bromelain, papain, clerodendrum, bromhexine, carbocysteine, eprazinone, mesna, ambroxol, sobrerol, domiodol, letosteine, stepronin, tiopronin, gelsolin, thymosin β4, dornase alfa, neltenexin, and erdosteine), and DNases (e.g., rhDNase). Surface modifiers can be disposed within the nanoparticles and / or on the surface of the nanoparticle composition (e.g., by coating, adsorption, covalent bonding, or other process).
[0342] The nanoparticle composition can also contain one or more functionalized lipids.For example, lipids can be functionalized with alkyne groups that can undergo cycloaddition reaction when exposed to azide under suitable reaction conditions.In particular, lipid bilayers can be functionalized in this way with one or more groups that are useful for promoting membrane permeation, cell recognition, or imaging.The surface of the nanoparticle composition can also be bound with one or more useful antibodies.Functional groups and conjugates that are useful for target cell delivery, imaging, and membrane permeation are well known in the art.
[0343] In addition to these components, the nanoparticle composition may include any substance useful in pharmaceutical compositions. For example, the nanoparticle composition may include one or more pharmaceutically acceptable excipients or auxiliary ingredients, such as, but not limited to, one or more solvents, dispersion media, diluents, dispersing aids, suspending aids, granulation aids, disintegrants, fillers, lubricants, liquid vehicles, binders, surfactants, isotonicity agents, thickeners or emulsifiers, buffers, lubricants, oils, preservatives, and other species. Excipients such as waxes, butters, colorants, coating agents, flavors, and fragrances may also be included. Pharmaceutically acceptable excipients are well known in the art (e.g., see Remington's The Science and Practice of Pharmacy, 1999). of Pharmacy, 21st ed., by A.R. Gennaro; Lippincott, Williams & Wilkins, Baltimore, MD, 2006).
[0344] Examples of diluents include, but are not limited to, calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate, lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, corn starch, powdered sugar, and / or combinations thereof. Granulating and dispersing agents may be selected from the non-limiting list consisting of potato starch, corn starch, tapioca starch, sodium starch glycolate, clay, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood products, natural sponge, cation exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked poly(vinyl-pyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethylcellulose, cross-linked sodium carboxymethylcellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethylcellulose, magnesium aluminum silicate (VEEGUM®), sodium lauryl sulfate, quaternary ammonium compounds, and / or combinations thereof.
[0345] Surfactants and / or emulsifiers include, but are not limited to, natural emulsifiers (e.g., acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidal clays (e.g., bentonite [aluminum silicate] and VEEGUM® [magnesium aluminum silicate]), long-chain amino acid derivatives, high molecular weight alcohols (e.g., stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g., carboxypolymethylene, polyacrylic acid, acrylic acid polymers, and carboxyvinyl polymers), carrageenan, cellulose derivatives (e.g., sodium carboxymethylcellulose, powdered cellulose, hydroxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, ... cellulose), sorbitan fatty acid esters (e.g., polyoxyethylene sorbitan monolaurate [TWEEN® 20], polyoxyethylene sorbitan [TWEEN® 60], polyoxyethylene sorbitan monooleate [TWEEN® 80], sorbitan monopalmitate [SPAN® 40], sorbitan monostearate [SPAN® 60], sorbitan tristearate [SPAN® 65], ], glyceryl monooleate, sorbitan monooleate [SPAN® 80]), polyoxyethylene esters (e.g., polyoxyethylene monostearate [MYRJ® 45], polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate, and SOLUTOL®), sucrose fatty acid esters, polyethylene glycol fatty acid esters (e.g., CREMOPHOR®), polyoxyethylene ethers,(e.g., polyoxyethylene lauryl ether [BRIJ® 30]), poly(vinyl-pyrrolidone), diethylene glycol monolaurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, PLURONIC® F, 68, POLOXAMER® 188, cetrimonium bromide, cetylpyridinium chloride, benzalkonium chloride, docusate sodium, and / or combinations thereof.
[0346] The binder may be starch (e.g., corn starch and starch paste); gelatin; sugars (e.g., sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol); natural and synthetic gums (e.g., acacia, sodium alginate, extract of Irish moss, panwar gum, ghatti gum, isapol husk mucilage, carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, microcrystalline cellulose, cellulose acetate, poly(vinyl-pyrrolidone), magnesium aluminum silicate (VEEGUM®), and larch arabinogalactan); alginates; polyethylene oxide; polyethylene glycol; inorganic calcium salts; silicic acid; polymethacrylates; waxes; water; alcohol; and combinations thereof, or any other suitable binder.
[0347] Examples of preservatives include, but are not limited to, antioxidants, chelating agents, antibacterial preservatives, antifungal preservatives, alcohol preservatives, acidic preservatives, and / or other preservatives. Examples of antioxidants include, but are not limited to, alpha-tocopherol, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, and / or sodium sulfite. Examples of chelating agents include ethylenediaminetetraacetic acid (EDTA), citric acid monohydrate, edetate disodium, edetate dipotassium, edetate, fumaric acid, malic acid, phosphoric acid, edetate sodium, tartaric acid, and / or edetate trisodium. Examples of antibacterial preservatives include, but are not limited to, benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and / or thimerosal. Examples of antifungal preservatives include, but are not limited to, butylparaben, methylparaben, ethylparaben, propylparaben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and / or sorbic acid. Examples of alcohol preservatives include, but are not limited to, ethanol, polyethylene glycol, benzyl alcohol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoates, and / or phenylethyl alcohol. Examples of acidic preservatives include, but are not limited to, vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroascorbic acid, ascorbic acid, sorbic acid, and / or phytic acid.Other preservatives include, but are not limited to, tocopherol, tocopheryl acetate, deteroxime mesylate, cetrimide, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, GLYDANT PLUS®, PHENONIP®, methylparaben, GERMALL® 115, GERMABEN® II, NEOLONE™, KATHON™, and / or EUXYL®.
[0348] Examples of buffering agents include, but are not limited to, citrate buffer, acetate buffer, phosphate buffer, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glubionate, calcium gluceptate, calcium gluconate, d-gluconic acid, calcium glycerophosphate, calcium lactate, calcium lactobionate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, dibasic potassium phosphate, dibasic potassium phosphate, potassium mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium mixtures, tromethamine, amino-sulfonic acid buffers (e.g., HEPES), magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free distilled water, isotonic saline, Ringer's solution, ethyl alcohol, and / or combinations thereof. The lubricant may be selected from the non-limiting group consisting of magnesium stearate, calcium stearate, stearic acid, silica, talc, malt, glyceryl behenate, hydrogenated vegetable oil, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, and combinations thereof.
[0349] Examples of oils include, but are not limited to, almond, apricot kernel, avocado, babassu, bergamot, blackcurrant seed, borage, cade, chamomile, canola, caraway, carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee, corn, cottonseed, emu, eucalyptus, evening primrose, fish, flaxseed, geraniol, gourd, grape seed, hazelnut, hyssop, isopropyl myristate, jojoba, kukui nut, lavandin, lavender, lemon, litsea cucumber, macadamia nut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange, orange raspberry, Palm, palm kernel, peach kernel, peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood, sasquana, savory, sea buckthorn, sesame, shea butter, silicone, soybean, sunflower, tea tree, thistle, camellia, vetiver, walnut, and wheat germ oils as well as butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360, simethicone, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and / or combinations thereof.
[0350] formulation Nanoparticle compositions can include a lipid component and one or more additional components, such as therapeutic and / or prophylactic agents. Nanoparticle compositions can be designed for one or more specific applications or targets. The components of the nanoparticle composition can be selected based on the specific application or target and / or based on efficacy, toxicity, cost, ease of use, availability, or other characteristics of one or more components. Similarly, a particular formulation of a nanoparticle composition can be selected for a particular application or target, depending, for example, on the efficacy and toxicity of a particular combination of components.
[0351] The lipid component of the nanoparticle composition can include, for example, a lipid represented by formula (I), (IA), (IB), (II), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), or (III), a phospholipid (an unsaturated lipid, such as DOPE or DSPC), a PEG-lipid, and a structured lipid. The elements of the lipid component can be provided in specific ratios.
[0352] In some embodiments, the lipid component of the nanoparticle composition comprises a lipid represented by Formula (I), (IA), (IB), (II), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), or (III), a phospholipid, a PEG-lipid, and a structured lipid. In certain embodiments, the lipid component of the nanoparticle composition comprises about 30 mol% to about 60 mol% of a compound of Formula (I), (IA), (IB), (II), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), or (III), about 0 mol% to about 30 mol% of a phospholipid, about 18.5 mol% to about 48.5 mol% of a structured lipid, and about 0 mol% to about 10 mol% of a PEG-lipid, provided that the total mol% does not exceed 100%. In some embodiments, the lipid component of the nanoparticle composition comprises about 35 mol% to about 55 mol% of a compound of Formula (I), (IA), (IB), (II), (IIa), (IIb), (IIc), (IId), (IIe), (IIIf), (IIg), or (III), about 5 mol% to about 25 mol% of a phospholipid, about 30 mol% to about 40 mol% of a structural lipid, and about 0 mol% to about 10 mol% of a PEG lipid. In certain embodiments, the lipid component comprises about 50 mol% of the compound, about 10 mol% of a phospholipid, about 38.5 mol% of a structural lipid, and about 1.5 mol% of a PEG lipid. In another specific embodiment, the lipid component comprises about 40 mol% of the compound, about 20 mol% of a phospholipid, about 38.5 mol% of a structural lipid, and about 1.5 mol% of a PEG lipid. In some embodiments, the phospholipid can be DOPE or DSPC. In other embodiments, the PEG lipid can be PEG-DMG and / or the structural lipid can be cholesterol.
[0353] Nanoparticle compositions can be designed for one or more specific applications or targets. For example, nanoparticle compositions can be designed to deliver therapeutic and / or prophylactic agents, such as RNA, to specific cells, tissues, organs, or systems or groups thereof in the mammalian body. The physiochemical properties of nanoparticle compositions can be modified to enhance selectivity for specific bodily targets. For example, particle size can be adjusted based on the size of fenestrations in various organs. The therapeutic and / or prophylactic agents included in nanoparticle compositions can also be selected based on one or more desired delivery targets. For example, therapeutic and / or prophylactic agents can be selected for a particular indication, condition, disease, or disorder and / or for delivery (e.g., localized or specific delivery) to specific cells, tissues, organs, or systems or groups thereof. In certain embodiments, nanoparticle compositions can contain mRNA encoding a polypeptide of interest that can be translated intracellularly to produce the polypeptide of interest. Such compositions can be designed for specific delivery to a specific organ. In certain embodiments, compositions can be designed for specific delivery to the mammalian liver.
[0354] The amount of therapeutic and / or prophylactic agent in a nanoparticle composition can depend on the size, composition, desired target and / or use, or other characteristics of the nanoparticle composition, as well as the characteristics of the therapeutic and / or prophylactic agent. For example, the amount of RNA useful in a nanoparticle composition can depend on the size, sequence, and other characteristics of the RNA. The relative amounts of therapeutic and / or prophylactic agent and other components (e.g., lipids) in the nanoparticle composition can also vary. In certain embodiments, the wt / wt ratio of lipid component to therapeutic and / or prophylactic agent in the nanoparticle composition can be from about 5:1 to about 60:1, e.g., 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 25:1, 30:1, 35:1, 40:1, 45:1, 50:1, and 60:1. For example, the wt / wt ratio of lipid component to therapeutic and / or prophylactic agent can be from about 10:1 to about 40:1. In certain embodiments, the wt / wt ratio is about 20:1. The amount of therapeutic and / or prophylactic agent in the nanoparticle composition can be measured, for example, using absorption spectroscopy (e.g., UV-visible spectroscopy).
[0355] In certain embodiments, the nanoparticle composition comprises one or more RNAs, and the one or more RNAs, lipids, and their amounts can be selected to provide a specific N:P ratio. The N:P ratio of a composition refers to the molar ratio of nitrogen atoms in one or more lipids to the number of phosphate groups in the RNA. Generally, lower N:P ratios are preferred. The one or more RNAs, lipids, and their amounts can be selected to provide an N:P ratio of about 2:1 to about 30:1, e.g., 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 12:1, 14:1, 16:1, 18:1, 20:1, 22:1, 24:1, 26:1, 28:1, or 30:1. In certain embodiments, the N:P ratio can be about 2:1 to about 8:1. In other embodiments, the N:P ratio is about 5:1 to about 8:1. For example, the N:P ratio can be about 5.0:1, about 5.5:1, about 5.67:1, about 6.0:1, about 6.5:1, or about 7.0:1. For example, the N:P ratio can be about 5.67:1.
[0356] physical properties The properties of nanoparticle compositions can depend on their components. For example, a nanoparticle composition that contains cholesterol as a structural lipid can have different properties from a nanoparticle composition that contains a different structural lipid. Similarly, the properties of nanoparticle compositions can depend on the absolute or relative amounts of their components. For example, a nanoparticle composition that contains a higher molar fraction of phospholipids can have different properties from a nanoparticle composition that contains a lower molar fraction of phospholipids. The properties can also vary depending on the method and conditions of preparing the nanoparticle composition.
[0357] Nanoparticle compositions can be characterized by various methods. For example, microscopy (e.g., transmission electron microscopy or scanning electron microscopy) can be used to examine the morphology and size distribution of nanoparticle compositions. Dynamic light scattering or potentiometry (e.g., potentiometric titration) can be used to measure zeta potential. Dynamic light scattering can also be used to determine particle size. Instruments such as the Zetasizer Nano ZS (Malvern Instruments Ltd, Malvern, Worcestershire, UK) can also be used to determine several properties of nanoparticle compositions, such as particle size, polydispersity index, and zeta potential.
[0358] The average size of the nanoparticle composition can be, for example, tens of nanometers to hundreds of nanometers, as measured by dynamic light scattering (DLS). For example, the average size can be about 40 nm to about 150 nm, such as about 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 110 nm, 115 nm, 120 nm, 125 nm, 130 nm, 135 nm, 140 nm, 145 nm, or 150 nm. In certain embodiments, the average size of the nanoparticle composition can be about 50 nm to about 100 nm, about 50 nm to about 90 nm, about 50 nm to about 80 nm, about 50 nm to about 70 nm, about 50 nm to about 60 nm, about 60 nm to about 100 nm, about 60 nm to about 90 nm, about 60 nm to about 80 nm, about 60 nm to about 70 nm, about 70 nm to about 150 nm, about 70 nm to about 130 nm, about 70 nm to about 100 nm, about 70 nm to about 90 nm, about 70 nm to about 80 nm, about 80 nm to about 150 nm, about 80 nm to about 130 nm, about 80 nm to about 100 nm, about 80 nm to about 90 nm, about 90 nm to about 150 nm, about 90 nm to about 130 nm, or about 90 nm to about 100 nm. In certain embodiments, the average size of the nanoparticle composition can be about 70 nm to about 130 nm or about 70 nm to about 100 nm. In certain embodiments, the average size can be about 80 nm. In other embodiments, the average size can be about 100 nm. In other embodiments, the average size can be about 120 nm.
[0359] The nanoparticle composition can be relatively homogeneous. The polydispersity index can be used to indicate the homogeneity of a nanoparticle composition, e.g., the particle size distribution of the nanoparticle composition. A small polydispersity index (e.g., less than 0.3) generally indicates a narrow particle size distribution. The nanoparticle composition can have a polydispersity index of about 0 to about 0.25, e.g., 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.23, 0.24, or 0.25. In some embodiments, the polydispersity index of the nanoparticle composition can be about 0.10 to about 0.20.
[0360] The zeta potential of a nanoparticle composition can be used to indicate the kinetic potential of the composition. For example, the zeta potential can represent the surface charge of the nanoparticle composition. Nanoparticle compositions with a relatively low charge (whether positive or negative) are generally desirable because more highly charged species can undesirably interact with cells, tissues, and other elements in the body. In certain embodiments, the zeta potential of the nanoparticle composition can be about -10 mV to about +20 mV, about -10 mV to about +15 mV, about -10 mV to about +10 mV, about -10 mV to about +5 mV, about -10 mV to about 0 mV, about -10 mV to about -5 mV, about -5 mV to about +20 mV, about -5 mV to about +15 mV, about -5 mV to about +10 mV, about -5 mV to about +5 mV, about -5 mV to about 0 mV, about 0 mV to about +20 mV, about 0 mV to about +15 mV, about 0 mV to about +10 mV, about 0 mV to about +5 mV, about +5 mV to about +20 mV, about +5 mV to about +15 mV, or about +5 mV to about +10 mV.
[0361] The encapsulation efficiency of a therapeutic and / or prophylactic agent refers to the amount of therapeutic and / or prophylactic agent encapsulated or otherwise associated with a nanoparticle composition after preparation, relative to the initial amount provided. A high encapsulation efficiency is desirable (e.g., near 100%). The encapsulation efficiency can be measured, for example, by comparing the amount of therapeutic and / or prophylactic agent in a solution containing the nanoparticle composition before and after dissolving the nanoparticle composition with one or more organic solvents or detergents. Fluorescence can be used to measure the amount of free therapeutic and / or prophylactic agent (e.g., RNA) in solution. In the nanoparticle compositions described herein, the encapsulation efficiency of a therapeutic and / or prophylactic agent can be at least 50%, e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%. In some embodiments, the encapsulation efficiency can be at least 80%. In certain embodiments, the encapsulation efficiency may be at least 90%.
[0362] Nanoparticle composition can optionally comprise one or more coatings.For example, nanoparticle composition can be formulated in capsule, film or tablet with coating.The capsule, film or tablet comprising the composition described herein can have any useful size, tensile strength, hardness or density.
[0363] Pharmaceutical Composition The nanoparticle composition can be formulated in whole or in part as a pharmaceutical composition. A pharmaceutical composition can contain one or more nanoparticle compositions. For example, a pharmaceutical composition can contain one or more nanoparticle compositions containing one or more different therapeutic and / or prophylactic agents. A pharmaceutical composition can further contain one or more pharmaceutically acceptable excipients or auxiliary ingredients, such as those described herein. General guidelines for the formulation and manufacture of pharmaceutical compositions and medicaments are available, for example, in Remington's The Science and Practice of Pharmacy, 21st ed., A.R. Gennaro; Lippincott, Williams & Wilkins, Baltimore, MD, 2006. Conventional excipients and auxiliary ingredients can be used in any pharmaceutical composition, except insofar as any conventional excipient or auxiliary ingredient is incompatible with one or more components of the nanoparticle composition. An excipient or auxiliary ingredient may be incompatible with a component of the nanoparticle composition if its combination with the component of the nanoparticle composition may result in some undesirable biological or other form of adverse effect.
[0364] In some embodiments, one or more excipients or auxiliary ingredients may comprise more than 50% of the total mass or volume of a pharmaceutical composition containing a nanoparticle composition. For example, one or more excipients or auxiliary ingredients may comprise 50%, 60%, 70%, 80%, 90%, or more, according to pharmaceutical convention. In some embodiments, a pharmaceutically acceptable excipient is at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% pure. In some embodiments, the excipient is approved for human and veterinary use. In some embodiments, the excipient is approved by the United States Food and Drug Administration. In some embodiments, the excipient is pharmaceutical grade. In certain embodiments, the excipients meet the standards of the United States Pharmacopoeia (USP), the European Pharmacopoeia (EP), the British Pharmacopoeia, and / or the International Pharmacopoeia.
[0365] The relative amounts of one or more nanoparticle compositions, one or more pharmaceutically acceptable excipients, and / or any additional components in a pharmaceutical composition according to the present disclosure will vary depending on the identity, size, and / or condition of the subject being treated, as well as the route by which the composition is administered. By way of example, a pharmaceutical composition may contain from 0.1% to 100% (wt / wt) of one or more nanoparticle compositions.
[0366] In certain embodiments, the nanoparticle compositions and / or pharmaceutical compositions of the present disclosure are refrigerated or frozen for storage and / or transportation (e.g., stored at a temperature of 4°C or less, such as about -150°C to about 0°C or about -80°C to about -20°C (e.g., about -5°C, -10°C, -15°C, -20°C, -25°C, -30°C, -40°C, -50°C, -60°C, -70°C, -80°C, -90°C, -130°C, or -150°C). For example, a pharmaceutical composition comprising a compound of any of Formulas (I), (IA), (IB), (II), and (IIa) to (IIg) can be refrigerated or frozen for storage and / or transportation (e.g., stored at a temperature of about -20°C, -30°C, -40°C, -50°C, -60°C, -70°C, or or -80°C, and the solution is refrigerated for storage and / or transportation. In certain embodiments, the present disclosure also relates to methods of increasing the stability of a nanoparticle composition and / or pharmaceutical composition comprising a compound of any of Formulas (I), (IA), (IB), (II), and (IIa)-(IIg) by storing the nanoparticle composition and / or pharmaceutical composition at a temperature of 4°C or lower, e.g., from about -150°C to about 0°C or from about -80°C to about -20°C, e.g., about -5°C, -10°C, -15°C, -20°C, -25°C, -30°C, -40°C, -50°C, -60°C, -70°C, -80°C, -90°C, -130°C, or -150°C. For example, the nanoparticle compositions and / or pharmaceutical compositions disclosed herein are stable for at least about 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, at least 6 weeks, at least 1 month, at least 2 months, at least 4 months, at least 6 months, at least 8 months, at least 10 months, at least 12 months, at least 14 months, at least 16 months, at least 18 months, at least 20 months, at least 22 months, or at least 24 months, e.g., at temperatures below 4°C (e.g., about 4°C to -20°C). In one embodiment, the formulation is stable at about 4°C for at least 4 weeks. In certain embodiments, the pharmaceutical composition of the present disclosure comprises a nanoparticle composition disclosed herein and a pharmaceutically acceptable carrier selected from one or more of Tris, acetate (e.g., sodium acetate), citrate (e.g., sodium citrate), saline, PBS, and sucrose. In certain embodiments, the pharmaceutical composition of the present disclosure has a pH of about 7 to 8 (e.g., 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, or 8.0, or 7.5 to 8, or 7 to 7.8). For example, the pharmaceutical composition of the present disclosure comprises a nanoparticle composition disclosed herein, Tris, saline, and sucrose, and has a pH of about 7.5 to 8, suitable for storage and / or transportation at, for example, about -20°C. For example, the pharmaceutical composition of the present disclosure comprises a nanoparticle composition disclosed herein and PBS, and has a pH of about 7 to 7.8, suitable for storage and / or transportation at, for example, about 4°C or below. In the context of this disclosure, "stability," "stabilized," and "stable" refer to the resistance of the nanoparticle compositions and / or pharmaceutical compositions disclosed herein to chemical or physical changes (e.g., degradation, particle size change, aggregation, change in encapsulation, etc.) under given conditions of manufacture, preparation, transportation, storage, and / or use, for example, when subjected to stresses such as shear forces, freeze-thaw stress, etc.
[0367] Nanoparticle compositions and / or pharmaceutical compositions containing one or more nanoparticle compositions can be administered to any patient or subject, including those who may benefit from a therapeutic effect provided by delivery of a therapeutic and / or prophylactic agent to one or more specific cells, tissues, organs, or systems or groups thereof (e.g., the renal system). While the description of nanoparticle compositions and pharmaceutical compositions provided herein primarily relates to compositions suitable for administration to humans, it will be understood by those skilled in the art that such compositions are generally suitable for administration to any other mammal. Modifications of compositions suitable for administration to humans to make them suitable for administration to various animals are well understood, and an ordinary veterinary pharmacologist can design and / or implement such modifications, if any, with no more than routine experimentation. Subjects to which the compositions are contemplated include, but are not limited to, humans, other primates, and other mammals, including commercially valuable mammals such as cows, pigs, horses, sheep, cats, dogs, mice, and / or rats.
[0368] Pharmaceutical compositions containing one or more nanoparticle compositions can be prepared by any method known or hereafter developed in the art of pharmacology. Generally, such preparative methods include the step of bringing into association the active ingredient with an excipient and / or one or more other accessory ingredients, and then, if desired or necessary, dividing, shaping, and / or packaging the product into desired single- or multi-dosage units.
[0369] Pharmaceutical compositions according to the present disclosure can be prepared, packaged, and / or sold in bulk as single unit doses and / or multiple single unit doses. As used herein, a "unit dose" is a discrete amount of a pharmaceutical composition comprising a predetermined amount of an active ingredient (e.g., a nanoparticle composition). The amount of the active ingredient is generally equal to the dosage of the active ingredient that would be administered to a subject and / or a convenient fraction of such a dosage, e.g., one-half or one-third of such a dosage.
[0370] Pharmaceutical compositions can be prepared in a variety of forms suitable for various routes and methods of administration. For example, pharmaceutical compositions can be prepared in liquid dosage forms (e.g., emulsions, microemulsions, nanoemulsions, solutions, suspensions, syrups, and elixirs), injectable forms, solid dosage forms (e.g., capsules, tablets, pills, powders, and granules), dosage forms for topical and / or transdermal administration (e.g., ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, and patches), suspensions, powders, and other forms.
[0371] Liquid dosage forms for oral and parenteral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, nanoemulsions, solutions, suspensions, syrups, and / or elixirs. In addition to the active ingredient, liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizers and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil, and sesame oil), glycerin, tetrahydrofurfuryl alcohol, polyethylene glycol, and fatty acid esters of sorbitan, and mixtures thereof. In addition to inert diluents, oral compositions may contain additional agents, such as additional therapeutic and / or prophylactic agents, wetting agents, emulsifying and suspending agents, sweeteners, flavorings, and / or fragrances. In certain embodiments for parenteral administration, the composition is mixed with a solubilizing agent such as Cremophor®, alcohol, oil, modified oil, glycol, polysorbate, cyclodextrin, polymer, and / or combinations thereof.
[0372] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions, can be formulated according to known techniques using suitable dispersants, wetting agents, and / or suspending agents. Sterile injectable preparations can be sterile injectable solutions, suspensions, and / or emulsions in non-toxic parenterally acceptable diluents and / or solvents, such as solutions in 1,3-butanediol. Among the acceptable vehicles and solvents that can be used are water, Ringer's solution, USP, and isotonic sodium chloride solution. Sterile fixed oils are usually used as solvents or suspending media. For this purpose, any non-irritating fixed oil can be used, including synthetic mono- or diglycerides. Fatty acids, such as oleic acid, can be used in the preparation of injectables.
[0373] Injectable formulations can be sterilized, for example, by filtration through a bacteria-retaining filter, and / or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
[0374] In order to prolong the effect of an active ingredient, it is often desirable to slow the absorption of the active ingredient from subcutaneous or intramuscular injection. This can be accomplished by using a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug depends on its rate of dissolution, which in turn may depend on crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form can be accomplished by dissolving or suspending the drug in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending on the drug-to-polymer ratio and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissues.
[0375] Compositions for rectal or vaginal administration are typically suppositories, which can be prepared by mixing the composition with a suitable non-irritating excipient such as cocoa butter, polyethylene glycol or a suppository wax which is solid at ambient temperature but liquid at body temperature and therefore melts in the rectum or vaginal cavity and releases the active ingredient.
[0376] Solid dosage forms for oral administration include capsules, tablets, pills, films, powders, and granules. In such solid dosage forms, the active ingredient is mixed with at least one inert pharmaceutically acceptable excipient, such as sodium citrate or dicalcium phosphate and / or fillers or extenders (e.g., starches, lactose, sucrose, glucose, mannitol, and silicic acid), binders (e.g., carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia), humectants (e.g., glycerol), disintegrating agents (e.g., agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate), solution retarders (e.g., paraffin), absorption accelerators (e.g., quaternary ammonium compounds), wetting agents (e.g., cetyl alcohol and glycerol monostearate), absorbents (e.g., kaolin and bentonite clays, silicates), and lubricants (e.g., talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate), and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.
[0377] Solid compositions of a similar type can be used as fillers in soft and hard-filled gelatin capsules using excipients such as lactose or milk sugar and high molecular weight polyethylene glycols. Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical formulation art. They may optionally contain opacifying agents and can be of a composition that releases the active ingredient(s) preferentially, or optionally, in a certain part of the intestinal tract. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type can be used as fillers in soft and hard-filled gelatin capsules using excipients such as lactose or milk sugar and high molecular weight polyethylene glycols.
[0378] Dosage forms for topical and / or transdermal administration of the composition include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, and / or patches. Generally, the active ingredient is mixed with a pharmaceutically acceptable excipient and / or any necessary preservatives and / or buffers, if necessary, under sterile conditions. Furthermore, the present disclosure contemplates the use of transdermal patches, which often have the additional advantage of providing controlled delivery of the compound to the body. Such dosage forms can be prepared, for example, by dissolving and / or dispersing the compound in a suitable medium. Alternatively or additionally, the rate can be controlled by either providing a rate-controlling membrane and / or dispersing the compound in a polymer matrix and / or gel.
[0379] Suitable devices for use in delivering the intradermal pharmaceutical compositions described herein include short needle devices, such as those described in U.S. Patent Nos. 4,886,499; 5,190,521; 5,328,483; 5,527,288; 4,270,537; 5,015,235; 5,141,496; and 5,417,662.Intradermal compositions can be administered by devices that limit the effective penetration length of the needle into the skin, such as those described in PCT Publication WO 99 / 34850, and their functional equivalents.Preferably, liquid jet injectors and / or jet injection devices deliver liquid compositions to the dermis through a needle that penetrates the stratum corneum and generates a jet that reaches the dermis. Jet injection devices are described, for example, in U.S. Patent Nos. 5,480,381; 5,599,302; 5,334,144; 5,993,412; 5,649,912; 5,569,189; 5,704,911; 5,383,851; 5,893,397; 5,466,220; 5,339,163 Nos. 5,312,335; 5,503,627; 5,064,413; 5,520,639; 4,596,556; 4,790,824; 4,941,880; 4,940,460; and PCT Publications WO 97 / 37705 and WO 97 / 13537. A ballistic powder / particle delivery device is suitable, using compressed gas to accelerate powdered vaccines from the outer layer of the skin into the dermis. Alternatively or additionally, a conventional syringe can be used for the classic Mantoux method of intradermal administration.
[0380] Formulations suitable for topical administration include, but are not limited to, liquid and / or semi-liquid formulations such as oil-in-water and / or water-in-oil emulsions, and / or solutions and / or suspensions, such as liniments, lotions, creams, ointments, and / or pastes. Topically administrable formulations may contain, for example, about 1% to about 10% (wt / wt) active ingredient, although the concentration of the active ingredient may be as high as the solubility limit of the active ingredient in the solvent. Formulations for topical administration may further include one or more of the additional ingredients described herein.
[0381] Pharmaceutical compositions can be prepared, packaged, and / or sold as formulations suitable for pulmonary administration via the buccal cavity. Such formulations can include dry particles containing the active ingredient. Such compositions are conveniently in the form of a dry powder for administration using a device containing a dry powder reservoir capable of dispersing the powder by directing a flow of propellant, and / or using a self-propelling solvent / powder dispensing container, such as a device containing the active ingredient dissolved and / or suspended in a low-boiling propellant in a sealed container. Dry powder compositions may include a solid fine powder diluent, such as sugar, and are conveniently provided in a unit dosage form.
[0382] Low-boiling propellants generally include liquid propellants having a boiling point below 18.3°C (65°F) at atmospheric pressure. Generally, the propellant may comprise 50% to 99.9% (wt / wt) of the composition, and the active ingredient may comprise 0.1% to 20% (wt / wt) of the composition. The propellant may further comprise additional ingredients such as a liquid nonionic and / or solid anionic surfactant and / or a solid diluent (which may have a particle size similar to that of the particles containing the active ingredient).
[0383] Pharmaceutical compositions formulated for pulmonary delivery may provide the active ingredient in the form of droplets of a solution and / or suspension. Such formulations may be prepared, packaged, and / or sold as optionally sterile aqueous and / or dilute alcoholic solutions and / or suspensions containing the active ingredient, and may conveniently be administered using any suitable spray and / or atomizing device. Such formulations may further contain one or more additional ingredients, including, but not limited to, flavorings such as saccharin sodium, volatile oils, buffers, surfactants, and / or preservatives such as methylhydroxybenzoates. The droplets provided by this administration route may have an average diameter ranging from about 1 nm to about 200 nm.
[0384] The formulations described herein as being useful for pulmonary delivery are also useful for intranasal delivery of pharmaceutical compositions. Another formulation suitable for intranasal administration is a coarse powder containing the active ingredient and having an average particle size of about 0.2 μm to 500 μm. Such formulations are administered by nasal inhalation, i.e., by high-velocity inhalation through the nasal passages from a container of the powder held close to the nose.
[0385] Formulations suitable for nasal administration may contain, for example, as little as about 0.1% (wt / wt) to as much as 100% (wt / wt) of the active ingredient, and may include one or more additional ingredients described herein. Pharmaceutical compositions may also be prepared, packaged, and / or sold in formulations suitable for buccal administration. Such formulations may be, for example, in the form of tablets and / or lozenges made using conventional methods and may contain, for example, 0.1% to 20% (wt / wt) of the active ingredient, with the remainder comprising an orally dissolvable and / or degradable composition and, optionally, one or more additional ingredients described herein. Alternatively, formulations suitable for buccal administration may comprise a powdered and / or aerosolized and / or atomized solution and / or suspension comprising the active ingredient. Such powdered, aerosolized, and / or aerosolized formulations, when dispersed, may have an average particle and / or droplet size in the range of about 0.1 nm to about 200 nm and may further comprise one or more of any of the additional ingredients described herein.
[0386] The pharmaceutical composition may be prepared, packaged, and / or sold in a formulation suitable for ocular administration. Such a formulation may be in the form of, for example, eye drops, comprising, for example, a 0.1 / 1.0% (wt / wt) solution and / or suspension of the active ingredient in an aqueous or oily liquid vehicle. Such eye drops may further comprise one or more buffering agents, salts, and / or any other additional ingredients described herein. Other ophthalmically administrable formulations that are useful include those comprising the active ingredient in microcrystalline form and / or in a liposomal formulation. Ear drops and / or eye drops are considered within the scope of the present disclosure.
[0387] mRNA therapeutics mRNA as a drug modality has the potential to deliver transmembrane and intracellular proteins, i.e., targets that are inaccessible to standard biologics due to their inability to cross the cell membrane (see Sahin, U., Kariko K., Tureci O. Nat. Rev. Drug. Discov. 2014, 13, 759-780, the contents of which are incorporated herein by reference in their entirety). One of the major challenges toward the realization of mRNA-based therapeutics is the identification of an optimal delivery vehicle. Due to its large size, chemical instability, and potential immunogenicity, mRNA requires a delivery vehicle that provides protection from endo- and exo-nucleases and also hides the cargo from immune sentinels. Lipid nanoparticles (LNPs) have been identified as a superior option in this regard (see Hajj, K.A., Whitehead, K.A. Nat. Rev. Mater. 2017, 2, 1-17, the contents of which are incorporated herein by reference in their entirety). This approach has recently been validated by demonstrating the safe and effective delivery of mRNA-based vaccines formulated in LNPs (see Bahl, K. et al. Mol. Ther. 2017, 25, 1316-1327, the contents of which are incorporated herein by reference in their entirety).
[0388] Key performance criteria for lipid nanoparticle delivery systems are maximizing cellular uptake and efficiently releasing mRNA from endosomes. At the same time, LNPs should provide a stable drug product and be able to be safely administered at therapeutically relevant levels. LNPs are typically multi-component systems consisting of amino lipids, phospholipids, cholesterol, and PEG lipids. Each component is required for efficient delivery of nucleic acid cargo and particle stability. The key component thought to drive cellular uptake, endosomal escape, and tolerability is the amino lipid. While cholesterol and PEG lipids contribute to the stability of the drug product both in vivo and on the shelf, phospholipids provide additional membrane fusogenicity to the LNP, thereby helping to drive endosomal escape and making the nucleic acid bioavailable within the cellular cytosol.
[0389] Over the past 20 years, several aminolipid series have been developed for oligonucleotide delivery (see Stanton MG, Murphy-Benenato, KERNA Therapeutics. Topics in Medicinal Chemistry, 2017, vol. 27., A. Garner eds., (Springer, Cham) pp. 237-253, the contents of which are incorporated herein by reference in their entirety). This document highlights a direct relationship between the structure of the aminolipid and the delivery efficiency and tolerability of the resulting LNP. Aminolipid MC3 (DLin-MC3-DMA) is the most clinically advanced oligonucleotide delivery system, as siRNA formulated in MC3-based LNPs has progressed to Phase III for the treatment of transthyretin-mediated amyloidosis (see Coelho, T. et al. N. Engl. J. Med. 2013, 369, 819-829; Butler, J. Set al. Amyloid 2016, 23, 109-118, the contents of which are incorporated herein by reference in their entirety). More recently, literature reports have demonstrated the effectiveness of MC3-based LNPs for delivering mRNA (see Nanbhan, J. F. et al. Sci. Rep. 2016, 6, 2019, the contents of which are incorporated herein by reference in their entirety). When delivered intravenously, this class of LNPs is rapidly opsonized by apolipoprotein E (ApoE), allowing cellular uptake by the low-density lipoprotein receptor (LDLr) (see Akinc, A. et al. Mol. Ther. 2010, 18, 1357-1364, the contents of which are incorporated herein by reference in their entirety). However, concerns remain that the long tissue half-life of MC3 may contribute to adverse side effects that prevent its use for long-term treatment (see Maier MA et al. Mol. Ther. 2013, 21, 1570-1578, the contents of which are incorporated herein by reference in their entirety).In addition, extensive literature evidence suggests that long-term administration of lipid nanoparticles may result in several toxic side effects, including complement activation-associated pseudoallergy (CARPA) and liver damage (see Szebeni J. Mol. Immunol. 2014, 61, 163-173, the contents of which are incorporated herein by reference in their entirety). Therefore, to realize the potential of mRNA therapeutics for humans, a group of LNPs with increased delivery efficiency, along with metabolic and toxicity profiles that would allow long-term administration in humans, is needed.
[0390] The ability to treat a wide range of diseases requires flexibility for safe administration at various dose levels over long periods of time. Through systematic optimization of amino lipid structures, compounds of the present disclosure were identified that offer a balance of chemical stability, improved delivery efficiency due to improved endosomal escape, rapid in vivo metabolism, and a clean toxicity profile (Example 26). The combination of these features provides a drug candidate that can be administered long-term without activating the immune system. Initial rodent screening led to the identification of lead lipids with favorable delivery efficiency and pharmacokinetics. The lead LNPs were further profiled in non-human primates for delivery efficiency after single and repeated administration. Finally, the optimized LNPs were evaluated in a 1-month repeated-dose toxicity study in rats and non-human primates. Without wishing to be bound by theory, the novel ionic lipids of the present disclosure enable the safe and effective use of mRNA-based therapeutics in acute and chronic diseases.
[0391] Method for producing polypeptides in cells The present disclosure provides a method for producing a polypeptide of interest in a mammalian cell. The method for producing the polypeptide comprises contacting the cell with a nanoparticle composition containing mRNA encoding the polypeptide of interest. When the cell is contacted with the nanoparticle composition, the mRNA can be taken up by the cell and translated within the cell to produce the polypeptide of interest.
[0392] Generally, contacting mammalian cells with a nanoparticle composition containing mRNA encoding a polypeptide of interest can be performed in vivo, ex vivo, in culture, or in vitro. The amount of nanoparticle composition contacted with cells and / or the amount of mRNA therein can depend on the type of cell or tissue contacted, the means of administration, the physicochemical properties (e.g., size, charge, and chemical composition) of the nanoparticle composition and the mRNA therein, and other factors. Generally, an effective amount of the nanoparticle composition enables efficient polypeptide production in cells. Metrics of efficiency include polypeptide translation (indicated by polypeptide expression), the level of mRNA degradation, and immune response indicators.
[0393] The step of contacting a cell with a nanoparticle composition containing mRNA can include or cause transfection. The phospholipids comprising the lipid component of the nanoparticle composition can facilitate transfection and / or increase transfection efficiency, for example, by interacting with and / or fusing with the cell membrane or intracellular membrane. Transfection can allow translation of the mRNA within the cell.
[0394] In certain embodiments, the nanoparticle compositions described herein can be used therapeutically. For example, the mRNA contained in the nanoparticle composition can encode (e.g., in a translatable region) a therapeutic polypeptide and produce the therapeutic polypeptide upon contacting and / or entering (e.g., transfecting) a cell. In other embodiments, the mRNA contained in the nanoparticle composition can encode a polypeptide that can improve or enhance a subject's immunity. For example, the mRNA can encode granulocyte colony-stimulating factor or trastuzumab.
[0395] In certain embodiments, the mRNA contained in the nanoparticle composition may encode a recombinant polypeptide that can replace one or more polypeptides that are substantially absent in cells contacted with the nanoparticle composition. The one or more substantially absent polypeptides may be absent due to mutations in the encoding gene or its regulatory pathway. Alternatively, the recombinant polypeptide produced by translation of the mRNA may antagonize the activity of an endogenous protein present within the cell, on the surface of the cell, or secreted from the cell. Antagonistic recombinant polypeptides may be desirable to counter adverse effects caused by the activity of endogenous proteins, such as altered activity or localization caused by mutations. In another modification, the recombinant polypeptide produced by translation of the mRNA may indirectly or directly antagonize the activity of a biological moiety present within the cell, on the surface of the cell, or secreted from the cell. Antagonized biological moieties include, but are not limited to, lipids (e.g., cholesterol), lipoproteins (e.g., low-density lipoprotein), nucleic acids, carbohydrates, and small molecule toxins. Recombinant polypeptides produced by translation of mRNA can be engineered for localization within a specific compartment within the cell, for example, the nucleus, or can be engineered for secretion from the cell or translocation to the cell membrane.
[0396] In some embodiments, contacting cells with a nanoparticle composition containing mRNA can reduce the cellular innate immune response to exogenous nucleic acids. Cells can be contacted with a first nanoparticle composition containing a first amount of a first exogenous mRNA containing a translatable region, and the level of the cellular innate immune response to the first exogenous mRNA can be determined. Subsequently, the cells can be contacted with a second composition containing a second amount of the first exogenous mRNA, where the second amount is a lower amount of the first exogenous mRNA compared to the first amount. Alternatively, the second composition can contain a first amount of a second exogenous mRNA that is different from the first exogenous mRNA. The step of contacting cells with the first and second compositions can be repeated one or more times. Furthermore, the efficiency of intracellular polypeptide production (e.g., translation) can be optionally determined, and the cells can be repeatedly re-contacted with the first and / or second compositions until a target protein production efficiency is achieved.
[0397] Methods for delivering therapeutic agents to cells and organs The present disclosure provides methods for delivering therapeutic and / or prophylactic agents to mammalian cells or organs. Delivery of the therapeutic and / or prophylactic agent to a cell comprises administering to a subject a nanoparticle composition comprising the therapeutic and / or prophylactic agent, where administering the composition comprises contacting the cell with the compositio...
Claims
1. [Claim 1-1] [Case 1-2] [Case 1-3] [C1-4] [Case 1-5] [Case 1-6] [Case 1-7] [Case 1-8] [Case 1-9] [C1-10] [C1-11] or a salt thereof.
2. The compound is [chemical 2] 2. The compound according to claim 1, wherein:
3. The compound, [C3] 2. The compound according to claim 1, wherein:
4. The compound, [C4] 2. The compound of claim 1, or a salt thereof, selected from:
5. The compound, [C5-1] [C5-2] 2. The compound of claim 1, or a salt thereof, selected from:
6. The compound, [C6] 2. The compound of claim 1, or a salt thereof, selected from:
7. The compound or salt thereof according to any one of claims 1 to 6, wherein the salt is a pharma- ceutically acceptable salt.
8. A nanoparticle composition comprising a lipid component containing a compound or salt thereof according to any one of claims 1 to 7.
9. The nanoparticle composition of claim 8, wherein the lipid component further comprises a phospholipid.
10. The phospholipid is 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-diundecanoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-diureto ... 1-Oleyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 diether PC), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), 1,2-dilinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0 PE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), dipalmitoylphosphatidylglycerol (DPPG), palmitoyloleoylphosphatidylethanolamine (POPE), distearoyl-phosphatidyl-ethanolamine (DSPE), dipalmitoylphosphatidylethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), 1-stearoyl-2-oleoyl-phospha 10. The nanoparticle composition of claim 9, wherein the phosphatidylcholine is selected from the group consisting of sphingomyelin, phosphatidylcholine, phosphatidylethanolamine (SOPE), 1-stearoyl-2-oleoyl-phosphatidylcholine (SOPC), sphingomyelin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyloleoylphosphatidylcholine, lysophosphatidylcholine, lysophosphatidylethanolamine (LPE), and mixtures thereof.
11. The nanoparticle composition of claim 10, wherein the phospholipid is DSPC or DOPE.
12. The nanoparticle composition of claim 9, wherein the lipid component further comprises a structured lipid.
13. The nanoparticle composition of claim 12, wherein the structured lipid is selected from the group consisting of cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, α-tocopherol, and mixtures thereof.
14. The nanoparticle composition of claim 13, wherein the structured lipid is cholesterol.
15. The nanoparticle composition of claim 12, wherein the lipid component further comprises a PEG lipid.
16. The nanoparticle composition of claim 15, wherein the PEG lipid is selected from the group consisting of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, PEG-modified dialkylglycerol, and mixtures thereof.
17. The nanoparticle composition of claim 15, wherein the lipid component comprises about 30 mol% to about 60 mol% of the compound, about 0 mol% to about 30 mol% of phospholipid, about 18.5 mol% to about 48.5 mol% of structural lipid, and about 0 mol% to about 10 mol% of PEG lipid.
18. The nanoparticle composition of claim 15, wherein the lipid component comprises about 35 mol% to about 55 mol% of the compound, about 5 mol% to about 25 mol% of phospholipid, about 30 mol% to about 40 mol% of structural lipid, and about 0 mol% to about 10 mol% of PEG lipid.
19. The nanoparticle composition described in claim 15, wherein the lipid component comprises about 50 mol% of the compound, about 10 mol% phospholipid, about 38.5 mol% structural lipid, and about 1.5 mol% PEG lipid.
20. The nanoparticle composition of any one of claims 8 to 19, further comprising a therapeutic and / or prophylactic agent.
21. The nanoparticle composition of claim 20, wherein the therapeutic and / or prophylactic agent is a nucleic acid.
22. The nanoparticle composition of claim 21, wherein the therapeutic and / or prophylactic agent is ribonucleic acid (RNA).
23. The nanoparticle composition of claim 22, wherein the RNA is selected from the group consisting of small interfering RNA (siRNA), asymmetric interfering RNA (aiRNA), microRNA (miRNA), dicer substrate RNA (dsRNA), small hairpin RNA (shRNA), messenger RNA (mRNA), and mixtures thereof.
24. The nanoparticle composition described in claim 22, wherein the RNA is mRNA.
25. The nanoparticle composition of claim 24, wherein the mRNA comprises one or more of a stem loop, a chain terminating nucleoside, a polyA sequence, a polyadenylation signal, and / or a 5' cap structure.
26. A nanoparticle composition described in any one of claims 20 to 25, wherein the encapsulation efficiency of the therapeutic and / or prophylactic drug is 80% to 100%.
27. The nanoparticle composition described in claim 24 or 25, wherein the wt / wt ratio of the lipid component to the mRNA is from about 10:1 to about 60:
1.
28. The nanoparticle composition of claim 27, wherein the wt / wt ratio of the lipid component to the mRNA is about 20:
1.
29. A nanoparticle composition according to any one of claims 21 to 25, wherein the N:P ratio is from about 5:1 to about 8:
1.
30. A pharmaceutical composition comprising the nanoparticle composition of any one of claims 20 to 29 and a pharma- ceutically acceptable carrier.
31. The nanoparticle composition of any one of claims 20 to 29, for use in delivering a therapeutic and / or prophylactic agent to mammalian cells in a mammalian subject, wherein the composition is administered to the subject, and wherein the cells are contacted with the nanoparticle composition upon administration, thereby delivering the therapeutic and / or prophylactic agent to the cells.
32. The nanoparticle composition of any one of claims 20 to 29, for use in producing a target polypeptide in a mammalian cell, wherein the nanoparticle composition contacts the cell and the therapeutic and / or prophylactic agent is an mRNA encoding the target polypeptide, whereby the mRNA is capable of being translated in the cell to produce the target polypeptide.
33. The nanoparticle composition of any one of claims 20 to 29, for use in treating a disease or disorder in a mammal in need of treatment, wherein a therapeutically effective amount of the nanoparticle composition is administered to the mammal.
Citation Information
Patent Citations
Novel Lipid and Lipid Nanoparticle Formulations for Delivery of Nucleic Acids
JP2017522376A
Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria.
JP2019519601A
Immunomodulatory therapeutic mRNA compositions encoding activating oncogene mutant peptides
JP2020514321A
JPP6948313B
Lipid nanoparticles containing combinations of cationic lipids
WO2013089152A1
